

# Bibliographie : Cannabis et Cannabinoïdes thérapeutiques en Psychiatrie

**Docteur Christian SUEUR, GRECC, janvier 2022.**

- 1 - Généralités : 1 – 11
- 2 - Cannabinoïdes et anxiété : 13
- 3 - Cannabidiol anxiolytique : 14 - 16
- 4 - Cannabidiol antipsychotique : 17 - 22
- 5 - Cannabinoïdes et dépression : 23 - 27
- 6 - Cannabidiol antidépresseur : 28
- 7 - Cannabinoïdes et Sommeil : 29 - 30
- 8 - Cannabinoïdes et addiction / Substance Use Disorders : 31 - 33
- 9 - Cannabinoïdes et addiction au Cannabis : 34 - 43
- 10 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 44 - 57
- 11 - Cannabinoides et syndrome de Gilles de la Tourette : 58 - 59
- 12 - Cannabinoides et Hyperactivité - Déficit de l'Attention (HA-DA, TDAH) : 60 - 61
- 13 - Cannabinoides et PTSD : 62 - 65
- 14 - Cannabinoides et stress : 66
- 15 - Cannabinoides en pédiatrie (TED, autismes, troubles psychocomportementaux) : 67-72

1. ALMEIDA-SANTOS A.F., GOBIRA P.H., ROSA L.C., GUIMARAES F.S., MOREIRA F.A., AGUIAR D.C. : Modulation of anxiety-like behavior by the endocannabinoid 2-arachidonoylglycerol (2-AG) in the dorsolateral periaqueductal gray, *Behavioural Brain Research*, 2013, 252, 10-17.  
Doi : 10.1016/j.bbr.2013.05.027
2. AMSTERDAM van J., VERVLOET J., de WEERT G., BUWALDA V.J.A., GOUDRIAAN A.E., van den BRINK W. : Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia, *Harm Reduction Journal*, 2018, 15, 47, 1-4.  
Doi : 10.1186/s12954-018-0253-7
3. ANDERSON P., VEGA C.P. : Is There a Role for Cannabis in Mental Health Disorders ?, *Medscape, CME / ABIM MOC / CE Released* : 12/13/2019.  
<https://www.medscape.org/viewarticle/922367>
4. ANDRADE C. : Cannabis and neuropsychiatry, 1 : benefits and risks, *Journal of Clinical Psychiatry*, 2016, 77, (5), e551-4.  
Doi : 10.4088/JCP.16f10841
5. BATISTA L.A., GOBIRA P.H., VIANA T.G., AGUIAR D.C., MOREIRA F.A. : Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs, *Behavioral Pharmacology*, 2014, 25, 425-433.  
Doi : 10.1097/FBP.0000000000000073

6. BATTISTELLA G., FORNARI E., ANNONI J.-M., CHTIOUI H., DAO K., FABRITIUS M., FAVRAT B., MALL J.-F., MAEDER P., GIROUD C. : Long-Term Effects of Cannabis on Brain Structure, *Neuropsychopharmacology*, 2014, 39, 2041-2048.  
Doi : 10.1038/npp.2014.67
7. BEALE C., BRODY S.J., CHYE Y., SUO C., SCHIRA M., GALETTIS P., MARTIN J.H., YÜCEL M., SOLOWIJ N. : Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users, *Cannabis and Cannabinoid Research*, 2018, 3, (1), 94-107.  
Doi : 10.1089/can.2017.0047
8. BIH C.I., CHEN T., NUNN A.V.W., BAZELOT M., DALLASMA, WHALLEY B.J. : Molecular Targets of Cannabidiol in Neurological Disorders, *Neurotherapeutics*, 2015, 12, 699-730.  
Doi : 10.1007/s13311-015-0377-3
9. BLACK N., STOCKINGS E., CAMPBELL G., TRAN L.T., ZAGIC D., HALL W.D., FARRELL M., DEGENHARDT L. : Cannabinoids for the treatment of mental disorders and symptoms of mental disorders : a systematic review and meta-analysis, *The Lancet Psychiatry*, 2019.  
Doi : 10.1016/S2215-0366(19)30401-8
10. BIOQUE M., MAS S., COSTANZO M.C., CABRERA B., LOBO A., GONZALES-PINTO A., RODRIGUEZ-TOSCANO E., CORRIPIO I. et al. : Gene-environment interaction between an endocannabinoid system genetic polymorphism and cannabis use in first episode of psychosis, *European Neuropsychopharmacology*, 2019, 1-9.  
Doi : 10.1016/j.euroneuro.2019.04.005
11. BONN-MILLER M.O., POLLACK C.V. Jr, CASARETT D., DART R., EISOHLY M., GOOD L., GUZMAN M., HANUS L., HILL K.P., HUESTIS M.A., MARSH E., SISLEY S., SKINNER N., SPAHR J., VANDREY R., VISCUSI E., WARE M.A., ABRAMS D. : Priority Considerations for Medicinal Cannabis-Related Research, *Cannabis and Cannabinoid Research*, 2019, 4, 3, 1-19.  
Doi : 10.1089/can.2019.0045
12. BORGAN F., LAURIKAINEN H., VERONESE M., MARQUES T.R., HAAPARANTA-SOLIN M., SOLIN O., DAHOUN T., ... METSY Group et al. : In Vivo Availability of Cannabinoid 1 Receptor Level in Patients With First-Episode psychosis, *JAMA Psychiatry*, 2019.  
Doi : 10.1001/jamapsychiatry.2019.1427
13. BOUSO J.C., JIMENEZ-GARRIDO D., ONA G., WOZNICA D., dos SANTOS R.G., HALLAK J.E.C., PARAHOS B. A., de ALMEIDA MENDES F., YONAMINE M. et al. : Quality of Life, Mental Health, Personality and Patterns of Use in Self-Medicated Cannabis Users with Chronic Diseases : A 12-Month Longitudinal Study, *Phytotherapy Research*, 2020.  
Doi : 10.1002/ptr.6639
14. BREUER A., HAJ C.G., FOGACA M.V., GOMES F.V., RODRIGUES SILVA N., PEDRAZZI F., Del BEL E.A., HALLAK J.C., CRIPPA J.A., ZUARDI A.W., MECHOULAM R., GUIMARAES F.S. : Fluorinated Cannabidiol Derivatives : Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects, *PLOS ONE, Research Article*, 2016.  
Doi : 10.1371/journal.pone.0158779
15. BRITSCH S.C., BABALONIS S., WALSH S.L. : Cannabidiol Pharmacology and Therapeutic Targets, *Psychopharmacology (Berl.)*, 2021, 238, (1), 9-28.  
Doi : 10.1007/s00213-020-05712-8

16. BUDNEY A.J., SOFIS M.J., BORODOVSKY J.T. : An update on cannabis use disorder with comment on the impact of policy related to therapeutic and recreational cannabis use, *European Archives of Psychiatry and Clinical Neuroscience*, 2019.
- Doi : 10.1007/s00406-018-0976-1
17. CALAPAI G., MANNUCCI C., CHINOU I., CARDIA L., CALAPAI F., SORBARA E.E., FIRENZUOLI B., RICCA V., GENNINI G.-F., FIRENZUOLI F. : Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry, *Hindawi - Evidence-Based Complementary and Alternative Medicine*, 2019, Article ID 2509129, 11 pages.
- Doi : 10.1155/2019/2509129
18. CAMPOS A.C., MOREIRA F.A., GOMES F.V., DEL BEL E.A., GUIMARAES F.S. : Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, *Philosophical Transactions of the Royal Society*, 2012, 367, 3364-3378.
- Doi : 10.1098/rstb.2011.0389
19. CAMPOS A.C., FOGACA M.V., SCARANTE F.F. et al. : Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders, *Frontiers in Pharmacology*, 2017, 8, article 269.
- Doi : 10.3389/fphar.2017.00269
20. CASTILLO P.E., YOUNTS T.J., CHAVEZ A.E., HASHIMOTODANI Y. : Endocannabinoid Signaling and Synaptic Function, *Neuron - Cell Press*, 2012, 76, 70-81.
- Doi : 10.1016/j.neuron.2012.09.020
21. CLEIREC G., POLOMENI P. : Le Cannabidiol, l'autre cannabinoïde présent dans le cannabis : une piste thérapeutique prometteuse ?, *Revue SWAPS*, 2019, n°90, "Du Cannabis Thérapeutique à la Régulation".  
<http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891>
22. COOPER Z.D., HANEY M. : Actions of delta-9-tetrahydrocannabinol in cannabis, *International Review of Psychiatry*, 2009, 21, (2), 104-112.
- Doi : 10.1080/09540260902782752
23. CRIPPA J.A., ZUARDI A.W., HALLAK J.E.C. : Therapeutic use of the cannabinoids in psychiatry, *Revista Brasileira de Psiquiatria*, 2010, 32, Suppl 1, 56-65.
24. CRIPPA J.A., GUIMARAES F. S., CAMPOS A.C., ZUARDI A.W. : Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age, *Frontiers in Immunology*, 2018, 9, Article 2009, 1-16..
- Doi : 10.3389/fimmu.2018.02009
25. CUTTLER C., SPRADLIN A., McLAUGHLIN R.J. : A naturalistic examination of the perceived effects of cannabis on negative affect, *Journal of Affective Disorders*, 2018.
- Doi : 10.1016/j.jad.2018.04.054
26. DE AQUINO J.P., SHERIF M., RADHAKRISHNAN R., CAHILL J.D., RANGANATHAN M., D'SOUZA D.C. : The Psychiatric Consequences of Cannabinoids, *Clinical Therapeutics*, 2018, 40, (9), 1448-1456
- Doi : 10.1016/j.clinthera.2018.03.013
27. DEIANA S., WATANABE A., YAMASAKI Y., AMADA N., ARTHUR M., FLEMING S., WOODCOCK H., DORWARD P., PIGLIACAMPO B., CLOSE S., PLATT B., RIEDEL G. : Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Delta (9)- tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on

- obsessive-compulsive behaviour, *Psychopharmacology (Berl)*, 2012, 219, (3), 859–73.
28. Di MARZO V., PISCITELLI F. : The Endocannabinoid System and its Modulation by Phytocannabinoids, *Neurotherapeutics*, 2015, 12, 692-698.  
Doi : 10.1007/s13311-015-0374-6
29. DIVIANT J.P., VIGIL J.M., STITH S.S. : The Role of Cannabis within an Emerging Perspective on Schizophrenia, *Medicines*, 2018, 5, (86), 1-11.  
Doi : 10.3390/medicines5030086
30. ELSAID S., KLIBER S., Le FOLL B. : Effects of cannabidiol (CBD) in neuropsychiatric disorders : A review of pre-clinical and clinical findings, *Progress in Molecular Biology and Translational Science*, 2019, 167, 25-75.  
Doi : 10.1016/bs.pmbts.2019.06.005
31. FAKHOURY M. : Could cannabidiol be used as an alternative to antipsychotics ?, *Journal of Psychiatric Research*, 2016, 80, 14-21.
32. FAKHOURY M. : Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia, *Molecular Neurobiology*, 2017, 54, (1), 768-778.  
Doi : 10.1007/s12035-016-9697-5
33. FASINU P.S., PHILLIPS S., ELSOHLY M.A., WALKER L.A. : Current Status and Prospects for Cannabidiol Preparations as New Therapeutic Agents, *Pharmacotherapy*, 2016, 36, (7), 781-796.  
Doi : 10.1002/phar.1780
34. FERNANDEZ-RUIZ J., SAGREDO O., PAZOS M.R., GARCIA C., PERTWEE R., MECHOULAM R., MARTINEZ-ORGADO J. : Cannabidiol for neurodegenerative disorders : important new clinical applications for this phytocannabinoid ?, *The British Journal of Clinical Pharmacology*, 2013, 75, (2), 323-333.
35. FERNANDEZ-ESPEJO E., NUNEZ-DOMINGUEZ L. : Endocannabinoid-mediated synaptic plasticity and substance use disorders, *Neurologia*, 2019.  
Doi : 10.1016/j.nrl.2018.12.004
36. FILIPIUC L.E., ABADEI D.C., ALEXA-STRATULAT T., PRICOPE C.V., BILD V., STEFANESCU R., STANCIU G.D. TAMBA B.-I. : Major Phytocannabinoids and Their Related Compounds : Should we Only Search for Drugs that Act on Cannabinoid Receptors ?, *Pharmaceutics*, 2021, 13, 1823, ,1-35.  
Doi : 10.3390/pharmaceutics13111823
37. FITZGIBBON M., FINN D.P., ROCHE M. : High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity, *International Journal of Neuropsychopharmacology*, 2015, 19, (3) : pyv095.  
Doi : 10.1093/ijnp/pyv095
38. FOWLER C.J. : The potential of inhibitors of endocannabinoid metabolism as anxiolytic and antidepressive drugs—a practical view, *European Neuropsychopharmacology*, 2015, 25, 749–762.
39. FUSAR-POLI et al. : Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing, *Archives General of Psychiatry*, 2009, 66, 1, 95-105.
40. FUSAR-POLI P., ALLEN P., BHATTACHARYYA S., CRIPPA J.A., MECHELLI A., BORGWARDT S., MARTIN-SANTOS R., SEAL M.L., O'CARROL C., ATAKAN Z., ZUARDI A.W., McGUIRE P. : Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol, *International Journal of Neuropsychopharmacology*, 2010, 13, (4), 421-432.  
PMID : 19775500

41. GAETANI S., DIPASQUALE P., ROMANO A., RIGHETTI L., CASSANO T., PIOMELLI D., CUOMO V. : The Endocannabinoid System as a Target for Novel Anxiolytic and Antidepressant Drugs, *International Review of Neurobiology*, 2009, 85, 57-66.  
Doi : 10.1016/S0074-7742(09)85005-8
42. GAMBI F., de BERARDIS D., SEPEDE G., QUARTESAN R., CALCAGNI E., SALERNO R.M., FERRO F.M. : Cannabinoid receptors and their relationships with neuropsychiatric disorders, *International Journal of Immunopathology and Pharmacology*, 2005, 18, 1, 5 p.
43. GATES P.J., ALBERTELLA L., COPELAND J. : The effects of cannabinoid administration on sleep: a systematic review of human studies, *Sleep Medicine Reviews*, 2014, 1e11.  
Doi : 10.1016/j.smrv.2014.02.005
44. GOBBI G. : A role for cannabidiol in psychiatry? Keep calm and follow the drug development rules, Commentary, *The World Journal of Biological Psychiatry*, 2019, Vol. 20, No. 2, 98–100.  
Doi : 10.1080/15622975.2019.1584680
45. GROTHENHERMEN F. : THC can improve symptoms of schizophrenia, *Cannabinoids*, 2008, 4, (4), 1-3.
46. GROTHENHERMEN F., RUSSO E., ZUARDI A.W. : Even High Doses of Oral Cannabidiol Do Not Cause THC-Like Effects in Humans : Comment on Merrick et al., *Cannabis and Cannabinoid Research*, 2016, 1, (1), 102–112, (Doi : 10.1089/can.2015.0004), *Cannabis and Cannabinoid Research*, 2017, 2, (1), 1-4.  
Doi : 10.1089/can.2016.0036
47. GUIDALI C., VIGANO D., PETROSINO S., ZAMBERLETTI E., REALINI N., BINELLI G., RUBINO T., Di MARZO V., PAROLARO D. : Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine, *International Journal of Neuropsychopharmacology*, 2011, 14, 17-28.  
Doi : 10.1017/S1461145710000209
48. HALL W., HOCH E., LORENZETTI V. : Cannabis use and mental health : risks and benefits, *European Archives of Psychiatry and Clinical Neuroscience*, 2019.  
Doi : 10.1007/s00406-019-00986-2
49. HAWLEY P. : A Randomized, double-bind, placebo-controlled, multiple crossover N-of-1 study design of the use of medicinal cannabis oil-based extracts for symptom management in cancer patients, 2019.  
<https://clinicaltrials.gov/ct2/show/NCT03948074?term=cannabis&cond=Anxiety&draw=2>
50. HENRY R.J., KERR D.M., FINN D.P., ROCHE M. : For whom the endocannabinoid tolls : Modulation of innate immune function and implications for psychiatric disorders, *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 2015, 14 p.  
Doi : 10.1016/j.pnpbp.2015.03.006
51. HILL M.N., McLAUGHLIN R.J., BINGHAM B., SHRESTHA L., LEE T.T.Y., GRAY J.M., HILLARD C.J., GORZALKA B.B., VIAU V. : Endogenous cannabinoid signaling is essential for stress adaptation, *PNAS*, 2010, 107, (20), 9406-9411.  
Doi : 10.1073/pnas.0914661107
52. HILL K.P. : Medical marijuana for treatment of chronic pain and other medical and psychiatric problems : A clinical review, *The Journal of the American Medical Association*, 2015, 313, 2474-2483.

53. HOCH E., NIEMANN D., Von KELLER R., SCHNEIDER M., FRIEMEL C.M., PREUSS U.W., HASAN A., POGARELL O. : How effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review, *European Archives of Psychiatry and Clinical Neuroscience*, 2019, 1-19.  
Doi : 10.1007/s00406-019-00984-4
54. HWANG E.-S., KIM H.-B., LEE S., KIM M.-J., KIM K.-J., HAN G., HAN S.-Y., LEE E.-A., YOON J.-H., KIM D.-O., MAENG S., PARK J.-H. : Antidepressant-like effects of  $\beta$ -caryophyllene on restraint plus stress-induced depression, *Behavioural Brain Research*, 2020, 380, 112439.  
Doi : 10.1016/j.bbr.2019.112439
55. IFFLAND K., GROTHENHERMEN F. : An Update on Safety and Side Effects of Cannabidiol : A Review of Clinical Data and Relevant Animal Studies, *Cannabis and Cannabinoid Research*, 2017, 2, (1), 139–154.  
Doi : 10.1089/can.2016.0034
56. INGOLD F-R., SUEUR C., KAPLAN C. : Contribution à une exploration des propriétés thérapeutiques du cannabis, *Annales Médico-psychologiques*, 2015, 173, 5, 453-459.  
Doi : 10.1016/j.amp.2015.04.001
57. INGOLD F-R., KAPLAN C., SUEUR C. : De Cannabis Bono, *Annales Médico-psychologiques*, 2020, 178, 296-302.  
Doi : 10.1016/j.amp.2020.01.018
58. ISHIGURO H., HORIUCH Y., TABATA K., LIU Q.-R., ARINAMI T., ONAIVI E.S. : Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders, *Molecules*, 2018, 23, 1836.  
Doi : 10.3390/molecules23081836
59. KAMAL B.S., KAMAL F., LANTELA D.E. : Cannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, *Frontiers in Neuroscience*, 2018, 12, article 730.  
Doi : 10.3389/fnins.2018.00730
60. KAYSER R.R., SNORRASON I., HANEY M., LEE F.S., SIMPSON H.B. : The Endocannabinoid System : A New Treatment Target for Obsessive Compulsive Disorder ?, *Cannabis and Cannabinoid Research*, 2019, 4, (2).  
Doi : 10.1089/can.2018.0049
61. KHAN R., NAVED S., MIAN N., FIDA A., RAAFEY M.A., AEDMA K.K. : The therapeutic role of Cannabidiol in mental health : a systematic review, *Journal of Cannabis Research*, 2020, 2, 2.  
Doi : 10.1186/s42238-019-0012-y
62. KHOURY J.M., NEVES M.C.L.D., ROQUE M.A.V., QUEIROZ D.A.B., CORRÊA de FREITAS A.A., de FATIMA Â., MOREIRA F.A., GARCIA F.D. : Is there a role for cannabidiol in psychiatry ?, *The World Journal of Biological Psychiatry*, 2019, 20, (2), 101-116.  
Doi : 10.1080/15622975.2017.1285049
63. KOETHE D., GIUFFRIDA A., SCHREIBER D. et al. : Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis, *British Journal of Psychiatry*, 2009, 194, (4), 371-372.
64. KOETHE D., PAHLISCH F., HELLMICH M., ROHLEDER C., MUELLER J.K., MEYER-LINDENBERG A., TORREY E.F., PIOMELLI D., LEWEKE F.M. : Familial abnormalities of endocannabinoid signaling in schizophrenia, *The World Journal of Biological Psychiatry*, 2018.

Doi : 10.1080/15622975.2018.1449966

65. KOSIBA J.D., MAISTO S.A., DITRE J.W. : Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms : Systematic review and meta-analysis, *Social Science & Medicine*, 2019, 233, 181-192.
66. KOZELA E., JUKNAT A., VOGEL Z. : Modulation of Astrocyte Activity by Cannabidiol, a Non-psychoactive Cannabinoid, *International Journal of Molecular Sciences*, 2017, 18, 1669, 20 pp.  
Doi : 10.3390/ijms18081669
67. KROGMANN A., PETERS L., von HARDENBERG L., BÖDEKER K., NÖHLES V.B., CORRELL C.U. : Keeping up with the therapeutic advances in schizophrenia : a review of novel and emerging pharmacological entities, *CNS Spectrums*, 2019, 24, (S1), 38-69.  
Doi : 10.1017/S109285291900124X
68. KROON E., KUHNS L., HOCH E., COUSIJN J. : Heavy cannabis use, dependence and the brain : a clinical perspective, *Addiction*, 2019.  
Doi : 10.1111/add.14776
69. KUCEROVA J., TABIOVA K., DRAGO F., MICALE V. : Therapeutic potential of cannabinoids in schizophrenia, *Recent Patents on CNS Drug Discovery*, 2014, 9, (1), 13-25.  
Doi : 10.2174/1574889809666140307115532
70. LEWEKE F. et al. : Elevated endogenous cannabinoids in schizophrenia, *Neuroreport*, 1999, 10, 1665-1669.
71. LEWEKE F.M., MUELLER J.K., LANGE B., FRITZE S., TOPOR C.E., KOETHE D., ROHLEDER C. : Role of the endocannabinoid System in the Pathophysiology of Schizophrenia : Implications for Pharmacological Intervention, *CNS Drug*, 2018, 32, 7, 605-619.  
Doi : 10.1007/s40263-018-0539-z
72. LISBOA S.F., REIS D.G., LOPES da SILVA A., CORREA F.M.A., GUIMARAES F.S., RESSTEL L.B.M. : Cannabinoid CB1 receptors in the medial prefrontal cortex modulate the expression of contextual fear conditioning, *International Journal of Neuropsychopharmacology*, 2010, 1-11.  
Doi : 10.1017/S1461145710000684
73. MANDOLINI G.M., LAZZARETTI M., PIGONI A., OLDANI L., DELVECCHIO G., BRAMBILLA P. : Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview, *Epidemiology and Psychiatric Sciences*, 2018, 27, 327-335.  
Doi : 10.1017/S2045796018000239
74. MANSEAU M.W., GOFF D.C. : Cannabinoids and Schizophrenia : Risks and Therapeutic Potential, *Neurotherapeutics*, 2015, 12, 816-824.  
Doi : 10.1007/s13311-015-0382-6
75. MARCO E.M., GARCIA-GUTIERREZ M.S., BERMUDEZ-SILVA F.-J., MOREIRA F.A., GUIMARAES F., MANZANARES J., VIVEROS M.-P. : Endocannabinoid system and psychiatry : in search of a neurobiological basis for detrimental and potential therapeutic effects, *Frontiers in Behavioral Neuroscience*, Vol 5, Article 63, 1-23.  
Doi : 10.3389/fnbeh.2011.00063
76. MCPARTLAND J.M., GUY G.W., Di MARZO V. : Care and Feeding of the Endocannabinoid System : A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System, *PLOS One*, 2014, 9, (3), 1-21.  
Doi : 10.1371/journal.pone.0089566

77. MINICHINO A., SENIOR M., BRONDINO N., ZHANG S.H. et al.: Measuring Disturbance of the Endocannabinoid System in Psychosis : A Systematic Review and Meta-analysis, *JAMA Psychiatry*, 2019.  
Doi : 10.1001/jamapsychiatry.2019.0970
78. MOREIRA F.A., AGUIAR D.C., RESSTEL L.B., LISBOA S.F., CAMPOS A.C., GOMES F.V., GUIMARAES F.S.: Neuroanatomical substrates involved in cannabinoid modulation of defensive response, *Journal of Psychopharmacology*, 2012, 26, (1), 40-55.  
Doi : 10.1177/0269881111400651
79. NAHLER G., GROTHENHERMEN F., ZUARDI A.W., CRIPPA J.A.S. : A Conversion of Oral Cannabidiol to Delta9-Tetrahydrocannabinol Seems Not to Occur in Humans, *Cannabis and Cannabinoid Research*, 2017, 2, (1), 81-86.  
Doi : 10.1089/can.2017.0009
80. NAHTIGAL I., BLAKE A., HAND A., FLORENTINUS-MEFAILOSKI A., HASHEMI H., FRIEDBERG J.: The pharmacological properties of cannabis, *Journal of Pain Management*, 2016, 9, (4), 481-491.
81. NAVARRETE F., ARACIL-FERNANDEZ A., MANZANARES J. : Cannabidiol regulates behavioural alterations and gene expression changes induced by spontaneous cannabinoid withdrawal, *British Journal of Pharmacology*, 2018.  
Doi : 10.1111/bph.14226
82. OLLA P., RYKULSKI N., HURTUBISE J.L., BARTOL S., FOOTE R., CUTLER L. : Short-term effects of cannabis consumption on cognitive performance in medical cannabis patients, *Applied Neuropsychology : Adult*, 2020, 1-11.  
Doi : 10.1080/23279095.2019.1681424
83. PANAGIS G., VLACHOU S., NOMIKOS G.G. : Behavioral Pharmacology of Cannabinoids with a Focus on Preclinical Models for Studying Reinforcing and Dependence-Producing Properties, *Current Drug Abuse Reviews*, 2008, 1, 350-374.
84. PANAGIS G., MACKEY B., VLACHOU S. : Cannabinoid regulation of brain reward processing with an emphasis on the role of CB1 receptors : a step back into the future, *Frontiers in Psychiatry*, 2014, Vol. 5, article 92, 1-20.  
Doi : 10.3389/fpsyg.2014.00092
85. PAROLARO D., REALINI N., VIGANO D., GUIDALI C., RUBINO T. : The endocannabinoid system and psychiatric disorders, *Experimental Neurology*, 2010, 224, 3-14.  
Doi : 10.1016/j.expneurol.2010.03.018
86. PATEL S., HILL M.N., CHEER J.F., WOTJACK C.T., HOLMES A. : The endocannabinoid system as a target for novel anxiolytic drugs, *Neuroscience and Biobehavioral Reviews*, 2017, 76, 56-66.  
Doi : 10.1016/j.neubiorev.2016.12.033
87. PELLATI F., BORGONETTI V., BIAGI M., BENVENUTI S., CORSI L. : Cannabis sativa L. and Non-psychoactive Cannabinoids : Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer, *Hindawi, BioMed Research International*, 2018, Vol 2018, Article ID 1691428, 15 pages.  
Doi : 10.1155/2018/1691428
88. PENN A. : Cannabinoids and Mental Health, Part 1 : The Endocannabinoid System and Exogenous Cannabinoids, *Journal of Psychosocial Nursing and Mental Health Services*, 2019, 57, (9), 7-10.  
Doi : 10.3928/02793695-20190813-01

89. PENN A. : Cannabinoids and Mental Health, Part 2 : The Search for Clinical Applications, *Journal of Psychosocial Nursing and Mental Health Services*, 2019, 57, (10), 7-11.  
 Doi : 10.3928/02793695-20190919-02
90. PERES F.F., DIANA M.C., SUIAMA M.A., JUSTI V., ALMEIDA V., BRESSAN R.A., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A., ABILIO V.C. : Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia, *Schizophrenia Research*, 2016, 172, (1-3), 220-221.
91. PERES F.F., DIANA M.C., LEVIN R., SUIAMA M.A., ALMEIDA V., VENDRAMINI A.M., SANTOS C.M., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A., ABILIO V.C. : Cannabidiol Administered During Peri-adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia, *Frontiers in Pharmacology*, 2018, 9, article 901.  
 Doi : 10.3389/fphar.2018.00901
92. PERTWEE R.G. : Targeting the endocannabinoid system with cannabinoid receptor agonists : pharmacological strategies and therapeutic possibilities, *Philosophical Transactions of the Royal Society B*, 2012, 367, 3353-3363.  
 Doi : 10.1098/rstb.2011.0381
93. PETROWSKI K., CONRAD R. : Comparison of cortisol stress response in patients with panic disorders, cannabis-induced panic disorders, and healthy controls, *Psychopathology*, 2019, 52, 26-32.
94. PIOMELLI D. : The molecular logic of endocannabinoid signaling, *Nature Reviews Neuroscience*, 2003, 4, 873-884.
95. PISANTI S., MALFITANO A.M., CIAGLIA E., LAMBERTI A., RANIERI R., CUOMO G., ABATE M., FAGGIANA G., PROTO M.C., FIORE D., LAEZZA C., BIFULCO M. : Cannabidiol : State of the art and new challenges for therapeutic applications, *Pharmacology & Therapeutics*, 2017, 175, 133-150.  
 Doi : 10.1016/j.pharmthera.2017.02.041
96. PREMOLI M., ARIA F., BONINI S.A., MACCARINELLI G., GIANONCELLI A., DELLA PINA S., TAMBARO S., MEMO M., MASTINU A. : Cannabidiol : Recent advances and new insights for neuropsychiatric disorders treatment, *Life Science*, 2019, 224, 120-127.  
 Doi : 10.1016/j.lfs.2019.03.053
97. RUSZNAK K., CSEKÖ K., VARGA Z., CSABAI D., BONA A., MAYER M., KOZMA Z., HELYES Z., CZEH B. : Long-Term Stress and Concomitant Marijuana Smoke Exposure Affect Physiology, Behavior and Adult Hippocampal Neurogenesis, *Frontiers in Pharmacology*, 2018, 9, 786.  
 Doi : 10.3389/fphar.2018.00786. eCollection 2018
98. SARRIS J., SINCLAIR J., KARAMACOSKA D., DAVIDSON M., FIRTH J. : Medicinal cannabis for psychiatric disorders : a clinically-focused systematic review, *BMC Psychiatry*, 2020, 20, 24, 1-14.  
 Doi : 10.1186/s12888-019-2409-8
99. SCHERMA M., MASIA P., DEIDDA M., FRATTA W., TANDA G., FADDA P. : New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders, *Medicines*, 2018, 5, 1071-17.  
 Doi : 10.3390/medicines5040107
100. SCHUBART C.D., SOMMER I.E.C., Van GASTEL W.A., GOETGEBUER R.L., KAHN R.S., BOKS M.P.M. : Cannabis with high cannabidiol content is associated with fewer psychotic experiences, *Schizophrenia Research*, 2011, 130, (1-3), 216-221.

101. SCHUBART C.D., SOMMER I.E., FUSAR-POLI P., de WITTE L., KAHN R.S., BOKS M.P.: Cannabidiol as a potential treatment for psychosis, *European Neuropsychopharmacology*, 2014, 24, (1), 51-64.  
Doi : 10.1016/j.euroneuro.2013.11.002
102. SHALLCROSS J., HAMOR P., BECHARD A.R., ROMANO M., KNACKSTEDT L., SCHWENDT M.: The Divergent Effects of CDPPB and Cannabidiol on Fear Extinction and Anxiety in a Predator Scent Stress Model of PTSD in Rats, *Frontiers in Behavioral Neuroscience*, 2019, Vol 13, Article 91.  
Doi : 10.3389/fnbeh.2019.00091
103. SIDHPURA N., PARSONS L.H.: Endocannabinoid-mediated synaptic plasticity and addiction-related behavior, *Neuropharmacology*, 2011, 61, (7), 1070-1087  
Doi : 10.1016/j.neuropharm.2011.05.034
104. SLOAN M.E., GRANT C.W., GOWIN J.L., RAMCHANDANI V.A., Le FOLL B.: Endocannabinoid signaling in psychiatric disorders : a review of positron emission tomography studies, *Acta Pharmacologica Sinica*, 2018, 1-9.  
Doi : 10.1038/s41401-018-0081-z
105. SOLOWIJ N., BROUD S.J., BEALE C. et al : Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis users : A Pragmatic Open-Label Clinical Trial, *Cannabis and Cannabinoid Research*, 2018, 3.1, 21-34.  
Doi : 10.1089/can.2017.0043
106. SONEGO A.B., GOMES F.V., Del BEL E.A., GUIMARAES F.S. : Cannabidiol attenuates haloperidol-induced catalepsy and c-Fos protein expression in the dorsolateral striatum via 5-HT1A receptors in mice, *Behavioural Brain Research*, 2016. doi : 10.1016/j.bbr.2016.04.042
107. SUMANASEKERA W.K., SPIO K. : Cannabis (Marijuana) : Psychoactive Properties, Addiction, Therapeutic Uses, and Toxicity, *Journal of Addictive Behaviors, Therapy & Rehabilitation*, 2016, 5, 2, 1-9.  
Doi : 10.4172/2324-9005.1000156
108. SUNDRAM S., DEAN B., COPOLOV D. : The endogenous cannabinoid system in schizophrenia, in "Marijuana and Madness : Psychiatry and Neurobiology", ed. D. Castle and R. Murray, Cambridge University Press, 2004, 127-141.
109. TURNA J., PATTERSON B., van AMERINGEN M. : Is cannabis treatment for anxiety, mood, and related disorders ready for prime time ?, *DepressAnxiety*, 2017, 1-12.  
Doi : 10.1002/da.22664
110. VANN R.E., GAMAGE T.F., WARNER J.A. et al. : Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Δ<sup>9</sup>-tetrahydrocannabinol, *Drug and Alcohol Dependence*, 2008.  
Doi : 10.1016/j.drugalcdep.2007.11.017
111. VIGANO D., GUIDALI C., PETROSINO S., REALINI N., RUBINO T., Di MARZO V., PAROLARO D. : Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia, *International Journal of Neuropsychopharmacology*, 2009, 12, 599-614.  
Doi : 10.1017/S1461145708009371
112. VITAL R.M., IANNOTTI F.A., AMODEO P. : The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders : Molecular

- Mechanisms and targets, *International Journal of Molecular Sciences*, 2021, 22, 4876, 1-20.  
 Doi : 10.3390/ijms22094876
113. VLACHOU S., NOMIKOS G.G., PANAGIS G. : Effects of endocannabinoid neurotransmission modulators on brain stimulation reward, *Psychopharmacology*, 2006, 188, 293-305.  
 Doi : 10.1007/s00213-006-0506-0
114. VLACHOU S., PANAGIS G. : Regulation of Brain Reward by the Endocannabinoid System : A Critical Review of Behavioral Studies in Animals, *Current Pharmaceutical Designs*, 2014, 201-17.
115. VOLK D.W., LEWIS D.A. : The Role of Endocannabinoid Signaling in Cortical Inhibitory Neuron Dysfunction in Schizophrenia, *Biological Psychiatry*, 2016, 79, 595-603.  
 Doi : 10.1016/j.biopsych.2015.06.015
116. VOLK D.W., LEWIS D.A. : Insights Into the Pathophysiology of Endocannabinoid Signaling in Schizophrenia, *JAMA Psychiatry*, 2019, 76, (9), 887-888.  
 Doi : 10.1001/jamapsychiatry.2019.0844
117. VOLKOW N.D. : The biology and potential therapeutic effects of cannabidiol, *National Institute on Drug Abuse, Senate Caucus on International Narcotics Control*, June 24, 2015.
118. WALSH Z., GONZALES R., CROSBY K., THIESSEN M.S., CARROLL C., BONN-MILLER M.O. : Medical cannabis and mental health : A guided systematic review, *Clinical Psychology Review*, 2017, 51, 15-29.  
 Doi : 10.1016/j.cpr.2016.10.002
119. WHITE C.M. : A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential, *The Journal of Clinical Pharmacology*, 2019, 59, (7), 923-934.  
 Doi : 10.1002/jcph.1387
120. WILKINSON S.T., RADHAKRISHNAN R., D'SOUZA D.C. : A Systematic Review of the evidence for Medical Marijuana in Psychiatric Indications, *Journal of Clinical Psychiatry*, 2016, 77, (8), 1050-1064  
 Doi : 10.4088/JCP.15r10036
121. WRIGHT M.J., VANDERWATER S.A., TAFFE M.A. : Cannabidiol attenuates deficits of visuospatial associative memory induced by Δ9-Tetrahydrocannabinol, *British Journal of Pharmacology*, 2013, 170, 1365-1373.  
 Doi : 10.1111/bph.12199
122. ZAYTSEVA Y., HORACEK J., HLINKA J., FAJNEROVA I., ANDROVICOVA R., TINTERA J., SALVI V., BALIKOVA M., HLOZEK T., SPANIEL F., PALENICEK T. : Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states, *Journal of Psychopharmacology*, 2019, 33, (7), 811-821.  
 Doi : 10.1177/0269881119849814
123. ZLEBNIK N., CHEER J.F. : Drug-Induced Alterations of Endocannabinoid-Mediated Plasticity in Brain Reward Regions, *The Journal of Neuroscience*, 2016, 36, (40), 10230-10238.  
 Doi : 10.1523/JNEUROSCI.1712-16.2016

124. ZLEBNIK N., CHEER J.F. : Beyond the CB1 Receptor : Is Cannabidiol the Answer for Disorders of motivation ?, *Annuel Review of Neuroscience*, 2016, 39, 1-17.  
Doi : 10.1146/annurev-neuro-070815-014038
125. ZUARDI A.W., GUIMARÃES F.S. : Cannabidiol as an anxiolytic and antipsychotic, in *Mathre ML (Editor), Cannabis in Medical Practice.*, McFarland & Company, Inc., Jefferson, NC, USA, 1997, 133-141.
126. ZUARDI A.W. : Cannabidiol : From an inactive cannabinoid to a drug with wide spectrum of action, *Revista Brasileira Psiquiatrica*, 2008, 30, 271-280.
127. ZUARDI A.W., CRIPPA J.A.S., HALLAK J.E.C., PINTO J.P., CHAGAS M.H.N., RODRIGUES G.G.R. et al. : Cannabidiol for the treatment of psychosis in Parkinson's disease, *Journal of Psychopharmacology*, 2009, 23, 8, 979-983.

CANNABIDIOL (CBD) , Pre-Review Report , Agenda Item 5.2  
Expert Committee on Drug Dependence, Thirty-ninth Meeting ,  
Geneva, 6-10 November 2017

[https://www.who.int/medicines/access/controlled-substances/5.2\\_CBD.pdf](https://www.who.int/medicines/access/controlled-substances/5.2_CBD.pdf)

Expert Committee on Drug Dependence, World Health Organization : Cannabidiol (CBD), Critical Review Report, Fortieth Meeting, Geneva, 4-7 June 2018.

<https://who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf>

## Cannabinoïdes et anxiété

1. CRIPPA J.A., ZUARDI A.W., MARTIN-SANTOS R., BHATTACHARYYA S., ATAKAN Z., McGUIRE P., FUSAR-POLI P. : Cannabis and anxiety : a critical review of the evidence, *Human Psychopharmacology*, 2009, 24, 515-523.  
Doi : 10.1002/hup.1048
1. CUTTLER C., SPRADLIN A., NUSBAUM A.T., WHITNEY P., HINSON J.M., McLAUGHLIN R.J. : Blunted stress reactivity in chronic cannabis users, *Psychopharmacology (Berl)*, 2017.  
Doi : 10.1007/s00213-017-4648-z
2. FABRE L.F., McLENDON D. : The Efficacy and Safety of Nabilone (A Synthetic Cannabinoid) in the Treatment of Anxiety, *Journal of Clinical Pharmacology*, 1981.  
Doi : 10.1002/j.1552-4604.1981.tb02617.x
3. KAMAL B.S., KAMAL F., LANTELA D.E. : Cannabis and the Anxiety of Fragmentation - A Systems Approach for Finding an Anxiolytic Cannabis Chemotype, *Frontiers in Neuroscience*, 2018, 12, article 730.  
Doi : 10.3389/fnins.2018.00730
4. KOSIBA J.D., MAISTO S.A., DITRE J.W. : Patient-reported use of medical cannabis for pain, anxiety, and depression symptoms : Systematic review and meta-analysis, *Social Science & Medicine*, 2019, 233, 181-192.
5. MUSTY R.E. : Cannabinoids and anxiety, *Cannabinoids as Therapeutics*, Edited by R. Mechoulam, 2005, Birkhäuser Verlag/Switzerland, 141-147.
6. PAPAGIANNI E.P., STEVENSON C.W. : Cannabinoid regulation of fear and anxiety : An update, *Current Psychiatry Reports*, 2019, 21, 38, 1-10.  
Doi : 10.1007/s11920-019-1026-z
7. PATEL S., HILLARD C.J. : Role of Endocannabinoid Signaling in Anxiety and Depression, *Current Topics in Behavioral Neurosciences* (book series CTBN, volume 1), 2009, 2013, 347-371.
8. PETROWSKI K., CONRAD R. : Comparison of cortisol stress response in patients with panic disorders, cannabis-induced panic disorders, and healthy controls, *Psychopathology*, 2019, 52, 26-32.
9. SAITO V.M., MOREIRA F.A. : Cannabinoids, anxiety, and the periaqueductal gray, *Psychology and Neuroscience*, 2010, 3, 1, 39-42.  
Doi : 10.3922/j.psns.2010.1.004
10. TAMBARO S., BORTOLATO M. : Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives, *Recent Patents on CNS Drug Discovery*, 2012, 7, (1), 25-40.
11. TURNA J., PATTERSON B., van AMERINGEN M. : Is cannabis treatment for anxiety, mood, and related disorders ready for prime time ?, *DepressAnxiety*, 2017, 1-12.  
Doi : 10.1002/da.22664
12. Van AMERINGEN M., ZHANG J., PATTERSON B., TURNA J. : The Role of Cannabis in Treating Anxiety : An Update, Medscape, *Current Opinion in Psychiatry*, 2019, 33, (1), 1-7.  
[www.medscape.com/viewarticle/9222111\\_print](http://www.medscape.com/viewarticle/9222111_print)

## Cannabidiol anxiolytique

1. ALMEIDA V., LEVIN R., PERES F.F., NIIGAKI S.T., CALZAVARA M.B., ZUARDI A.W., HALLAK J.E., CRIPPA J.A., ABILIO V.C. : Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2013, 41, 30-35.  
Doi : 10.1016/j.pnpbp.2012.10.024
2. BERGAMASCHI M.M., QUEIROZ R.H.C., CHAGAS M.H.N. et al. : Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients, *Neuropsychopharmacology*, 2011, 36, 1219-1226.  
Doi : 10.1038/npp.2011.6
3. BLESSING E.M., STEENKAMP M.M., MANZANARES J., MARMAR C.R. : Cannabidiol as a Potential Treatment for Anxiety Disorders, *Neurotherapeutics*, 2015, 12, 4, 825-836.  
Doi : 10.1007/s13311-015-0387-1
4. CAMPOS A.C., FERREIRA F.R., GUIMARÃES F.S. : Cannabidiol blocks long-lasting behavioral consequences of predator threat stress : possible involvement of 5HT1A receptors, *Journal of Psychiatric Research*, 2012, 46, (11), 1501-1510.  
Doi : 10.1016/j.jpsychires.2012.08.012
5. CAMPOS A.C., ORTEGA Z., PALAZUELOS J. et al. : The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis : Involvement of the endocannabinoid system, *International Journal of Neuropsychopharmacology*, 2013, 16: 1407-1419.
6. CRIPPA J.A., ZUARDI A.W., GARRIDO G.E., WICHERT-ANA L., GUARNIERI R., FERRARI L., AZEVEDO-MARQUES P.M., HALLAK J.E. ? McGuire P.K., FILHO BUSSATO G. : Effects of cannabidiol (CBD) on regional cerebral blood flow, *Neuropharmacology*, 2004, 29, (2), 417-426.
7. CRIPPA J.A., ZUARDI A.W., MARTIN-SANTOS R., BHATTACHARYYA S., ATAKAN Z., McGuire P., FUSAR-POLI P. : Cannabis and anxiety : a critical review of the evidence, *Human Psychopharmacology*, 2009, 24, (7), 515-523.  
Doi : 10.1002/hup.1048
8. CRIPPA J.A., DERENUSSON G.N., FERRARI T.B., WICHERT-ANA L., DURAN F.L., MARTIN-SANTOS R., SIMOES M.V., BHATTACHARYYA S., FUSAR-POLI P., ATAKAN Z., SANTOS FILHO A., FREITAS-FERRARI M.C., McGuire P.K., ZUARDI A.W., BUSATTO G.F., HALLAK J.E. : Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder : a preliminary report, *Journal of Psychopharmacology*, 2011, 25, (1), 121-130.  
Doi : 10.1177/0269881110379283
9. DAS R.K., KAMBOJ S.K., RAMADAS M., YOGAN K., GUPTA V., REDMAN E., CURRAN H.V., MORGAN C.J.A. : Cannabidiol enhances consolidation of explicit fear extinction in humans, *Psychopharmacology*, 2013, 226, 781-792.
10. DEGROOT A. : Role of Cannabinoid Receptors in Anxiety Disorders, chapter 24, A. KÖFALVI (ed ;), « *Cannabinoids and the Brain* », Springer 2008, 559-557.
11. FOGAÇA, M.V., REIS, F.M., CAMPOS, A.C., GUIMARÃES, F.S. : Effects of intra-prelimbic prefrontal cortex injection of cannabidiol on anxiety-like behavior: involvement of 5HT1A receptors and previous stressful experience, *European Neuropsychopharmacology*, 2014, 24, 410-419.

12. FOGAÇA M.V., CAMPOS A.C., COELHO L.D., DUMANR.S., GUIMARAES F.S. : The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling, *Neuropharmacology*, 2018, 135, 22-23.  
Doi : 10.1016/j.neuropharm.2018.03.001
13. FORESTOR B.P. : Open-label trial of a cannabidiol solution for the treatment of behavioral symptoms in older adults with Alzheimer's Dementia, 2019.  
[https://clinicaltrial.gov/ct2/show/NCT04075435?term=CBD&cond=Anxiety&dr\\_aw=2rank=5](https://clinicaltrial.gov/ct2/show/NCT04075435?term=CBD&cond=Anxiety&dr_aw=2rank=5)
14. GALLILY R., YEKHTIN Z., HANUS L.O. : Overcoming the Bell-Shaped Dose-Response of cannabidiol by Using Cannabis Extract Enriched in Cannabidiol, *Pharmacology & Pharmacy*, 2015, 6, 75-85.  
Doi : 10.4236/pp.2015.62010
15. GOBBI G. : A role for cannabidiol in Psychiatry ? Keep calm and follow the drug development rules, *The World Journal of Biological Psychiatry*, 2019, 20, (2), 98-100.  
Doi : 10.1080/15622975.2019.1584680
16. GUIMARAES F.S., CHIARETTI T.M., GRAEFF F.G., ZUARDI A.W. : Antianxiety effect of cannabidiol in the elevated plus-maze, *Psychopharmacology*, 1990, 100, 558-559.
17. JURKUS R., DAY H.L.L., GUIMARÃES F.S., LEE J.L.C., BERTOGLIO L.J., STEVENSON C.W. : Frontiers in Pharmacology, 2016, Vol 7, Article 454.  
Doi : 10.3389/fphar.2016.00454
18. KHOURY J.M., NEVES M.C.L.D., ROQUE M.A.V., QUEIROZ D.A.B., CORRÊA de FREITAS A.A., de FATIMA Â., MOREIRA F.A., GARCIA F.D. : Is there a role for cannabidiol in psychiatry ?, *The World Journal of Biological Psychiatry*, 2019, 20, (2), 101-116.  
Doi : 10.1080/15622975.2017.1285049
19. LEE J.L.C., BERTOGLIO L.J., GUIMARÃES F.S. et al. : Cannabidiol regulation of emotion and emotional memory processing : Relevance for treating anxiety-related and substance abuse disorders, *British Journal of Pharmacology*, 2017, 174: 3242-3256.  
DOI : 10.1111/BPH.13724
20. LINARES I.M., ZUARDI A.W., PEREIRA L.C., QUEIROZ R.H., MECHOULAM R., GUIMARAES F.S., CRIPPA J.A. : Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test, *Brazilian Journal of Psychiatry*, 2018, 6 p.  
Doi : 10.1590/1516-4446-2017-0015
21. MECHOULAM R., PARKER L.A., GALLILY R. : Cannabidiol : an overview of some pharmacological aspects, *Journal of Clinical Pharmacology*, 2002, 42, 11S-19S.
22. MOREIRA F.A., AGUIAR D.C., GUIMARÃES F.S. : Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test, *Progress in Neuro-psychopharmacol & Biological Psychiatry*, 2006, 30, 8, 1466-1471.  
Doi : 10.1016/j.pnpbp.2006.06.004
23. MORGAN C.J. et al. : Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis : naturalistic study, *British Journal of Psychiatry*, 2010, 197, 285-290.
24. MURRILLO-RODRIGUEZ E. ? LILLAN-ALDACO D., PALOMERO-RIVERO M., MECHOULAM R., DRUCKER-COLIN R. : Cannabidiol, a constituent of Cannabis

- sativa, modulates sleep in rats, *FEBS Letters (Federation of European Biochemical Societies)*, 2006, 580, 4337-4345.
25. SCHIER A.R. de MELLO, RIBEIRO N.P., SILVA A.C., HALLAK J.E., CRIPPA J.A., NARDI A.E., ZUARDI A.W. : Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug, *Brazilian Journal of Psychiatry (Revista Brasileira de Psiquiatria)*, 2012, 34, suppl 1, 104-117.
26. SCHLEICHER E.M., OTT F.W., MÜLLER M. et al. : Prolonged cannabidiol treatment lacks on detrimental effects on memory, motor performance and anxiety in C57BL/6J mice, *Frontiers in Behavioral Neuroscience*, 2019, 13, 94.  
Doi : 10.3389/fnbeh.2019.00094
27. SHANNON S., OPILA-LEHMAN J. : Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder : A Case Report, *The Permanent Journal*, 2016, 20, 4, 108-111.
28. SHANNON S. : Cannabidiol in the Treatment of Anxiety : A Large Case Series, Präsentiert am 21 April 2017 bei der *Psychodelic Science 2017, 19-24 April 2017*, San Francisco, USA.
29. SHANNON S., LEWIS N., LEE H., HUGHES S. : Cannabidiol in Anxiety and Sleep: A Large Case Series, *The Permanente Journal*, 2019, 23, 18-041. Doi : 10.7812/TPP/18-041
30. SOARES V.P., CAMPOS A.C. : Evidences for the Anti-panic Actions of Cannabidiol, *Current Neuropharmacology*, 2017, 15, 291-299  
Doi : 10.2174/ 1570159X14666160509123955
31. SOLOWIJ N., BROYD S.J., BEALE C. et al: Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis users : A Pragmatic Open-Label Clinical Trial, *Cannabis and Cannabinoid Research*, 2018, 3.1, 21-34.
32. VOLKOW N.D. : The biology and potential therapeutic effects of cannabidiol, *National Institute on Drug Abuse, Senate Caucus on International Narcotics Control*, June 24, 2015.
33. WHITE C.M. : A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential, *The Journal of Clinical Pharmacology*, 2019, 59, (7), 923-934.  
Doi : 10.1002/jcph.1387
34. WRIGHT M., Di CIANO P., BRANDS B. : Use of Cannabidiol for the Treatment of Anxiety: A Short Synthesis of Pre-Clinical and Clinical Evidence, *Cannabis and Cannabinoid research*, 2020.  
Doi 10.1089/can.2019.0052
35. ZUARDI A.W., SHIRAKAWA I., FINKELFARB E., KARNIOL I.G. : Action of cannabidiol on the anxiety and other effects produced by  $\delta^9$ -THC in normal subjects, *Psychopharmacology (Berl)*, 1982, 76, 3, 245-250.
36. ZUARDI A.W., RODRIGUES N.P., SILVA A.L., BERNARDO S.A., HALLAK J.E.C., GUIMARAES F.S., CRIPPA J.A.S. : Inverted U-Shape Dose-Reponse Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life, *Frontiers in Pharmacology*, 2017.  
Doi : 10.3389/fphar.2017.00269
37. ZUARDI A.W., de SOUZA CRIPPA J.A., HALLACK J.A. et al. : The Anxiolytic Effects of Cannabidiol (CBD), December 2017.

## Cannabidiol antipsychotique

1. BATALLA A., JANSEN H., GANGADIN S.S., BOSSONG M.G. : The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, *Journal of Clinical Medicine*, 2019, 8, 1058.  
Doi : 10.3390/jcm8071058
2. BHATTACHARYYA S., MORRISON P.D., FUSAR-POLI P., MARTIN-SANTOS R., BORGWARDT S., WINTON-BROWN T., NOSARTI C., O'CARROLL C.M., SEAL M., ALLEN P., MEHTA M.A., STO ?NE J.M., TUNSTALL N., GIAMPIETRO V., KAPUR S., MURRAY R.M., ZUARDI A.W., CRIPPA J.A., ATAKAN Z., McGUIRE P.K. : Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology, *Neuropsychopharmacology*, 2010, 35, (3), 764-774.  
Doi : 10.1038/npp.2009.184
3. BHATTACHARYYA S., WILSON R., APPIAH-KUSI E., O'NEILL A., BRAMMER M., PEREZ J., MURRAY R., ALLEN P., BOSSONG M.G., McGUIRE P. : Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis : A Randomized Clinical Trial, *JAMA Psychiatry*, 2018.  
Doi : 10.1001/jamapsychiatry.2018.2309
4. BOGGS D.L., NGUYEN J.D., MORGENSEN D., TAFFE M.A., RANGANATHAN M. : Clinical and Preclinical Evidence for functional Interactions of Cannabidiol and delta-9-Tetrahydrocannabinol, *Neuropsychopharmacology*, 2018, 43, (1), 142-154.  
Doi : 10.1038/npp.2017.209
5. BOGGS D.L., SURTI T., GUPTA A., GUPTA S., NICIU M., PITTMAN B., SCHNAKENBERG MARTIN A.M., THURNAUER H., DAVIES A., D'SOUZA D.C., RANGANATHAN M. : The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial, *Psychopharmacology*, 2018.  
Doi : 10.1007/s00213-018-4885-9
6. BORGAN F. et al. : In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis, *JAMA Psychiatry*, 2019.  
Doi : 10.1001/jamapsychiatry.2019.1427
7. CALAPAI G., MANNUCCI C., CHINOU I., CARDIA L., CALAPAI F., SORBARA E.E., FIRENZUOLI B., RICCA V., GENESINI G.-F., FIRENZUOLI F. : Preclinical and Clinical Evidence Supporting Use of Cannabidiol in Psychiatry, *Hindawi - Evidence-Based Complementary and Alternative Medicine*, 2019, Article ID 2509129, 11 pages.  
Doi : 10.1155/2019/2509129
8. CAMPOS A.C., MOREIRA F.A., GOMES F.V., Del BEL E.A., GUIMARAES F.S. : Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders, *Philosophical Transactions of the Royal Society*, 2012, 367, 3364-3378.  
Doi : 10.1098/rstb.2011.0389
9. COLLIZI M., BHATTACHARYYA S. : Does Cannabis Composition Matter ? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition, *Current Addiction Reports*, 2017, 4, (2), 62-74  
Doi : 10.1007/s40429-017-0142-2
10. CRIPPA J.A., HALLAK J.E., ABILIO V.C., de LACERDA A.L., ZUARDI A.W. : Cannabidiol and Sodium Nitroprusside : Two Novel Neuromodulatory Pharmacological Interventions to Treat and Prevent Psychosis, *CNS and Neurological Disorders -*

*Drug Targets*, 2015, 14, 8, 970-978. Doi : 10.2174/18715273146661500909113930

11. DAVIES C., BHATTACHARYYA S.: Cannabidiol as a potential treatment for psychosis, *Therapeutic Advances in Psychopharmacology*, 2019, Vol. 9, 1-16.  
Doi : 10.1177/2045125319881916
12. ELSAID S., KLOIBER S., Le FOLL B.: Effects of cannabidiol (CBD) in neuropsychiatric disorders : A review of preclinical and clinical findings, *Progress in Molecular Biology and Translational Science*, 2019, 167, 25-75.  
Doi : 10.1016/bs.pmbts.2019.06.005
13. ENGLUND A., MORRISON P.D., NOTTAGE J., HAQUE D., KANE F., BONACCORSO S., STONE J.M., REICHENBERG A., BRENNER R., HOLT D., FEILDING A., WALKER L., MURRAY R.M., KAPUR S. : Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment, *Journal of Psychopharmacology*, 2013, 27, (1), 19-27.  
Doi : 10.1177/0269881112460109
14. FAKHOURY M. : Could cannabidiol be used as an alternative to antipsychotics ?, *Journal of Psychiatric Research*, 2016, 80, 14-21.
15. FAKHOURY M. : Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia, *Molecular Neurobiology*, 2017, 54, (1), 768-778.  
Doi : 10.1007/s12035-016-9697-5
16. FUSAR-POLI P., CRIPPA J., BHATTACHARYYA S. et al. : Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing, *Archives of General Psychiatry*, 2009, 66, (1), 95-105.  
Doi : 10.1001/archgenpsychiatry.2008.519
17. GOMES F.V., LLORENTE R., Del BEL E.A., VIVEROS M.P., LOPEZ-GALLARDO M., GUIMARAES F.S. : Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol, *Schizophrenia Research*, 2015, 164, (1-3), 155-163.  
Doi : 10.1016/j.schres.2015.01.015
18. GUIDALI C., VIGANÒ D., PETROSINO S., ZAMBERLETTI E., REALINI N., BINELLI G., RUBINO T., Di MARZO V., PAROLARO D. : Cannabinoid CB1 receptor antagonism prevents neurochemical and behavioural deficits induced by chronic phencyclidine, *International Journal of Neuropsychopharmacology*, 2011, 14, 17-28.
19. GUINGUIS R., RUIZ M.I., RADA G. : Is cannabidiol an effective treatment for schizophrenia ?, *Medwave*, 2017, 17, 7, e7010  
Doi : 10.5867/medwave.2017.07.7010
20. GURURAJAN A., TAYLOR D.A., MALONE D.T. : Effects of cannabidiol in a MK-801-rodent model of aspects of schizophrenia, *Behavioral Brain Research*, 2011, 222, (2), 299-308.  
Doi : 10.1016/j.bbr.2011.03.053
21. GURURAJAN A., MALONE D.T. : Does Cannabidiol have a role in the treatment of schizophrenia ? *Schizophrenia Research*, 2016, 176, (2-3), 281-290.
22. HAHN B. : The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis, *Schizophrenia Bulletin*, 2018, 44, 1, 46-53.  
[www.medscape.com/viewarticle/893134\\_print](http://www.medscape.com/viewarticle/893134_print)
23. HALLAK J.E., MACHADO de SOUSA J.P., CRIPPA J.A., SANCHES R.F., TRZESNIAK C., BERNARDO S.A., REGALO S.C., ZUARDI A.W. : Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after

- acute administration of cannabidiol (CBD), *Revista Brasileira de Psiquiatria*, 2010, 32, (1), 56-61.  
 PMID : 20339735
24. ISEGER T.A., BOSSONG M.G. : A systematic review of the antipsychotic properties of cannabidiol in humans, *Schizophrenia Research*, 2015, 162, (1-3), 153-161.  
 Doi : 10.1016/j.schres.2015.01.033
25. KLOFT L. : Review : The Efficacy of Cannabidiol (CBD) as Potential Antipsychotic Medication, *Maastricht Student Journal of Psychology and Neuroscience*, 2017, 6, 1, 118-132.
26. KHOURY J.M., NEVES M.C.L.D., ROQUE M.A.V., QUEIROZ D.A.B., CORRÊA de FREITAS A.A., de FATIMA Â., MOREIRA F.A., GARCIA F.D. : Is there a role for cannabidiol in psychiatry ?, *The World Journal of Biological Psychiatry*, 2019, 20, (2), 101-116.  
 Doi : 10.1080/15622975.2017.1285049
27. KÖCK P., LANG E., TRULLEY V.-N., DECENT F., MERCER-CHALMERS-BENDER K., FREI P., HUBER C., BORGWARDT S. : Cannabidiol Cigarettes as Adjunctive Treatment for Psychotic Disorders – A Randomized, Open-Label Pilot-Study, *Frontiers in Psychiatry*, 2021, 12, art 736822, 1-11.  
 Doi : 10.3389/fpsyg.2021.736822
28. KÖFALVI A., FRITZSCHE M. : The Endocannabinoid System is a Major Player in Schizophrenia, chapter 22, A. KÖFALVI (ed ;), « *Cannabinoids and the Brain* », Springer 2008, 485-528.
29. KOZELA E., KRAWCZYK M., KOS T., JUKNAT A., VOGEL Z., POPIK P. : Cannabidiol Improves Cognitive Impairment and Reverses Cortical Transcriptional Changes Induced by Ketamine, in Schizophrenia-Like Model in Rats, *Molecular Neurobiology*, 2019, 15 p.  
 Doi : 10.1007/s12035-019-018331-2
30. LEVIN R., PERES F.F., ALMEIDA V., CALZAVARA M.B., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A.S., ABILIO V.C. : Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia : the SHR strain, *Frontiers in Pharmacology*, 2014, 5, article 10.  
 Doi : 10.3389/fphar.2014.00010
31. LEWEKE F.M., SCHNEIDER U., RADWAN M., SCHMIDT E., EMRICH H.M. : Different effects of Nabilone and cannabidiol on binocular depth inversion in man, *Pharmacology, Biochemistry and Behavior*, 2000, 66, 1, 175-181.
32. LEWEKE F.M., KOETHE D., PAHLISCH F. et al. : Antipsychotic effects of cannabidiol, *European Psychiatry*, 2009, 24, suppl 1, 207,
33. LEWEKE F.M., PIOMELLI D., PAHLISCH F., MUHL D., GERTH C.W., HOYER C., KLOSTERKÖTTER J., HELLMICH M., KOETHE D. : Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, *Translational Psychiatry*, 2012, 2, e94.  
 Doi : 10.1038/tp.2012.15
34. LEWEKE F.M., MUELLER J.K., LANGE B., ROHLEDER C. : Therapeutic potential of cannabinoids in psychosis, *Biological Psychiatry*, 2016, 79, 7, 604-612.  
 Doi : 10.1016/j.biopsych.2015.11.018
35. LEWEKE F.M., KOETHE D., GERTH C.W., NOLDEN B.M. et al. : Cannabidiol as an antipsychotic : a double-blind, controlled clinical trial of cannabidiol versus amisulpride in acute schizophrenia, *15th Annual Symposium on Cannabinoids*, Clearwater, Florida, Cannabinoid Research Society.

36. LEWEKE F.M., MUELLER J.K., LANGE B., FRITZE S., TOPOR C.E., KOETHE D., ROHLEDER C. : Role of the endocannabinoid System in the Pathophysiology of Schizophrenia : Implications for Pharmacological Intervention, *CNS Drug*, 2018, 32, 7, 605–619.  
Doi : 10.1007/s40263-018-0539-z
37. LONG L.E., MALONE D.T., TAYLOR D.A. : Cannabidiol Reverses MK-801-Induced Disruption of Prepulse Inhibition in Mice, *Neuropsychopharmacology*, 2006, 31, 795-803.
38. MANDOLINI G.M., LAZZARETTI M., PIGONI A., OLDANI L., DELVECCHIO G., BRAMBILLA P. : Pharmacological properties of cannabidiol in the treatment of psychiatric disorders : a critical overview, *Epidemiology and Psychiatric Sciences*, 2018, 27, (4) 327-335.  
Doi : 10.1017/S2045796018000239
39. McGUIRE P., ROBSON P., CUBALA W.J., VASILE D., MORRISON P.D., BARRON R., TAYLOR A., WRIGHT S. : Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia : A Multicenter Randomized Controlled Trial, *American Journal of Psychiatry*, 2018, 175, 3, 225-231.  
Doi : 10.1176/appi.ajp.2017.17030325
40. McLOUGHLIN B.C., PUSHPA-RAJAH J.A., GILLIES D., RATHBONE J., VARIEND H., KALAKOUTI E., KYPRIANOU K. : Cannabis and schizophrenia (Review), *The Cochrane Collaboration, Published by John Wiley & Sons, Ltd*, 2014, 10, Art n° CD004837  
Doi : 10.1002/14651858.CD004837.pub3
41. MECHOULAM R., PARKER L.A., GALLILY R. : Cannabidiol : an overview of some pharmaceutical aspects, *Journal of Clinical Pharmacology*, 2002, 42, (11 suppl), 11S-19S.
42. MECHOULAM R., PETERS M., MURILLO-RODRIGUEZ E., HANUS L.O. : Cannabidiol – Recent Advances, *Chemistry & Biodiversity*, 2007, 4, 8, 1678-1692.  
Doi : 10.1002/cbdv.200790147
43. MILLAR S.A., STONE N.L., YATES A.S., O'SULLIVAN S.E. : A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans, *Frontiers in Pharmacology*, 26 November 2018  
Doi : 10.3389/fphar.2018.01365
44. MORGAN C.J., CURRAN H.V. : Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis, *British Journal of Psychiatry*, 2008, 192, (4), 306-307.  
Doi : 10.1192/bjp.bp.107.046649
45. O'NEILL A., WILSON R., BLEST-HOPLEY G., ANNIBALE L., BHATTACHARYYA S. et al. : Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis, *Psychological Medicine*, 2020.  
Doi : 10.1017/S0033291719003519
46. OSBORN A.L., SOLOWIJ N., BABIC I., HUANG X.F., WESTON-GREEN K. : Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (Poly I:C) Rat Model, *Neuropsycho-pharmacology*, 2017, 42, (7), 1447-1457.
47. OSBORN A.L., SOLOWIJ N., WESTON-GREEN K. : A systematic review of the effect of cannabidiol on cognitive function : relevance to schizophrenia, *Neuroscience & Behavioral Reviews*, 2017, 72, 310-324.

Doi : 10.1016/j.neubiorev.2016.11.012

48. PARKER L.A., BURTON P., SORGE R.E., YAKIWCHUK C., MECHOULAM R. : Effect of low doses of Delta-9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats, *Psychopharmacology (Berl)*, 2004, 175, 3, 360-366  
Doi : 10.1007/s00213-004-1825-7
49. PERES F.F., DIANA M.C., SUIAMA M.A., JUSTI V., ALMEIDA V., BRESSAN R.A., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A., ABILIO V.C. : Peripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia, *Schizophrenia Research*, 2016, 172, (1-3), 220-221.
50. PERES F.F., DIANA M.C., LEVIN R., SUIAMA M.A., ALMEIDA V., VENDRAMINI A.M., SANTOS C.M., ZUARDI A.W., HALLAK J.E.C., CRIPPA J.A., ABILIO V.C. : Cannabidiol Administered During Peri-adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia, *Frontiers in Pharmacology*, 2018, 9, article 901.  
Doi : 10.3389/fphar.2018.00901
51. ROBSON P. : Therapeutic aspects of cannabis and cannabinoids, *British Journal of Psychiatry*, 2001, 178, 107-115.
52. ROBSON P.J., GUY G.W. : Metabolic abnormalities, abnormal stress response and chronic inflammation in schizophrenia - Potential Targets for Cannabinoid Medicine, *IACM Conference*, 2009.
53. ROHLEDER C., MÜLLER J.K., LANGE B., LEWEKE F.M. : Cannabidiol as a Potential New Type of an Antipsychotic. A Critical Review of the Evidence, *Frontiers in Pharmacology*, 2016, 7, 422, eCollection 2016  
Doi : 10.3389/fphar.2016.00422
54. ROSEN P., HAUSLEITER I.S. : Antipsychotic-like effects of cannabidiol and rimonabant: systematic review of animal and human studies, *Current Pharmaceutical Design*, 2012, 18, (32), 5141-5155.
55. RUGGIERO R.N., ROSSIGNOLI M.T., De ROSS J.B., HALLAK J.E.C., LEITE J.P., BUENO-JUNIOR L.S. : Cannabinoids and Vanilloids in Schizophrenia : Neurophysiological Evidence and Directions for Basic Research, *Frontiers in Pharmacology*, 2017, 8, article 39927 pp.  
Doi : 10.3389/fphar.2017.00399
56. RUSSO E.B., BURNETT A., HALL B., PARKER K.K. : Agonistic properties of cannabidiol at 5-HT1A receptors, *Neurochemical Research*, 2005, 30, 1037-1043.
57. SCHOEDEL K.A., HARRISON S.J. : Subjective and physiological effects of oromucosal sprays containing cannabinoids (nabiximols) : potentials and limitations for psychosis research, *Current Pharmaceutical Design*, 2012, 18, (32), 5008-5014.
58. SCHUBART C.D., SOMMER I.E.C., Van GASTEL W.A., GOETGEBER R.L., KAHN R.S., BOKS M.P.M. : Cannabis with high cannabidiol content is associated with fewer psychotic experiences, *Schizophrenia Research*, 2011, 130, (1-3), 216-221.
59. SCHUBART C.D., SOMMER I.E.C., FUSAR-POLI P., De WITTE L., KAHN R.S., BOKS M.P.M. : Cannabidiol as a potential treatment for psychosis, *European Neuropsychopharmacology*, 2014, 24, 1, 51-64.  
Doi : 10.1016/j.euroneuro.2013.11.002
60. SEEMAN P. : Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose, *Translational Psychiatry*, 2016, 6, e920.  
Doi : 10.1038/tp.2016.195
61. STARK T., Di BARTOLOMEO M., Di MARCO R., DRAZANOVA E., PLATANIA C.B.M., ... MECHOULAM R., Di MARZO V., MICALE V. : Altered dopamine D3 receptor gene

- expression in MAM model of schizophrenia is reversed by peripubertal cannabidiol treatment, *Biochemical Pharmacology*, 2020, 1-12.  
 Doi : 10.1016/j.bcp.2020.114004
62. TABITHA A.I., MATTHIJS G.B. : A systematic review of the antipsychotic properties of cannabidiol in humans, *Schizophrenia Research*, 2015, 162, (1-3), 153-161.
63. WALL M.B., POPE R., FREEMAN T.P., KOWALCZYK O.S., DEMETRIOU L., MOKRYSZ C., HINDOCHA C., LAWN W., BLOOMFIELD A.P., FREEMANA.M., FEILDING A., NUTT D.J., CURRAN H.V. : Dissociable effects of cannabis with and without cannabidiol on the human brain's resting-state functional connectivity, *Journal of Psychopharmacology*, 2019, 1-9.  
 Doi : 10.1177/0269881119841568
64. WHITE C.M. : A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential, *The Journal of Clinical Pharmacology*, 2019, 59, (7), 923-934.  
 Doi : 10.1002/jcph.1387
65. YASGUR B.S. : Cannabidiol May Reset Brain Function in Psychosis, *Medscape Psychiatry News*, 2018 Sept 04,  
[https://www.medscape.com/viewarticle/901533\\_print](https://www.medscape.com/viewarticle/901533_print)
66. ZUARDI A.W., RODRIGUES J.A. CUNHA J.M. : Effects of cannabidiol in animal models predictive of antipsychotic activity, *Psychopharmacology*, 1991, 104, 2, 260-264.
67. ZUARDI A.W., MORAIS S.L., GUIMARÃES F.S., MECHOULAM R. : Antipsychotic effect of cannabidiol, *Journal of Clinical Psychiatry*, 1995, 56, 485-486.
68. ZUARDI A.W., GUIMARÃES F.S. : Cannabidiol as an anxiolytic and antipsychotic, in *Mathre ML (Editor), Cannabis in Medical Practice.*, McFarland & Company, Inc., Jefferson, NC, USA, 1997, 133-141.
69. ZUARDI A.W., CRIPPA J.A.S., HALLAK J.E.C., MOREIRA F.A., GUIMARÃES F.S. : Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug, *Brazilian Journal of Medical and Biological Research*, 2006, 39, (4), 421-429.
70. ZUARDI A.W. et coll.: Cannabidiol monotherapy for treatment-resistant schizophrenia, *Journal of Psychopharmacology*, 2006, 20, (5), 683-686..  
<https://fr.scribd.com/document/77189626/Antonio-Waldo-Zuardi-et-al-Cannabidiol-monotherapy-for-treatment-resistant-schizophrenia>
71. ZUARDI A.W., HALLAK J.E.C., DURSUN S.M., MORAIS S., SANCHES R.F., MUSTY R.E., CRIPPA J.A.S. : Cannabidiol monotherapy for treatment-resistant schizophrenia, *Journal of Psychopharmacology*, 2006, 20, 5, 683-686.
72. ZUARDI A.W. : History of cannabis as a medicine : a review, *Revista Brasileira Psiquiatrica*, 2006, 28, (2), 153-157.
73. ZUARDI A.W. : Cannabidiol : From an inactive cannabinoid to a drug with wide spectrum of action, *Revista Brasileira Psiquiatrica*, 2008, 30, 271-280.
74. ZUARDI A.W., CRIPPA J.A.S., HALLAK J.E.C., PINTO J.P., CHAGAS M.H.N., RODRIGUES G.G.R. et al. : Cannabidiol for the treatment of psychosis in Parkinson's disease, *Journal of Psychopharmacology*, 2009, 23, 8, 979-983.
75. ZUARDI A.W., CRIPPA J.A.S., HALLAK J.E.C., BHATTACHARYYA S., ATAKAN Z., MARTIN-SANTOS R., McGUIRE P.K., GUIMARAES F.S. : A critical review of the antipsychotic effects of cannabidiol : 30 years of translational investigation, *Current Pharmaceutical Design*, 2012, 18, (32), 5131-5140.  
 PMID : 22716160

## Cannabinoïdes et dépression

1. ADAMCZYK P., GOLDA A., McCREARY A.C., FILIP M, PRZEGALINSKI E. : Activation of endocannabinoid transmission induces antidepressant-like effects in rats, *Journal of Physiology and Pharmacology*, 2008, 59, 2, 217-228.
2. ARJMAND S., BEHZADI M., KOHLMEIER K.A., MAZHARI S., SABAHI A., SHABANI M. : Bipolar disorder and the endocannabinoid system, *Acta Neuropsychiatrica*, 2019, 1-9.  
Doi : 10.1017/neu.2019.21
3. BAHORIK A.L., LEIBOWITZ A., STERLING S.A., TRAVIS A., WEISNER C., SATRE D.D. : Patterns of marijuana use among psychiatry patients with depression and its impact on recovery, *Journal of Affective Disorders*, 2017, 213, 168-171.
4. BAMBICO F.R., KATZ N., DEBONNEL G., GOBBI G. : Cannabinoids Elicit Antidepressant-Like Behavior and Activate Serotonergic Neurons through the Medial Prefrontal Cortex, *The Journal of Neuroscience*, 2007, 27, (43), 11700 - 11711.  
Doi : 10.1523/JNEUROSCI.1636-07.2007
5. BAMBICO F.R., DURANTI A., TONTINI A., TARZIA G., GOBBI G. : Endocannabinoids in the Treatment of Mood Disorders : Evidence from Animal Model, *Current Pharmaceutical Design*, 2009, 15, 24 p.
6. BLASS K., Treating depression with cannabinoids, *Cannabinoids*, 2008, 3, (2), 8-10.
7. BODEN J.M., MONK N.J. : Commentary on Pacek et al. (2019) : Cannabis and major depression – a network theory proposal, *Addiction*, 2020, 115, 5, 944-945.  
Doi : 10.1111/add.14949
8. CAMPOS A.C., FOGACA M.V, SCARANTE F.F. et al. : Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders, *Frontiers in Pharmacology*, 2017, 8, article 269.  
Doi : 10.3389/fphar.2017.00269
9. CHEN C.Y., WAGNER F.A., ANTHONY J.C. : Marijuana use and the risk of Major depressive Episode. Epidemiological evidence from the United States National Comorbidity Survey, *Social Psychiatry and Psychiatric Epidemiology*, 2002, 37, (5), 199-206.  
Doi : 10.1007/s00127-002-0541-z
10. CRANE N.A., LANGENECKER S.A., MERMELSTEIN R.J. : Gender differences in the associations among marijuana use, cigarette use, and symptoms of depression during adolescence and young adulthood, *Addictive Behaviors*, 2015, 49, 33-39.
11. DEGENHARDT L., HALL W., LYNSKEY M. : Exploring the association between cannabis use and depression, *Addiction*, 2003, 98, 1493-1504.
12. De MELLO SCHIER A., de OLIVEIRA RIBEIRO N.P., COUTINHO D.S., MACHADO S., ARIAS-CARRION O., CRIPPA J.A., ZUARDI A.W., NARDI A.E., SILVA A.C. : Antidepressant-Like and Anxiolytic-Like Effects of Cannabidiol : A Chemical Compounds of *Cannabis Sativa*, *CNS & Neurological Disorders – Drug Targets*, 2014, 13, 953-960.
13. EL-ALFYA A.T., IVEYA K., ROBINSONA K., AHMEDB S., RADWAND M., SLADEB D., KHAND I., EISOHLYB M., ROSS S. : Antidepressant-like effect of  $\Delta 9$ -tetrahydrocannabinol and other cannabinoids isolated from *Cannabis sativa* L, *Pharmacology Biochemistry and Behavior*, 2010, 95, (4), 434-442.  
Doi : 10.1016/j.pbb.2010.03.004

14. ELBATSH M.M., MOKLAS M.A., MARSDEN C.A., KENDALL D.A. : Antidepressant-like effects of delta9-tetrahydrocannabinol and rimonabant in the olfactory bulbectomised rat model of depression, *Pharmacology Biochemistry and Behavior*, 2012, 102, (2), 357-365.  
Doi : 10.1016/j.pbb.2012.05.009
15. FEINGOLD D., WEISER M., REHM J., LEV-RAN S. : The association between cannabis use and mood disorders : A longitudinal study, *Journal of Affective Disorders*, 2014, 172, 211-218.
16. FEINGOLD D., REHM J., LEV-RAN S. : Cannabis use and the course and outcome of major depressive disorder : A population based longitudinal study, *Psychiatry Research*, 2017, 251, 225-234.  
Doi : 10.1016/j.psychres.2017.02.027
17. FOGACA M.V. et al. : Cannabinoids, Neurogenesis and Antidepressant Drugs : is there a Link ?, *Current Neuropharmacology*, 2013, 11, (3), 263-275.
18. GAETANI S., DIPASQUALE P., ROMANO A., RIGHETTI L., CASSANO T., PIOMELLI D., CUOMO V. : The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs, *International Review of Neurology*, 2009, 85, 57-72.
19. GIBBS M., WINSPER C., MARWAHA S., GILBERT E., BROOME M., SINGH S.P. : Cannabis use and mania symptoms: A systematic review and meta-analysis, *Journal of Affective Disorders*, 2015, 171, 39-47.
20. GRUBER A.J., POPE Jr H.G., BROWN M.E. : Do patients use marijuana as an antidepressant ?, *Depression*, 1996, 4, 77-80.
21. HARTSEL J.A, ... MAKRIYANNIS A. : Cannabichromene – an overview. Cannabis Sativa and Hemp, *Nutraceuticals*, 2016, ScienceDirect Topics.
22. HILL M.N., PATEL S., CARRIER E.J., RADEMACHER D.J., ORMEROD B.K., HILLARD C.J., GORZALKA B.B. : Downregulation of Endocannabinoid Signaling in the Hippocampus following Chronic Unpredictable Stress, *Neuropharmacology*, 2005, 30, 508-515.  
Doi : 10.1038/sj.npp.1300601
23. HILL M.N., HO W.-S. V., SINOPOLI K.J., VIAU V., HILLARD C.J., GORZALKA B.B. : Involvement of the Endocannabinoid System in the Ability of Long-Term Tricyclic Antidepressant Treatment to Suppress Stress-Induced Activation of the Hypothalamic-Pituitary-Adrenal Axis, *Neuropsychopharmacology*, 2006, 31, 2591-2599.  
Doi : 10.1038/sj.npp.1301092
24. HILL M.N., HILLARD C.J., BAMBICO F.R., PATEL S., GORZALKA B.B., GOBBI G. : The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants, *Trends in Pharmacological Sciences (CellPress)*, 2009, 30, 9.  
Doi : 10.1016/j.tips.2009.06.006
25. HILL K.P. : Cannabis Use and Risk for Substance Use Disorders and Mood or Anxiety Disorders, *JAMA*, 2017, 317, (10), 1070-1071.  
Doi : 10.1001/jama.2016.19706
26. HORWOOD L., FERGUSSON D.M., COFFEY C., PATTON G.C., TAIT R.J., SMART D. et al. : Cannabis and depression : an integrative data analysis of four Australasian cohorts, *Drug and Alcohol Dependence*, 2012, 126, 369-378.
27. HUANG W.-J., CHEN W.-W., ZHANG X. : Endocannabinoid system : Role in depression, reward and pain control (Review), *Molecular Medicine Reports*, 2016, 14, 2899-2903.

Doi : 10.3892/mmr.2016.5585

28. ISHIGURO H., LEONARD C.M., SGRO S., ONAIVI E.S. : Cannabinoid Receptor Gene Variations in Neuropsychiatric Disorders, (Yamanashi University, Japan, William Paterson University et NIDA-NIH, Baltimore, USA), In « *Endocannabinoids : Molecular, Pharmacological, Behavioural and Clinical Features* », E.M. Murillo et al, 2013, Bentham Science Publishers).
29. JIANG W. et al. : Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic and antidepressant-like effects, *Journal of Clinical Investigation*, 2005, 115, (11), 3104-3116.
30. JOHNSON J., CARTER A. : Can CBD help treat depression?, *Medical News Today*, Fri 29 March 2019.  
<https://www.medicalnewstoday.com/articles/324846.php>
31. KAUR R., AMBWANI S.R., SINGH S. : Endocannabinoid System : A Multi-Facet Therapeutic Target, *Current Clinical Pharmacology*, 2016, 11, (2), 110-117.  
Doi : 10.2174/1574884711666160418105339
32. KOLAR D. : Addictive potential of novel treatments for refractory depression and anxiety, *Neuropsychiatric Disease and Treatment*, 2018, 14, 1513-1519.  
Doi : 10.2147/NDT.S167538
33. LINGE R., JIMENEZ-SANCHEZ L., CAMPA L., PILAR-CUELLAR F., VIDAL R., PAZOS A., ADELL A., DIAZ A. : Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission : role of 5-HT-1A receptors, *Neuropharmacology*, 2016, 103, 16-26.  
Doi : 10.1016/j.neuropharm.2015.12.017
34. LUCATCH A.M., COLES A.S., HILL K.P., GEORGE T.P. : Cannabis and Mood Disorders, *Current Addiction Reports*, 2018, 5, (3), 336-345.  
Doi : 10.1007/s40429-018-0214-v
35. MICALE V., Di MARZO V., SULCOVA A., WOTJAK C.T., DRAGO F. : Endocannabinoid system and mood disorders : Priming a target for new therapies, *Pharmacology & Therapeutics*, 2013, 138, 18-37.  
Doi : 10.1016/j.pharmthera.2012.12.002
36. MICALE V., TABIOVA K., KUCEROVA J., DRAGO F. : Role of the Endocannabinoid System in Depression : From Preclinical to Clinical Evidence, Chapter 5, in P. Campolongo, L. Fattore (eds.), « *Cannabinoids and Modulation of Emotion, Memory, and Motivation* », Springer Science + Business Media New York, 2015.  
Doi : 10.1007/978-1-4939-2294-9\_5
37. MORRISH A.C., HILL M.N., RIEBE C.J.N., GORZALKA B.B. : Protracted cannabinoid administration elicits antidepressant behavioral responses in rats : Role of gender and noradrenergic transmission, *Physiology & Behavior*, 2009, 98, 118-124.  
Doi : 10.1016/j.physbeh.2009.04.023
38. NAoSEM : The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research, Chapter 12 : Mental Health, Depression, *National Academies of Sciences, Engineering, and Medicine*, 2017, Washington, DC, The National Academies Press.  
Doi : 10.17226/24625  
<https://www.ncbi.nlm.nih.gov/books/NBK425748/>
39. PACEK L.R., WEINBERGER A.H., ZHU J., GOODWIN R.D. : Rapid increase in the prevalence of cannabis use among persons with depression in the U.S., 2005-2017 : the role of differentially changing risk perception, *Addiction*, 2020, 115, 5, 935-943.

Doi : 10.1111/add.14883

40. PATEL S., HILLARD C.J. : Role of Endocannabinoid Signaling in Anxiety and Depression, *Current Topics in Behavioral Neurosciences* (book series CTBN, volume 1), 2009, 2013, 347-371.
41. PERTWEE R.G. : Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities, *Philosophical Transactions of the Royal Society B : Biological Sciences*, 2012, 367, 3353-3363.  
Doi : 10.1098/rstb.2011.0381
42. POLESZAK E., WOSKO S., SLAWINSKA K., SZOPA A., WROBEL A., SEREFKO A. : Cannabinoids in depressive disorders, *Life Science*, 2018, 213, 18-24.  
Doi : 10.1016/j.lfs.2018.09.058
43. RAPAPORT L. : Cannabis Use Rising Faster Among Depressed Americans, *Medscape*, December 27, 2019.  
[www.medscape.com/viewarticle/923160](http://www.medscape.com/viewarticle/923160)
44. RODRIGUEZ-MUNOZ M., SANCHEZ-BLAZQUEZ P., CALLADO L.F., MEANA J.J., GARZON-NINO J. : Schizophrenia and depression, two poles of endocannabinoid system deregulation, *Translational Psychiatry*, 2017, 7, 1291.  
Doi : 10.1038/s41398-017-0029-y
45. ROSEN P. : Antidepressant effects of Cannabinoids, Abstract.
46. SALES A.J., CRESTANI C.C., GUIMARAES F.S., JOCA S.R.L. : Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels, *Progress in Neuro-Psychopharmacological Biological Psychiatry*, 2018, 86, 255-261.  
Doi : 10.1016/j.pnpbp.2018.06.002
47. SALES A.J., FOGACA M.V., SARTIM A.G., PEREIRA V.S., WEGENER G., GUIMARAES F.S., JOCA S.R.L. : Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex, *Molecular Neurobiology*, 2018, 12 p.  
Doi : 10.1007/s12035-018-1143-4
48. SARVET A.L., WALL M.M., KEYES K.M., OLFSON M., CERDA M., HASIN D.S. : Self-medication of mood and anxiety disorders with marijuana higher in states with medical marijuana laws, *Drug and Alcohol Dependence*, 2018, 186, 10-15.
49. SCHERMA M., MASIA P., DEIDDA M., FRATTA W., TANDA G., FADDA P. : New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders, *Medicines*, 2018, 5, 107, 17 p.  
Doi : 10.3390/medicines5040107
50. SCIENCE DIRECT : Cannabichromene – An Overview, *Science Direct Journal and Books*, 2019.  
<https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/cannabichromene>
51. STAMPANONI BASSI M., GILIO L., MAFFEI P., DOLCETTI E., BRUNO A., BUTTARI F., CENTONZE D., IEZZI E. : Exploiting the Multifaceted Effects of Cannabinoids on Mood to Boost Their Therapeutic Use Against Anxiety and Depression, *Frontiers in Molecular Neuroscience*, 2018, 11, art 424, 11 p.  
Doi : 10.3389/fnmol.2018.00424
52. SUEURC., INGOLD R. : Le Cannabis en Médecine (Neurologie et Psychiatrie). Revue de la Littérature, GRECC, 1978.  
<https://www.grecc.org/publications/dossiers-scientifiques/le-cannabis-en-medecine-neurologie-et-psychiatrie-revue-de-la-litterature/>

53. TURNA J., PATTERSON B., Van AMERINGEN M. : Is cannabis treatment for anxiety, mood, and related disorders ready for prime time ?, *Depression and Anxiety*, 2017, 1-12.  
Doi : 10.1002/da.22664.
54. TZAVARA E.T., WITKIN J.M. : The Cannabinoid Controversy : Cannabinoid Agonists and Antagonists as Potential Novel therapies for Mood disorders, chapter 23, A. KÖFALVI (ed ;), « *Cannabinoids and the Brain* », Springer 2008, 529-558.
55. Van LAAR M., van DORSSELAER S., MONSHOUWER K., de GRAAF R. : Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population ?, *Addiction*, 2007, 102, (8), 1251-1260.  
Doi : 10.1111/j.1360-0443.2007.01875.x
56. VILELA L.R., GOMIDES L.F., DAVID B.A., ANTUNES M.M., DINIZ A.B., de ARAUJO MOREIRA F., MENEZES G.B. : Cannabidiol rescue Acute Hepatic Toxicity and Seizure Induced by Cocaine, *Mediators of Inflammation*, Hindawi Publishing Corporation, 2015, Art 523418, 12 p.  
Doi : 10.1155/2015/523418
57. WITKIN J.M., TZAVARA E.T., DAVIS R.J., LI X., NOMIKOS G.G. : A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders, *Trends in Pharmacological Sciences*, 2005, 26, 609-617.
58. WOSKO S., SEREFKO A., SZOPA A., WLAZ P., WROBEL A., WLAZ A., GORSKA J., POLESZAK E. : CB1 cannabinoid receptor ligands augment the antidepressant-like activity of biometals (magnesium and zinc) in the behavioral tests, *Journal of Pharmacy and Pharmacology*, 2018.  
Doi : 10.1111/jphp.12880
59. ZLEBNIK N., CHEER J.F. : Beyond the CB1 Receptor : Is Cannabidiol the Answer for Disorders of motivation ?, *Annual Review of Neuroscience*, 2016, 39, 1-17.  
Doi : 10.1146/annurev-neuro-070815-014038

## Cannabidiol antidepresseur

1. BIS-HUMBERT C., GARCIA-CABRERIZO R., GARCIA-FUSTER M.J. : Decreased sensitivity in adolescent versus adult rats to the antidepressant-like effects of cannabidiol., *Psychopharmacology (Berl)*, 2020. Doi : 10.1007/s00213-020-05481-4
2. De MELLO SCHIER A.R., de OLIVEIRA RIBEIRO N.P., COUTINHO D.S., MACHADO S., ARIAS-CARRION O., CRIPPA J.A., ZUARDI A.W, NARDI A.E., SILVA A.C. : Antidepressant-like and anxiolytic-like effects of cannabidiol : a chemical compound of Cannabis sativa, *CNS & Neurological Disorders - Drug Targets*, 2014, 13, (6), 953-960.
3. EL-ALFY A.T., IVEY K., ROBINSON K., AHMED S., RADWAN M., SLADE D., KHAN I., ELSOHLY M., ROSS S. : Antidepressant-like effects of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L., *Pharmacology Biochemistry and Behavior*, 2010, 95, (4), 434-442.  
Doi : 10.1016/j.pbb.2010.03.004
4. JOHNSON J., CARTER A. : Can CBD help treat depression?, *Medical News Today*, Fri 29 March 2019.  
<https://www.medicalnewstoday.com/articles/324846.php>
5. LINGE R., JIMENEZ-SANCHEZ L., CAMPA L., PILAR-CUELLAR F., VIDAL R., PAZOS A., ADELL A., DIAZ A. : Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission : role of 5-HT-1A receptors, *Neuropharmacology*, 2016, 103, 16-26.  
Doi : 10.1016/j.neuropharm.2015.12.017
6. PINTO J.V., SARAF G., FRYSCHE C., VIGO D., KERAMATIAN K., CHAKRABARTY T. et al. : Cannabidiol as a treatment for Mood Disorder : A systematic Review, *Canadian Journal of Psychiatry*, 2020, 65, (4), 213-227.  
Doi : 10.1177/0706743719895195
7. SALES A.J., CRESTANI C.C., GUIMARAES F.S., JOCA S.R.L. : Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels, *Progress in Neuro-Psychopharmacological Biological Psychiatry*, 2018, 86, 255-261.  
Doi : 10.1016/j.pnpbp.2018.06.002
8. SALES A.J., FOGACA M.V., SARTIM A.G., PEREIRA V.S., WEGENER G., GUIMARAES F.S., JOCA S.R.L. : Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex, *Molecular Neurobiology*, 2018, 56, 1070-1081.  
Doi : 10.1007/s12035-018-1143-4
9. XU C., CHANG T., DU Y., YU C., TAN X., LI X. : Pharmacokinetics of oral and intravenous cannabidiol and its antidepressant-like effects in chronic mild stress mouse model, *Environmental Toxicology and Pharmacology*, 2019, 30, 70: 103202  
Doi : 10.1016/j.etap.2019.103202
10. ZANELATI T.V., BIOJONE C., MOREIRA F.A., GUIMARAES F.S., JOCA S.R. : Antidepressant-like effects of cannabidiol in mice : possible involvement of 5-HT1A receptors, *British Journal of Pharmacology*, 2010, 159, 1, 122-128.  
Doi : 10.1111/j.1476-5381.2009.00521.x
11. ZUARDI A.W., CRIPPA J.A.S., DURSUN S.M., MORAIS S., VILELA J.A.A., SANCHES R.F., HALLAK J.E.C. : Cannabidiol was ineffective for manic episodes of bipolar affective disorder, *Journal of Psychopharmacology*, 2010, 24, 1, 135-137.

## Cannabinoïdes et sommeil

1. ALCHIMIA : Cannabinol (CBN) : Le cannabinoïde contre l'insomnie.  
[www.principesactifs.org/cannabinol-cbn-le-cannabinoide-contre-linsomnie/](http://www.principesactifs.org/cannabinol-cbn-le-cannabinoide-contre-linsomnie/)  
[www.alchimiaweb.com/blogfr/cannabinol-cbn-cannabinoide-contre-linsomnie/](http://www.alchimiaweb.com/blogfr/cannabinol-cbn-cannabinoide-contre-linsomnie/)
2. BABSON K.A., SOTTILE J., MORABITO D. : Cannabis, Cannabinoids, and Sleep : a Review of the Literature, *Current Psychiatry Reports*, 2017, 19, 23.  
Doi : 10.1007/s11920-017-0775-9
3. BELENDIUK K.A., BABSON K.A., VANDREY R., BONN-MILLER M.O. : Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users, *Addictive Behaviors*, 2015, 50, 178-181.  
Doi : 10.1016/j.addbeh.2015.06.032
4. BREUS M.J. : What You Need to Know About Cannabis and Sleep, *Psychology Today*, May 16, 2019.  
[www.psychologytoday.com/us/blog/sleep-newzzz/201905/what-you-need-know-about-cannabis-and-sleep](http://www.psychologytoday.com/us/blog/sleep-newzzz/201905/what-you-need-know-about-cannabis-and-sleep)
5. CONROY D.A., KURTH M.E., STRONG D.R., BROWER K.J., STEIN M.D. : Marijuana use patterns and sleep among community-based young adults, *Journal of Addictive Diseases*, 2016, 35, (2), 135-143.  
Doi : 10.1080/10550887.2015.1132986
6. GATES P., ALBERTELLA L., COPELAND J.: The effects of cannabinoid administration on sleep : A systematic review of human studies, *Sleep Medicine Reviews*, 2014, 18, (6).  
Doi : 10.1016/j.smrv.2014.02.005
7. KUHATHASAN N., DUFORT A., MacKILLOP J., GOTTSCHALK R., MINUZZI L., FREY B.N. : The use of cannabinoids for sleep : A critical review on clinical trials, Experimental and *Clinical Psychopharmacology*, 2019, 27, (4), 383-401.  
Doi : 10.1037/pha0000285
8. LINARES I.M.P., GUIMARAES F.S., ECKELI A., CRIPPA A.C.S., ZUARDI A.W., SOUZA J.D.S., HALLAK J.E., CRIPPA J.A.S. : No Acute Effects of Cannabidiol on the Sleep-Wake Cycle of Healthy Subjects : A Randomized, Double-Blind, Placebo-Controlled, Crossover Study, *Frontiers in Pharmacology*, 2018, Vol 9, Article 315, 1-8.  
Doi : 10.3389/fphar.2018.00315
9. NICHOLSON A.N., TURNER C., STONE B.M., ROBSON P.J. : Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults, *Journal of Clinical Psychopharmacology*, 2004, 24, (3), 305-313.
10. SCHIERENBECK T., RIEMANN D., BERGER M., HORNYAK M. : Effect of illicit recreational drugs upon sleep : cocaine, ecstasy and marijuana, *Sleep Medical Review*, 2008, 12, (5), 381-389.  
Doi : 10.1016/j.smrv.2007.12.004
11. SHANNON S., OPILA-LEHMAN J. : Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder : A Case Report, *The Permanent Journal*, 2016, 20, 4, 108-111.
12. SHANNON S. : Cannabidiol in the Treatment of Anxiety : A Large Case Series, Präsentiert am 21 April 2017 bei der *Psychedelic Science 2017*, 19-24 April 2017, San Francisco, USA.

13. SHANNON S., LEWIS N., LEE H., HUGHES S. : Cannabidiol in Anxiety and Sleep: A Large Case Series, *The Permanente Journal*, 2019, 23, 18-041. Doi : 10.7812/TPP/18-041
14. SZNITMAN S.R., VULFSONS S., MEIRI D., WEINSTEIN G. : Medical cannabis and insomnia in older adults with chronic pain : a cross-sectional study, *BMJ Supportive & Palliative Care*, 2020, 0, 1-6.  
Doi : 10.1136/bmjspcare-2019-001938
15. VIGIL J.M., STITH S.S., DIVIANT J.P., BROCKELMAN F., KEELING K., HALL B. : Effectiveness of Raw, Natural Medical Cannabis Flower for Treating Insomnia under Naturalistic Conditions, *Medicines (Basel)*, 2018, 5, (75), 1-10.  
Doi : 10.3390/medicines5030075
16. VLESSIDES M. : Cannabis for Sleep : Short-Term Benefit, Long-Term Disruption ?, *Medscape*, January 24, 2020.  
[www.medscape.com/viewarticle/924202\\_print](http://www.medscape.com/viewarticle/924202_print)
17. WILSON D.R. : Can You Use Cannabis to Restore Your Natural Sleep Cycle ?, *Healthline.com*, April 24, 2019.  
<https://www.healthline.com/health/medical-marijuana/cannabis-for-sleeping>

## Cannabinoïdes et addiction / Substance Use Disorders

1. BATALLA A., JANSSEN H., GANGADIN S.S., BOSSONG M.G.: The Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review, *Journal of Clinical Medicine*, 2019, 8, 1058.  
Doi : 10.3390/jcm8071058
2. BONACCORSO S., RICCIARDI A., ZANGANI C., CHIAPPINI S., SCHIFANO F.: Cannabidiol (CBD) use in psychiatric disorders : A systematic review, *Neurotoxicology*, 2019, 74, 282-298.  
Doi : 10.1016/j.neuro.2019.08.002
3. CHYE Y., CHRISTENSEN E., SOLOWIJ N., YÜCEL M. : The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder, *Frontiers in Psychiatry*, 2019, Vol 10, Article 63.  
Doi : 10.3389/fpsyg.2019.00063
4. CLEIREC G., POLOMENI P. : Le Cannabidiol, l'autre cannabinoïde présent dans le cannabis : une piste thérapeutique prometteuse ?, *Revue SWAPS*, 2019, n°90, "Du Cannabis Thérapeutique à la Régulation".  
<http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891>
5. CRIPPA J.A., GUIMARAES F.S., CAMPOS A.C., ZUARDI A.W.: translational Investigation of the Therapeutic Potential of Cannabidiol (CBD) : Toward a New Age, *Frontiers in Immunology*, 2018, 9, Article 2009, 1-16.  
Doi : 10.3389/fimmu.2018.02009
6. DOS SANTOS R.G., HALLAK J.E.C., ZUARDI W., de SOUZA J.A. : Cannabidiol for the Treatment of Drug Use Disorders, Chapter 97, in "*Handbook of Cannabis and Related Pathologies. Biology, Pharmacology, Diagnosis, and Treatment*", 2017, pp. 939-946.  
Doi : 10.1016/B978-0-12-800756-3.00113-7
7. FERNANDEZ-ESPEJO E., NUNEZ-DOMINGUEZ L. : Endocannabinoid-mediated synaptic plasticity and substance use disorders, *Neurologia*, 2019.  
Doi : 10.1016/j.nrl.2018.12.004
8. FLEXON J.L., STOLZENBERG L., d'ALESSIO S.J. : The effect of cannabis laws on opioid use, *International Journal of Drug Policy*, 2019, 74, 152-159.  
Doi : 10.1016/j.drugpo.2019.09.013
9. GONZALEZ-CUEVAS G., MARTIN-FARDON R., KERR T.M., STOUFFER D.G., PARSONS L.H., HAMMELL D.C., BANKS S.L., STINCHCOMB A.L., WEISS F. : Unique treatment potential of cannabidiol for the prevention of relapse to drug use : Preclinical proof of principle, *Neuropsychopharmacology*, 2018, 43, (10), 2036-2045.  
Doi : 10.1038/S41386-018-0050-8
10. HSER Y.I., MOONEY L.J., HUANG D., ZHU Y., TOMKO R.L., McCLURE E., CHOU C.P., GRAY K.M. : Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life, *Journal of Substance Abuse Treatment*, 2017, 81, 53-58.  
Doi : 10.1016/j.jsat.2017.07.012
11. HURD Y.L., YOON M., MANINI A.F., HERNANDEZ S., OLMEDO R., OSTMAN M., JUTRAS-ASWAD D. : Early Phase in the Development of Cannabidiol as a Treatment

- for Addiction : Opioid Relapse Takes Initial Center Stage, *Neurotherapeutics*, 2015, 12, 807-815.  
Doi : 10.1007/s13311-015-0373-7
12. LEE J.L.C., BERTOGLIO L.J., GUIMARÃES F.S. et al. : Cannabidiol regulation of emotion and emotional memory processing : Relevance for treating anxiety-related and substance abuse disorders, *British Journal of Pharmacology*, 2017, 174: 3242-3256.
13. LOPEZ-MORENO J.A., GONZALEZ-CUEVAS G., MORENO G., NAVARRO M. : The pharmacology of the endocannabinoid system : functional and structural interactions with other neurotransmitter systems and their repercussions in behavioral addiction, *Addiction Biology*, 2008, 13, 160-187.  
Doi : 10.1111/j.1369-1600.2008.00105.x
14. MELIS M., MUNTONI A.L., PISTIS M. : Dynamic Interactions Between Drugs of Abuse and the Endocannabinoid System : Molecular Mechanisms and Functional Outcome (Departments of Biomedical Science and Neuroscience, University of Cagliari, Monserrato, Italy). In « *Endocannabinoids : Molecular, Pharmacological, Behavioural and Clinical Features* », E.M. Murillo et al, 2013, Bentham Science Publishers.
15. NAVARRETE F., GARCIA-GUTIERREZ M.S., GASPARYAN A., AUSTRICH-OLIVARES A., MANZANARES J. : Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders, *Frontiers in Pharmacology*, 2021, 12, Article 696010, 1-24.  
Doi : 10.3389/fphar.2021.626010
16. NEUMANN M., BÜHRINGER G., HÖFLER M., WITTCHEN H.U., HOCH E. : Is Cannabis Use Treatment Also Indicated for Patients with Low to Moderate Polysubstance Use, *European Addiction Research*, 2018, 24, (2), 79-87.  
Doi : 10.1159/000488345
17. PAROLARO D., VIGANO D., REALINI N., RUBINO T. : Role of the endocannabinoids in regulating drug dependence, *Neuropsychiatric Disease and Treatment*, 2007, 3, (6), 711-721.
18. PRUD'HOMME M., CATA R., JUTRAS-ASWAD D. : Cannabidiol as an intervention for addictive behaviors : a systematic review of evidence, *Substance Abuse : Research and Treatment*, 2015, 9, 33-38.  
Doi : 10.4137/SART.S25081
19. SIDHPURA N., PARSONS L.H. : Endocannabinoid-mediated synaptic plasticity and addiction-related behavior, *Neuropharmacology*, 2011, 61, (7), 1070-1087.  
Doi : 10.1016/j.neuropharm.2011.05.034
20. SLOAN M.E., GOWIN J.L., RAMCHANDANI V.A., HURD Y.L., Le FOLL B. : The endocannabinoid system as a target for addiction treatment : Trials and tribulations, *Neuropharmacology*, 2017, 124, 73-83.  
Doi : 10.1016/j.neuropharm.2017.05.031
21. WALSH Z. et al. : Medical cannabis and mental health : a guided systematic review, *Clinical Psychological Review*, 2017, 51, 15-29.

« le Cannabis comme outil de substitution à l'alcool, aux opiacés et au crack »,  
<http://www.ungass-on-drugs.eu/data/301>

<https://www.springer.com/gp/about-springer/media/research-news/all-english-research-news/non-psychoactive-cannabis-ingredient-could-help-addicts-stay-clean/15548156>

## Cannabinoïdes et addiction au Cannabis

1. BRAIDA D., IOSUE S., PEGORINI S., SALA M. : Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats, *European Journal of Pharmacology*, 2004, 506, 63-69.  
PMID : 15588625.
2. BUDNEY A.J., MOORE B.A., VANDREY R.A. : Health consequences of marijuana use, in "Handbook of the Medical Consequences of Alcohol and Drug Abuse", Edited by Brick J., Philadelphia, PA, Haworth Press/Taylor & Francis, 2008, 251-282.
3. COOPER Z.D., HANEY M. : Cannabis reinforcement and dependence : Role of the cannabinoid CB1 receptor, *Addiction Biology*, 2008, 13, 188-195.  
Doi : 10.1111/j.1369-1600.2007.00095.x
4. DEGENHARDT L., HALL W.D. : Extent of illicit drug use and dependence, and their contribution to the global burden of disease, *Lancet*, 2012, 379, (9810), 55-70.  
Doi : 10.1016/S0140-6736(11)61138-0
5. DEGENHARDT L., FERRARI A.J., CALABRIA B., HALL W.D., NORMAN R.E., McGRATH J., FLAXMAN A.D., ENGELL R.E., FREEDMAN G.D., WHITEFORD H.A., VOS T. : The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease : Results from the GBD 2010 Study, *PLoS One*, 2013, 8, (10), e76635, 1-13.  
Doi : 10.1371/journal.pone.0076635
6. FREEMAN T.P., HINDOCHA C., BAIO G., SHABAN NDC, THOMAS E.M., ASTBURY D. .... CURRAN H.V. : Cannabidiol for the treatment of cannabis use disorder : a phase 2a, double-blind, placebo-controlled, randomized, adaptative Bayesian trial, *Lancet Psychiatry*, 2020, 7, (10), 865-874.  
Doi : 10.1016/S2215-0366(20)30290-X
7. GRIM T.W., WIEBELHAUS J.M., NEGUS S.S., LICHTMAN A.H. : Effects of acute and repeated dosing of the synthetic cannabinoid CP55,940 on intracranial self-stimulation in mice, *Drug and Alcohol Dependence* 2015, 150, 31-37.  
Doi : 10.1016/j.drugalcdep.2015.01.022
8. HUTCHESON D.M., TZAVARA E.T., SMADJA C., VALJENT E., ROQUES B.P., HANOUNE J., MALDONADO R. : Behavioral and biochemical evidence for signs of abstinence in mice chemically treated with Δ-9-tetrahydrocannabinol, *British Journal of Pharmacology*, 1998, 125, 1567-1577.
9. JUSTINOVA Z., TANDA G., MUNZAR P., GOLBERG S.R. : The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys, *Psychopharmacology (Berl)*, 2004, 173, (1-2), 186-194.  
Doi : 10.1007/s00213-003-1693-6
10. KAYMAKÇALAN S., AYHAN I.H., TULUNAY F.C. : Naloxone-induced or post-withdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats, *Psychopharmacology (Berl)*, 1977, 55, (3), 243-249.
11. KONDO K.K., MORASCO B.J., NUGENT S.M., AYERS C.K., O'NEIL M.E., FREEMAN M., KANSAGARA D. : Pharmacotherapy for the Treatment of Cannabis Use Disorder. A systematic Review, *Annals of Internal Medicine*, 2020, 172, (6), 398-413.  
Doi : 10.7326/M19-1105
12. LICHTMAN A.H., MARTIN B.R. : Cannabinoid tolerance and dependence, *Handbook of Experimental Pharmacology*, 2005, (168), 691-717.  
PMID : 16596793

13. PANAGIS G., VLACHOU S., NOMIKOS G.G.: Behavioral Pharmacology of Cannabinoids with a Focus on Preclinical Models for Studying Reinforcing and Dependence-Producing Properties, *Current Drug Abuse Reviews*, 2008, 1, 350-374.
14. Van der POL P., LIEBREGTS N., BRUNT T., van AMSTERDAM J., de GRAAF R., KORF D.J., van den BRINK W., van LAAR M. : Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence : an ecological study, *Addiction*, 2014, 109, (7), 1101-1109.  
Doi : 10.1111/add.12508
15. Van der POL P., LIEBREGTS N., de GRAAF R., KORF D.J., van den BRINK W., van LAAR M. : Three-Year Course of Cannabis dependence and Prediction of Persistence, *European Addiction Research*, 2015, 21, (6), 279-290.  
Doi : 10.1159/000377625

### Cannabinoïdes et sevrage du cannabis

1. ACETO M.D., SCATES S.M., LOWE J.A., MARTIN B.R. : Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A, *European Journal of Pharmacology*, 1995, 282, 1995, R1-2.
2. ACETO M.D., SCATES S.M., MARTIN B.B. : Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2, *European Journal of Pharmacology*, 2001, 416, 75-81.
3. AGRAWAL A., PERGADIA M.L., LYNSKEY M.T. : Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions ?, *The American Journal on Addictions*, 2008, 17, (3) 199-208.
4. ALLSOP D.J., NORBERG M.M., COPELAND J. et al. : The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress, *Drug and Alcohol Dependence*, 2011, 119, (1-2), 123-129.
5. ALLSOP D.J., COPELAND J., NORBERG M.M., FU S., MOLNAR A., LEWIS J. : Quantifying the Clinical Significance of Cannabis Withdrawal, *PLoS One*, 2012, 7, (9), 1-12.  
Doi : 10.1371/journal.pone.0044864
6. ALLSOP D.J., LINTZERIS N., COPELAND J., DUNLOP A., McGREGOR I.S. : Cannabinoid replacement therapy (CRT) : Nabiximols (Sativex) as a novel treatment for cannabis withdrawal, *Clinical Pharmacology & Therapeutics*, 2015, 97, (6), 571-574.  
Doi : 10.1002/cpt.109
7. ARENDT M., ROSENBERG R., FOLDAGER L., SHER L., MUNK-JORGENSEN P. : Withdrawal symptoms do not predict relapse among subjects treated for cannabis dependence, *The American Journal on Addictions*, 2007, 16, (6), 461-467.
8. BAHJI A., STEPHENSON C., TYO R., HAWKEN E.R., SEITZ D.P. : Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids. A Systematic Review and Meta-analysis, *JAMA Network Open*, 2020, 3, (4), e202370.  
Doi : 10.1001/jamanetworkopen.2020.2370
9. BOGGS D.L., KELLY D.L., LIU F., LINTHICUM J.A., TURNER H., SCHROEDER J.R., McMAHON R.P., GORELICK D.A. : Cannabis withdrawal in chronic cannabis users with schizophrenia, *Journal of Psychiatric Research*, 2012.  
Doi : 10.1016/j.jpsychires.2012.10.010

10. BUDNEY A.J., HUGHES J.R., MOORE B.A., NOVY P.L. : Marijuana abstinence effects in marijuana smokers maintained in their home environment, *Archives General of Psychiatry*, 2001, 58, (10), 917-924.  
PMID : 11576029
11. BUDNEY A.J., HUGHES J.R., MOORE B.A., VANDREY R.A. : Review of the validity and significance of the cannabis withdrawal syndrome, *American Journal of Psychiatry*, 2004, 161, (11), 1967-1977.
12. BUDNEY A.J., HUGHES J.R. : The cannabis withdrawal syndrome, *Current Opinion in Psychiatry*, 2006, 19, (3), 233-238.  
Doi : 10.1097/01.yco.0000218592.00689.e5
13. BUDNEY A.J., VANDREY R.G., HUGHES J.R., MOORE B.A., BAHRENBURG B. : Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms, *Drug and Alcohol Dependence*, 2007, 86, (1), 22-29.  
PMID : 16769180
14. CASTANE A., MALDONADO R., VALVERDE O. : Role of different brain structures in the behavioral expression of WIN 55,212-2 withdrawal in mice, *British Journal of Pharmacology*, 2004, 142, 1309-1317.
15. CHUNG T., MARTIN C.S., CORNELIUS J.R., CLARK D.B. : Cannabis withdrawal predicts severity of cannabis involvement at 1-year follow-up among treated adolescents, *Addiction*, 2008, 103, (5), 787-799.
16. COPERSINO M.L., BOYD S.J., TASHKIN D.P. et al. : Cannabis withdrawal among non-treatment-seeking adult cannabis users, *The American Journal on Addiction*, 2006, 15, (1), 8-14.
17. COPERSINO M.L., BOYD S.J., TASHKIN D.P., HUESTIS M.A., HEISHMAN S.J., DERMAND J.C., SIMMONS M.S., GORELICK D.A. : Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal, *The American Journal of Drug and Alcohol Abuse*, 2010, 36, (6), 311-319.  
Doi : 10.3109/00952990.2010.503825
18. CORNELIUS J.R., CHUNG T., MARTIN C. et al. : Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence, *Addictive Behaviors*, 2008, 33, (11), 1500-1505.
19. CRIPPA J.A.S., HALLACK J.E.C., MACHADO de SOUSA J.P., QUEIROZ R.H.C., BERGAMASHI M., CHAGAS M.H.N. et al. : Cannabidiol for the treatment of cannabis withdrawal syndrome : a case report, *Journal of Clinical Pharmacology and Therapeutics*, 2013, 38, (2), 162-164.
20. GORELICK D.A., LEVIN K.H., COPERSINO M.L. et al. : Diagnostic Criteria for Cannabis Withdrawal Syndrome, *Drug and Alcohol Dependence*, 2012, 123, (1-3), 141-147.  
Doi : 10.1016/j.drugalcdep.2011.11.007
21. HANEY M., WARD A.S., COMER S.D., HART C.L., FOLTIN R.W., FISCHMAN M.W. : Bupropion SR worsens mood during marijuana withdrawal in humans, *Psychopharmacology (Berl)*, 2001, 155, (2), 171-179.
22. HANEY M., HART C.L., VOSBURG S.K. et al. : Marijuana withdrawal in humans : effects of oral THC or divalproex, *Neuropsychopharmacology*, 2004, 29, 1, 158-170.
23. HANEY M., HART C.L., VOSBURG S.K., COMER S.D., REED S.C., FOLTIN R.W. : Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse, *Psychopharmacology (Berl)*, 2008, 197, (1), 157-168.

24. HANEY M. : The marijuana withdrawal syndrome : diagnosis and treatment, *Current Psychiatry Report*, 2005, 7, (5), 360-366.
25. HANEY M., COOPER Z.D., BEDI G., VOSBURG S.K., COMER S.D., FOLTIN R.W. : Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse, *Neuropsychopharmacology*, 2013, 38, (8), 1557-1565.  
Doi : 10.1038/npp.2013.54
26. HANEY M., RAMESH D., GLASS A., PAVLICOVA M., BEDI G., COOPER Z. : Naltrexone Maintenance Decrease Cannabis Self-Administration and Subjective Effects in Daily Cannabis Smokers, *Neuropsychopharmacology*, 2015, 40, 2489-2498.
27. HASIN D.S., KEYES K.M., ALDERSON D. et al. : Cannabis withdrawal in the United States : results from NESARC, *Journal of Clinical Psychiatry*, 2008, 69, (9), 1354-1363.
28. KAYMAKCALAN K., AYHAN I.H., TULUNAY F.C. : Naloxone-induced or post-withdrawal abstinence signs in Δ<sup>9</sup>-tetrahydrocannabinol-tolerant rats, *Psychopharmacology*, 1977, 55, 243-249.
29. HEISHMAN S.J., SINGLETON E.G., LIGUORI A. : Marijuana Craving Questionnaire : development and initial validation of a self-report instrument
30. HERRMANN E.S., COOPER Z.D., BEDI G., RAMESH D., REED S.C., COMER S.D., FOLTIN R.W., HANEY M. : Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users, *Psychopharmacology (Berl)*, 2016.  
PMID : 27085870
31. LEVIN K.H., COPERSINO M.L., HEISHMAN S.J. et al. : Cannabis withdrawal symptoms in nontreatment-seeking adult cannabis smokers, *Drug and Alcohol Dependence*, 2010, 111, (1-2), 120-127.
32. MILIN R., MANION I., DARE G., WALKER S. : Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence : a pilot study, *Journal of the American Academy of Child and Adolescent Psychiatry*, 2008, 47, (2), 174-178.  
Doi : 10.1097/chi.0b013e31815cdd73
33. NAVARRETE F., ARACIL-FERNANDEZ A., MANZANARES J. : Cannabidiol regulates behavioral alterations and gene expression changes induced by spontaneous cannabinoid withdrawal, *British Journal of Pharmacology*, 2018.  
Doi : 10.1111/bph.14226
34. POKORSKI I., CLEMENT N., PHUNG N., WELTMANM., FU S., COPELAND J. : Cannabidiol in the management of in-patient cannabis withdrawal : clinical case series, *Future Neurology*, 2017, 12, (3), 133-140.  
Doi : 10.2217/fnl-2016-0035
35. PREUSS U.W., WATZKE A.B., ZIMMERMANN J., WONG J.W., SCHMIDT C.O. : Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients, *Drug and Alcohol Dependence*, 2010, 106, (2-3), 133-141.  
Doi : 10.1016/j.drugalcdep.2009.08.008
36. SCHUSTER R.M., FONTAINE M., NIP E., ZHANG H., HANLY A., EDEN EVINS A. : Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness, *Preventive Medicine*, 2017.  
Doi : 10.1016/j.ypmed.2017.02.019
37. TAPERT S.F., GRANHOLM E., LEEDY N.G., BROWN S.A. : Substance use and withdrawal : neuropsychological functioning over 8 years in youth, *Journal of the International Neuropsychological Society*, 2002, 8, 7, 873-883.

38. TSOU K., PATRICK S., WALKER J.M. : Physical withdrawal in rats tolerant to  $\Delta^9$ -tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist, *European Journal of Pharmacology*, 1995, 280, 13-15.
39. WAKEFORD A.G.P., WETZELL B.B., POMFREY R.L., CLASEN M.M., TAYLOR W.W., HEMPEL B.J., RILEY A.L. : The effects of cannabidiol (CBD) on  $\Delta^9$ -tetrahydrocannabinol (THC) self-administration in male and female Long-Evans rats, *Experimental and Clinical Psychopharmacology*, 2017, 25, (4), 242-248.  
Doi : 10.1037/pha0000135
40. VANDREY R.G., BUDNEY A.J., MOORE B.A., HUGHES J.R. : A cross-study comparison of cannabis and tobacco withdrawal, *The American Journal on Addictions*, 2005, 14, (1), 54-63.  
Doi : 10.1080/10550490899853
41. VORSPAN F., GUILLEM E., BLOCH V., BELLAIS L., SICOT R., NOBLE F., LEPINE J.-P., GORELICK D.A. : Syndrome de sevrage au cannabis dans une population de patients mono- et polydépendants (cannabis et opiacés), *L'Encéphale*, 2011, 37, (4), 266-272.  
Doi : 10.1016/j.encep.2010.12.007
42. WINSTON A.R. : LEA T., COPELAND J. : Lithium Carbonate in the management of cannabis withdrawal in humans : an open-label study, *Journal of Psychopharmacology*, 2009, 23, (1), 84-93.  
Doi : 10.1177/0269881108089584

### Traitement de la dépendance au Cannabis

1. ABAYOMI ., ADELUFOSI A.O. : Psychosocial interventions for cannabis abuse and/or dependence among persons with co-occurring cannabis use and psychotic disorders (Protocol), *Cochrane Database of Systematic Reviews*, Cochrane Library, John Whiley and Sons, Ltd, 2015
2. BAKER A.L., HIDES L., LUBMAN D.I. : Treatment of cannabis use among people with psychotic or depressive disorders : a systematic review, *Journal of Clinical Psychiatry*, 2010, 71, (3), 247-254.  
Doi : 10.4088/JCP.09r05119gry
3. BALTER R.E., COOPER Z.D., HANEY M. : Novel Pharmacologic Approaches to Treating Cannabis Use Disorder, *Current Addiction Reports*, 2014, 1, (2), 137-143.  
Doi : 10.1007/s40429-014-0011-1
4. BENYAMINA A., LECACHEUX M., BLECHA L., REYNAUD M., LUKASIEWCZ M. : Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence, *Expert Review of Neurotherapeutics*, 2008, 8, (3), 479-491.  
Doi : 10.1586/14737175.8.3.479
5. BREZING C.A., CHOI C.J., PAVLICOVA M., BROOKS D., MAHONY A.L., MARIANI J.J., LEVIN F.R. : Abstinence and Reduced Frequency of Use are Associated With Improvements in Quality of Life Among Treatment-Seekers With Cannabis Use Disorder, *The American Journal on Addictions*, 2018, 27, (2), 101-107.  
Doi : 10.1111/ajad.12660
6. BUDNEY A.J., VANDREY R.G., STANGER C. : Pharmacological and psychosocial interventions for cannabis use disorders, *Revista Brasileira de Psiquiatria*, 2010, 32, (Suppl 1), 46-55.  
PMCID : PMC3690346

7. CHAUCHARD E., SEPTFONS A., CHABROL H. : Motivations for cannabis cessation, coping and adaptation strategies, and perceived benefits : impact on cannabis use relapse and abstinence, *L'Encéphale*, 2013, 39, (6), 385-392.  
Doi : 10.1016/j.encep.2013.03.008
8. CLAPPER J.R., MANGIERI R.A., PIOMELLI D. : The endocannabinoid system as a target for the treatment of cannabis dependence, *Neuropharmacology*, 2009, 56, Suppl 1, 235-243.  
Doi : 10.1016/j.neuropharm.2008.07.018
9. COOPER K., CHATTERS R., KALTENTHALER E., WONG R. : Psychological and psychosocial interventions for cannabis cessation in adults : a systematic review short report, *Health Technology Assessment*, 2015, 19, (56), 1-130.  
Doi : 10.3310/hta19560
10. DANOVITCH I., GORELICK D.A. : State of the art treatments for cannabis dependence, *Psychiatric Clinics of North America*, 2012, 35, (2), 309-326.  
Doi : 10.1016/j.psc.2012.03.003
11. DAVIES M.L., POWERS M.B., HANDELSMAN P., MEDINA J.L., ZVOLENSKY M., SMITS J.A. : Behavioral therapies for treatment-seeking cannabis users : a meta-analysis of randomized controlled trials, *Evaluation & the Health Professions*, 2015, 38, (1), 94-114.  
Doi : 10.1177/0163278714529970
12. DENIS C., LAVIE E., FATSEAS M., AURIACOMBE M. : Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings, *Cochrane Database Systematic Review*, 2006, update 2013, (3), CD005336.
13. ESTINGOY P. L'abstinence cannabique : un enjeu pour la réhabilitation, *Annales Médico-Psychologiques*, 2018, 176, 84-88.  
Doi : 10.1016/j.amp.2017.11.006
14. GATES P.J., SABIONI P., COPELAND J., Le FOLL B., GOWING L. : Psychosocial interventions for cannabis use disorder, *Cochrane Database Systematic Review*, 2016, (5), CD005336.  
Doi : 10.1002/14651858.CD005336.pub4
15. HART C.L. : Increasing treatment options for cannabis dependence : a review of potential pharmacotherapies, *Drug and Alcohol Dependence*, 2005, 80, (2), 147-159.
16. HJORTHØJ C., FOHLMANN A., NORDENTOFT M. : Treatment of cannabis use disorders in people with schizophrenia spectrum disorders – a systematic review, *Addictive Behaviors*, 2009, 34, (6-7), 520-525.  
Doi : 10.1016/j.addbeh.2009.02.001
17. HOCH E., PREUSS U.W., FERRI M., SIMON R. : Digital Interventions for Problematic Cannabis Users in Non-Clinical Settings : Findings from a Systematic Review and Meta-Analysis, *European Addiction Review*, 2016, 22, 233-242.  
Doi : 10.1159/000445716
18. HSER Y.I., MOONEY L.J., HUANG D., ZHU Y., TOMKO R.L., McCLURE E., CHOU C.P., GRAY K.M. : Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life, *Journal of Substance Abuse Treatment*, 2017, 81, 53-58.  
Doi : 10.1016/j.ssat.2017.07.012
19. JUSTINOVA Z., MASCIA P., WU H.Q., SECCI M.E., RHEDI G.H., PANLILIO L.V., SCHERMA M., BARNES C., PARASHOS A., ZARA T., ..., GOLBERG S.R. : Reducing

- cannabis abuse and preventing relapse by enhancing endogenous brain levels of kynurenic acid, *Nature Neuroscience*, 2013, 16, (11), 1652-1561.  
Doi : 10.1038/nn.3540
20. LUNDQVIST T., ERICSSON D. : A treatment manual for chronic cannabis users, in "*Cognitive dysfunctions in chronic cannabis users observed during treatment, an integrative approach*", Lundqvist T., Stockholm, Almqvist & Wiksell International, 19951995
21. MARSHALL K., GOWING L., ALI R., Le FOLL B. : Pharmacotherapies for cannabis dependence, *Cochrane Database Systematic Review*, 2014, 12:CD008940.  
Doi : 10.1002/14651858
22. NIELSEN S., GOWING L., SABIONI P., Le FOLL B. : Pharmacotherapies pour la dépendance au Cannabis, *Cochrane Systematic Review*, Cochrane Library.
23. NIELSEN S., SABIONI P., GOWING L., Le FOLL B. : Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents, *Handbook of Experimental Pharmacology*, 2019.  
Doi : 10.1007/164\_2019\_258
24. NORDSTROM B.R., LEVIN F.R. : Treatment of cannabis use disorders : a review of the literature, *The American Journal on Addictions*, 2007, 16, (5), 331-342.  
Doi : 10.1080/10550490701525665
25. OLMO A., TIRADO-MUNOZ J., FARRE M., TORRENS M. : The efficacy of computerized interventions to reduce cannabis use : A systematic review and meta-analysis, *Addictive Behaviors*, 2017, 1-9.  
Doi : 10.1016/j.addbeh.2017.11.045
26. PACEK L.R., VANDREY R. : Cannabis use history and characteristics of quit attempts : a comparison study of treatment-seeking and non-treatment-seeking cannabis users, *Experimental and Clinical Psychopharmacology*, 2014, 22, (6), 517-523.  
Doi : 10.1037/a0037791
27. PIOMELLI D. : The endogenous cannabinoid system and the treatment of marijuana dependence, *Neuropharmacology*, 2004, 47, Suppl 1, 359-367.  
PMID : 15464150
28. RAMESH D., HANEY M. : Treatment of Cannabis Use Disorders, Chapter 22, in N. el-Guebaly et al. (eds.), "*Textbook of Addiction Treatment : International Perspectives*", Springer-Verlag Italia 2015.  
Doi : 10.1007/978-88-470-5322-9\_14
29. RIGTER H., PELC I., TOSSMANN P., PHAN O., GRICHTING E., HENDRIKS V., ROWE C. : INCANT : a transnational randomized trial of multidimensional family therapy versus treatment as usual for adolescents with cannabis use disorder, *BMC Psychiatry*, 2010, 10, 28.  
Doi : 101186/1471-244X-10-28
30. SLOAN M.E., GOWIN J.L., RAMCHANDANI V.A., HURD Y.L., Le FOLL B. : The endocannabinoid system as a target for addiction treatment : Trials and tribulations, *Neuropharmacology*, 2017, 124.  
Doi : 10.1016/j.neuropharm.2017.05.031
31. VANDREY R., HANEY M. : Pharmacotherapy for cannabis dependence : how close are we ?, *CNS Drugs*, 2009, 23, (7), 543-553.  
Doi : 10.2165/00023210-200923070-00001
32. WEINSTEIN A.M., GORELICK D.A. : Pharmacological treatment of cannabis dependence, *Current Pharmaceutical Design*, 2011, 17, (14), 1351-1358.

### Cannabidiol :

1. CLEIREC G., POLOMENI P. : Le Cannabidiol, l'autre cannabinoïde présent dans le cannabis : une piste thérapeutique prometteuse ?, *Revue SWAPS*, 2019, n°90, "Du Cannabis Thérapeutique à la Régulation".  
<http://vih.org/20190520/cannabidiol-lautre-canabinoide-present-cannabis-piste-therapeutique-prometteuse/141891>
2. GARCIA-GUTIERREZ M.S., NAVARRETE F., VIUDEZ-MARTINEZ A., GASPARYAN A., CAPARROS E., MANZANARES J. : Cannabidiol and Cannabis Use Disorder, Chapter in book "*Cannabis Use Disorders*", 2018, 31-42.  
Doi : 10.1007/978-3-319-90365-1\_5
3. SOLOWIJ N., BROYD S.J., BEALE C., PRICK J.A., GREENWOOD L.M., van HELL H., SUO C., GALETTIS P., PAI N., FU S., CROFT R.J., MARTIN J.H., YÜCEL M. : Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological symptoms and Cognitive Function in Regular Cannabis Users : A Pragmatic Open-Label Clinical trial, *Cannabis and Cannabinoid Research*, 2018, 3, (1), 21-34.  
Doi : 10.1089/can.2017.0043

### Nabiximol (Sativex®) :

1. LINTZERIS N., BHARDWAJ A., MILLS L., DUNLOP A., COPELAND J., McGREGOR I., BRUNO R., GUGUSHEFF J., .... KEVIN R., ALLSOP D. : Agonist Replacement for Cannabis Dependence (ARCD) study group : Nabiximols for the Treatment of Cannabis Dependence : A Randomized Clinical Trial, *JAMA Internal Medicine*, 2019.  
Doi : 10.1001/jamainternmed.2019.1993
2. TRIGO J.M., SOLIMAN A., STAIOS G., QUILTY L., FISCHER B., GEORGE T.P., REHM J., SELBY P., BARNES A.J., HUESTIS M.A., Le FOLL B. : Sativex Associated with Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence : A Case Series, *Journal of Addiction Medicine*, 2016, 10, (4), 274-279.  
Doi : 10.1097/ADM.0000000000000229
3. TRIGO J.M., LAGZDINS D., REHM J., SELBY P., GAMALEDDIN I., FISCHER B., BARNES A.J., HUESTIS M.A., Le FOLL B. : Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings, *Drug and Alcohol Dependence*, 2016, 161, 298-306.  
Doi : 10.1016/j.drugalcdep.2016.02.020
4. TRIGO J.M., SOLIMAN A., QUILTY L.C., FISCHER B., REHM J., SELBY P., BARNES A.J., HUESTIS M.A., GEORGE T.P., STREINER D.L., STAIOS G., Le FOLL B. : Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : a pilot randomized clinical trial, *PLOS One*, January 31, 2018.  
Doi : 10.1371/journal.pone.0190768

### Dronabinol / Nabilone :

1. BEDI G., COOPER Z.D., HANEY M. : Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers, *Addiction Biology*, 2013, 18, (5), 872-881.  
Doi 10.1111/j.1369-1600.2011.00427.x
2. HERMANN E.S., COOPER Z.D., BEDI G., RAMESH D., REED S.C., COMER S.D., FOLTIN R.W., HANEY M. : Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users, *Psychopharmacology (Berl.)*, 2016.
3. HILL K.P., PALASTRO M.D., GRUBER S.A., FITZMAURICE G.M., GREENFIELD S.F., LUKAS S.E., WEISS R.D. : Nabilone pharmacotherapy for cannabis dependence : A randomized, controlled pilot study, *The American Journal on Addiction*, 2017, 26, (8), 795-801.  
Doi : 10.1111/ajad.12622
4. LEVIN F.R., KLEBER H.D. : Use of dronabinol for cannabis dependence : two case reports and review, *American Journal of Addiction*, 2008, 17, 2, 161-164.  
Doi : 10.1080/10550490701861177
5. LEVIN F.R., MARIANI J.J. et al. : Dronabinol for the Treatment of Cannabis Dependence : A randomized, Double-Blind, Placebo-Controlled trial, *Drug and Alcohol Dependence*, 2011, 116, (1-3), 142-150.
6. LEVIN F.R., MARIANI J.J., PAVLICOVA M., BROOKS D., GLASS A., MAHONY A., NUNES E.V., BISAGA A., DAKWAR E., CARPENTER K.M., SULLIVAN M.A., CHOI J.C. : Dronabinol and lofexidine for cannabis use disorder : A randomized, double-blind, placebo-controlled trial, *Drug and Alcohol Dependence*, 2016, 159, 53-60.  
Doi : 10.1016/j.drugalcdep.2015.11.025
7. LILE J.A., KELLY T.H., HAYS L.R. : Separate and combined effects of the cannabinoid agonists nabilone and delta9-THC, *Drug and Alcohol Dependence*, 2011, 116, (1-3), 86-92.  
Doi : 10.1016/j.drugalcdep.2010.11.019
8. SCHLIENZ N.J., LEE D.C., STITZER M.L., VANDREY R. : The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration, *Drug and Alcohol Dependence*, 2017, 187, 254-260.  
Doi : 10.1016/j.drugalcdep.2018.02.022
9. VANDREY R., STITZER M.L., MINTZER M.Z., HUESTIS M.A., MURRAY J.A., LEE D. : The Dose Effects of Short-Term Dronabinol (Oral THC) Maintenance in Daily Cannabis Users, *Drug and Alcohol Dependence*, 2013, 128, (1-2), 64-70.  
Doi : 10.1016/j.drugalcdep.2012.08.001

#### **Naltrexone :**

1. HANEY M., RAMESH D., GLASS A., COOPER Z. et al. : Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers, *Neuropsychopharmacology*, 2015, 40, 2489-2498.
2. RANGANATHAN M., CARBUTO M., BRALEY G., ELANDER J., PERRY E., PITTMAN B., RADHAKRISHNAN R., SEWELL R.A., D'SOUZA D.C. : Naltrexone does not attenuate the effects of intravenous delta9-tetrahydrocannabinol in healthy humans, *International Journal of Neuropsychopharmacology*, 2012, 15, 1251-1264.  
Doi : 10.1017/S146114511001830

### **Baclofen :**

1. NANJAYYA S.B., SHIVAPPA M., CHAND P.K., MURPHY P., BENEGAL V. : Baclofen in cannabis dependence syndrome, *Biological Psychiatry*, 2010.  
PMID : 20494335

### **Quetiapine :**

1. COOPER Z.D., FOLTIN R.W., HART C.L., VOSBURG S.K., COMER S.D., HANEY M. : A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers, *Addiction Biology*, 2013, 18, (6), 993-1002.  
Doi : 10.1111/j.1369-1600.2012.00461.x.
2. MARIANI J.J., PAVLICOVA M., MAMCZUR A.K., BISAGA A., NUNES E.V., LEVIN F.R. : Open-label pilot study of quetiapine treatment for cannabis dependence, *American Journal on Drug and Alcohol Abuse*, 2014, 40, (4), 280-284.  
Doi : 10.3109/00952990.2014.884102

### **Vilazodone :**

1. MCRAE-CLARK A.L., BAKER N.L., GRAY K.M., KILLEEN T., HARTWELL K.J., SIMONIAN S.J. : Vilazodone for Cannabis Dependence A Randomized, Controlled Pilot Trial, *American Journal of Addiction*, 2016, 25, (1), 69-75.  
Doi : 10.1111/ajad.12324

### **N-acetylcysteine :**

1. GRAY K.M., SONNE S.C., McCLURE EA., GHITZA U.E., MATTHEWS A.G., ... VANDREY R.G., LEVIN F.R. : A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults, *Drug and Alcohol Dependence*, 2017, 177, 249-257.  
Doi : 10.1016/j.drugalcdep.2017.04.020
2. McCLURE E.A., SONNE S.C., WINHUSEN T., CARROLL K.M., GHITZA U.E. ... VANDREY R.G., LEVIN F.R. ... et al. : Achieving cannabis cessation – evaluating N-acetylcysteine treatment (ACCENT) : design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network, *Contemporary Clinical Trials*, 2014, 39, (2), 211-223.  
Doi : 10.1016/j.cct.2014.08.011

### **Tiagabine :**

1. WESLEY M.J., WESTGATE P.M., STOOPS W.W., KELLY T.H., HAYS L.R. : : Influence of Tiagabine Maintenance on Cannabis Effects and Related Behaviors in Daily Cannabis Users, *Experimental and Clinical Psychopharmacology*, 2018, 26, (3), 310-319.

## Cannabinoïdes et dépendance à la cocaine

1. ADAMCZYK P., MISZKIEL J., McCREARY A.C., FILIP M., PAPP M., PRZEGALINSKI E. : The effects of cannabinoid CB1, CB2 and vanilloid TRPV1 receptor antagonists on cocaine addictive behavior in rats, *Brain Research*, 2012, 1444, 45-54.  
Doi : 10.1016/J;brainres.2012.01.030
2. AHARONOVICH E., GARAWI F., BISAGA A., BROOKS D., RABY W.N., RUBIN E., NUNES E.V., LEVIN F.R. : Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence : effects on outcome, *American Journal of Drug and Alcohol Abuse*, 2006, 32, (4), 629-635.  
Doi : 10.1080/00952990600919005
3. CALPE-LÓPEZ C., GARCIA-PARDO M.P., AGUILAR M.A. : Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders : A Review of Possible Mechanisms, *Molecules*, 2019, 24, 2583.  
Doi : 10.3390/molecules24142583
4. FILIP M., GOLDA A., ZANIEWSKA M., McCREARY A.C., NOWAK E., KOLASIEWICZ W., PRZEGALINSKI E. : Involvement of cannabinoid CB1 receptors in drug addiction : effects of rimonabant on behavioral responses induced by cocaine, *Pharmacological Reports*, 2006, 58, 806-819.
5. GREEN C., SCHMITZ J., LINDSAY J., PEDROZA C., LANE S., AGNELLI R., KJOME K., MOELLER F.G. : The influence of baseline marijuana use on treatment of cocaine dependence : application of an informative-priors Bayesian approach, *Frontiers in Psychiatry*, 2012, Vol 3, Article 93, 1-10.  
Doi :: 10.3389/fpsyg.2012.00092
6. LABIGALINI E. Jr, RODRIGUES L.R., Da SILVEIRA D.X. : Therapeutic use of cannabis by crack addicts in Brazil, *Journal of Psychoactive Drugs*, 1999, 31, (4), 451-455.
7. LUJAN M.A., CANTACORPS L., VALVERDE O. : The Pharmacological reduction of hippocampal neurogenesis attenuates the protective effects of cannabidiol on cocaine voluntary intake, *Addiction Biology*, 2019, e12778.  
Doi : 10.1111/adb.12778
8. MAHMUD A., GALLANT S., SEDKI F., D'CUNHA T., SHALEV U. : Effects of an acute cannabidiol treatment on cocaine self-administration and cue-induced cocaine seeking in male rats, *Journal of Psychopharmacology*, 2017, 31, (1), 96-104.  
Doi : 10.1177/0269881116667706
9. McREYNOLDS J.R. et al. : CB1 receptor antagonism blocks stress-potentiated reinstatement of cocaine seeking in rats, *Psychopharmacology (Berlin)*, 2015 Oct 12.
10. PARKER L.A., BURTON P., SORGE R.E., YAKIWCHUK C., MECHOULAM R. : Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats, *Psychopharmacology (Berl)*, 2004, 175, (3), 360-366.  
Doi : 10.1007/s00213-004-1825-7
11. SOCIAS M.E., KERR T., WOOD E., DONG H., LAKE S., HAYASHI K., DeBECK K., JUTRAS-ASWAD D., MONTANER J., MILLOY M.-J. : Intentional cannabis use to reduce crack cocaine use in a Canadian setting : a longitudinal analysis, *Addiction Behaviors*, 2017, 72, 138-143.  
Doi : 10.1016/j.addbeh.2017.04.006

12. TANDA G. : Modulation of the Endo-Cannabinoid System : Therapeutic Potential Against Cocaine Dependence, *Pharmacological Research*, 2007, 56, (5), 406-417.
13. VILELA L. R., FERREIRA GOMIDES L., DAVID B.A., ANTUNES M.M., BARROS DINIZ A., de ARAUJO MOREIRA F., MENEZES B.G. : Cannabidiol Rescues Acute Hepatic Toxicity and Seizure Induced by Cocaine, *Mediators of Inflammation*, Hindawi Publishing Corporation, 2015, Article ID 523418, 12 p.  
Doi : 10.1155/2015/523418
14. VLACHOU S., NOMIKOS G.G., PANAGIS G. : WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation, *Behavioural Brain Research*, 2003, 141, 215-222.  
PII : S0166-4328(2)00370-4
15. XI Z.-X., GILBERT J.G., PENG X.-Q., PAK A.C., LI X., LI X., GARDNER E.L. : Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats : role of glutamate in the nucleus accumbens, *The Journal of Neuroscience*, 2006, 26, (33), 8531-8536.  
Doi : 10.1523/JNEUROSCI.0726-6.2006
16. XI Z.-X., PENG X.-Q., LI X., SONG R., ZHANG H., LIU Q.-R., YANG H.-J., BI G.-H., LI J., GARDNER E.L. : Brain Cannabinoid CB2 Receptors Modulate Cocaine's Actions in Mice, *Nature Neuroscience*, 2012, 14, (9), 1160-1166.  
Doi : 10.1038/nn.2874

## Cannabinoïdes et dépendance aux amphétamines

1. ANGGADIREDJA K., NAKAMICHI M., HIRANITA T., TANAKA H., SHOYAMA Y., WATANABE S., YAMAMOTO T. : Endocannabinoid system modulates relapse to methamphetamine seeking : possible mediation by the arachidonic acid cascade, *Neuropsychopharmacology*, 2004, 29, (8), 1470-1478.  
Doi : 10.1038/sj.npp.1300454
2. BOCTOR S.Y., MARTINEZ J.L., KOEK W., FRANCE C.P. : The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding, *European Journal of Pharmacology*, 2007, 571, (1), 39-43.
3. CALPE-LÓPEZ C., GARCIA-PARDO M.P., AGUILAR M.A. : Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders : A Review of Possible Mechanisms, *Molecules*, 2019, 24, 2583.  
Doi : 10.3390/molecules24142583
4. CASTELLI M.P., MADEDDU C., CASTI A., CASU A., CASTI P., SCHERMA M., FATTORI L., FADDA P., ENNAS M.G. : Delta9-Tetrahydrocannabinol Prevents Methamphetamine-Induced Neurotoxicity, *PLoS One*, 2014, 9, 5, e98079.  
Doi : 10.1371/journal.pone.0098079
5. GONZALEZ R., RIPPETH J.D., CAREY C.L., HEATON R.K., MOORE D.J., SCHWEINSBURG B.C., CHERNER M., GRANT I. : Neurocognitive performance of methamphetamine users discordant for history of marijuana exposure, *Drug and Alcohol Dependence*, 2004, 76, (2), 181-190.  
Doi : 10.1016/j.drugalcdep.2004.04.014

6. HAY G.L., BARACZ S.J., EVERETT N.A., ROBERTS J., COSTA P.A., ARNOLD J.C., McGREGOR I.S., CORNISH J.L. : Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats, *Journal of Psychopharmacology*, 2018, 32, (12), 1369-1378.  
Doi : 10.1177/0269881118799954
7. KARIMI-HAGHIGHI S., HAGHPARAST A., BESHESTI S. : Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats, *Neuropsychopharmacology & Biological Psychiatry*, 2017.  
Doi : 10.1016/j.pnpbp.2017.08.022
8. PARKER L.A., BURTON P., SORGE R.E., YAKIWCHUK C., MECHOULAM R. : Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats, *Psychopharmacology (Berl)*, 2004, 175, (3), 360-366.  
Doi : 10.1007/s00213-004-1825-7
9. RENARD J., LOUREIRO M., ROSEN L.G., ZUNDER J., de OLIVEIRA C., SCMID S., RUSHLOW W.J., LAVIOLETTE S.R. : Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway, *The Journal of Neurosciences*, 2016, 36, (18), 5160-5169.  
Doi : 10.1523/JNEUROSCI.3387-15.2016
10. SCHINDLER C.W., PANLILIO L.V., GILMAN J.P., JUSTINOVA Z., VEMURI K., MAKRIYANNIS A., GOLDBERG S.R. : Effects of cannabinoid-receptor antagonists on maintenance and reinstatement of methamphetamine self-administration in rhesus monkeys, *European Journal of Pharmacology*, 2010, 633, (1-3), 44-49.  
Doi : 10.1016/j.ejphar.2010.02.005
11. VALVASSORI S.S., ELIAS G., de SOUZA B., PETRONILHO F., DAL-PIZZOL F., KAPCZINSKI F., TRZESNIAK C., TUMAS V., DURSUN S., CHAGAS M.H., HALLAK J.E., ZUARDI A.W., QUEVEDO J., CRIPPA J.A. : Effects of cannabidiol on amphetamine-induced oxidative stress generation in an animal model of mania, *Journal of Psychopharmacology*, 2009.  
PMID : 19939866

## Cannabinoïdes et dépendance à l'alcool

1. ADEJUMO A.C., AJAYI T.O., ADEGBALA O.M., ADEJUMO K.L., ALLIU S., AKINJERO A.M., ONYEAKUSI N.E., OJELABI O., BUKONG T.N. : Cannabis use is associated with reduced prevalence of progressive stages of alcoholic liver diseases, *Liver International*, 2018.  
Doi : 10.1111/liv.13696
2. De TERNAY J., NAASSILA M., NOURREDINE M., LOUVET A., BAILLY F., SESCOUSSE G., MAURAGE P., COTTENCIN O., CARRIERI P.M., ROLLAND B. : Therapeutic Prospects of Cannabidiol for Alcohol Use Disorder and Alcohol-Related Damages on the Liver and the Brain, *Frontiers in Pharmacology*, 2019, Vol 10, Article 627.  
Doi : 10.3389/fphar.2019.00627

3. HAY E.A., McEWAN A., WILSON D., BARRETT P., D'AGOSTINO G., PERTWEE R.G., MacKENZIE A. : Disruption of an enhancer associated with addictive behaviour within the cannabinoid receptor-1 gene suggests a possible role in alcohol intake, cannabinoid response and anxiety-related behaviour, *Psychoneuroendocrinology*, 2019, 109, 104407.  
Doi : 10.1016/j.psyneuen.2019.104407
4. HUNGUND B.L., BASAVARAJAPPA B.S. : Role of endocannabinoids and cannabinoid CB1 receptors in alcohol-related behaviors, *Annals of the New York Academy of Sciences*, 2004.  
Doi : 10.1196/annals.1316.064
5. LAU N., SALES P., AVERILL S., MURPHY F., SATO S.O., MURPHY S. : A safer alternative : Cannabis substitution as harm reduction, *Drug and Alcohol Review*, 2015, 34, (6), 654-659.  
Doi : 10.1111/dar.12275
6. LIPUT D.J., HAMMEL D.C., STINCHCOMB A.L., NIXON K. : Transdermal Delivery of Cannabidiol Attenuates Binge Alcohol-Induced Neurodegeneration in a rodent Model of an Alcohol Use Disorder, *Pharmacology, Biochemistry and Behavior*, 2013, 111, 120-127.  
Doi : 10.1016/j.pbb.2013.08.013
7. LIPUT D.J., PAULY J.R., STINCHCOMB A.L., NIXON K. : Binge Alcohol Exposure Transiently Changes the Endocannabinoid System : A Potential Target to Prevent Alcohol-Induced Neurodegeneration, *Cannabis and Cannabinoid Research*, 2017, 2, 1, 133-138.  
Doi : 10.1089/can.2017.0006
8. LUCAS P., WALSH Z., CROSBY K., CALLAWAY R., BELLE-ISLE L., KAY R., CAPLER R., HOLTZMAN S. : Substituting cannabis for prescription drugs, alcohol and other substances among medical cannabis patients : The impact of contextual factors, *Drug and Alcohol Review*, 2015.  
Doi : 10.1111/dar.12323
9. MIKURYA T.H. : Cannabis as a Substitute for Alcohol : A harm-Reduction Approach, *Journal of Cannabis Therapeutics*, 2004, vol 4, 79-93.  
Doi : 10.1300/J175v04n01\_04
10. REIMAN A. : Cannabis as a substitute for Alcohol and other Drugs, *Harm Reduction Journal*, 2009, 6, 35, 1-5.  
Doi : 10.1186/1477-7517-6-35
11. SKALISKY J., LEICKLY E., OLUWOYE O., McPherson S.M., SREBNIK D., ROLL J.M., RIES R.K., McDONELL M.G. : Prevalence and Correlates of Cannabis Use in Outpatients with Serious Mental Illness receiving treatment for Alcohol Use Disorders, *Cannabis and Cannabinoid Research*, 2017, 2, 1, 133-138.  
Doi : 10.1089/can.2017.0006
12. TURNA J., SYAN S.K., FREY B.N., RUSH B., COSTELLO M.J., WEISS M., McKILLOP J. : Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy : A Systematic Review, *Alcoholism : Clinical and Experimental Research*, 2019, 1-14.  
Doi : 10.1111/acer.13964
13. VIUDEZ-MARTINEZ A., GARCIA-GUTIERREZ M.S., MANZANARES J. : Gender differences in the effects of cannabidiol on ethanol binge drinking in mice, *Addiction Biology*, 2019, e12765, 1-14..  
Doi : 10.1111/adb.12765

## Cannabinoïdes et tabac

1. ANTHONY J.C., WAENER L.A., KESSLER R.C. : Comparative Epidemiology of Dependence on Tobacco, Alcohol, Controlled Substances, and Inhalants : Basic Findings From the National Comorbidity Survey, *Experimental and Clinical Psychopharmacology*, 1994, 2, (3), 244-268.
2. GAGE S.H. : HICKMAN M., HERON J., MUNAFÒ M.R., LEWIS G., MACLEOD, ZAMMIT S. : Associations of Cannabis and Cigarette Use with Depression and Anxiety at Age 18 : Findings from the Avon Longitudinal Study of Parents and Children, *PLoS One*, 2015, 1-13.  
Doi : 10.1371/journal.pone.0122896
3. GAMALEDDIN I.H., TRIGO J.M., GUEYE A.B., ZVONOK A., MAKRIYANNIS A., GOLDBERG S.R., LE FOLL B. : Role of the endogenous cannabinoid system in nicotine addiction : novel insights, *Frontiers in Psychiatry*, 2015, Vol 6, Article 41, 1-12.  
Doi : 10.3389/fpsyg.2015.00041
4. HINDOCHA C., FREEMAN T.P., GRABSKI M., CRUDGINGTON H., DAVIES A.C., STROUD J.B., DAS R.K., LAWN W., MORGAN C.J.A., CURRAN H.V. : The effects of cannabidiol on impulsivity and memory during abstinence in cigarette dependent smokers, *Scientific Reports*, 2018, 8, 7568, 1-7.  
Doi : 10.1038/s41598-018-25846-2
5. MORGAN C.J.A., DAS R.K., JOYE A., CURRAN H.V., KAMBOJ S.K. : Cannabidiol reduces cigarette consumption in tobacco smokers : preliminary findings, *Addictive Behaviors*, 2013, 38, 2433-2436.

## Cannabinoïdes et dépendance aux opiacés

1. ABRAMS D.I., COUEY P., SHADE S.B., KELLY M.E., BENOIVITZ N.L. : Cannabinoid-opioid interaction in chronic pain, *Clinical Pharmacology and Therapeutics*, 2011, 90, 6, 844-851.  
Doi : 10.1038/cpt.2011.188
2. AYOUB S.M., SMOUN R., FARAG M., ATWAL H., COLLINS S.A., ROCK E.M., LIMEBEER C.L., PISCITELLI F., IANNOTTI F.A., LICHTMAN A.H., LERI F., Di MARZO V., MECHOULAM R., PARKER L.A. : Oleoyl alanine (HU595) : a stable monomethylated oleoyl glycine interferes with acute naloxone precipitated morphine withdrawal in male rats, *Psychopharmacology*, 2020, 1-13.  
Doi : 10.1007/s00213-020-05570-4
3. BIGAND T., ANDERSON C.L., ROBERTS M.L., SHAW M.R., WILSON M. : Benefits and adverse effects of cannabis use among adults with persistent pain, *Nursing Outlook*, 2019, 67, 223-231.  
Doi : 10.1016/j.outlook.2018.12.014

4. BISAGA A., SULLIVAN M.A., GLASS A., MISHLEN K., PAVLICOVA M., HANEY M., RABY W.N., LEVIN F.R., CARPENTER K.M., MARIANI J.J., NUNES E.V. : The effects of Dronabinol during detoxification and the initiation of treatment with extended release naltrexone, *Drug and Alcohol Dependence*, 2016, 154, 38-45.  
Doi : 10.1016/j.drugalcdep.2015.05.013
5. BOEHNKE K.F., LITINAS E., CLAUW D.J. : Medical Cannabis Use Is Associated with Decreased Opiate Medication Use in a Retrospective Cross-Sectional Survey of Patients with Chronic Pain, *Journal of Pain*, 2016.  
Doi : 10.1016/j.jpain.2016.03.002
6. BRAIDA D., POZZI M., CAVALLINI R., SALA M. : Conditioned place preference induced by the cannabinoid agonist CP 55,940 : interaction with the opioid system, *Neuroscience*, 2001, 104, 923-926.  
PMID : 11457579.
7. BRAIDA D., IOSUE S., PEGORINI S., SALA M. : Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats, *European Journal of Pharmacology*, 2004, 506, 63-69.  
PMID : 15588625.
8. BUDNEY A.J., BICKEL W.K., AMASS L. : Marijuana use and treatment outcome among opioid-dependent patients, *Addiction*, 1998, 93, 493-503.  
PMID : 9684388.
9. CADONI C., PISANU A., SOLINAS M., ACQUAS E., Di CHIARA G. : Behavioural sensitization after repeated exposure to Delta 9-tetrahydrocannabinol and cross-sensitization with morphine, *Psychopharmacology (Berl)*, 2001, 158, 259-266.  
PMID : 11713615
10. CAMPBELL G., HALL W.D., PEACOCK A., LINTZERIS N., DEGENHARDT L. et al. : Cannabis use, pain and prescription opioid use in people living with chronic non-cancer pain : Findings from a four-year prospective cohort, *Lancet Public Health*, 2018, 3, (7): e341-e350.  
Doi : 10.1016/S2468-2667(18)30110-5.
11. CAMPBELL G., HALL W.D., NIELSEN S. : What does the ecological and epidemiological evidence indicate about the potential for cannabinoids to reduce opioid use and harms ? A comprehensive review, *International Review of Psychiatry*, 2018, 1-16.  
Doi : 10.1080/09540261.2018.1509842
12. CAPANO A., WEAVER R., BURKMAN E. : Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients : a prospective cohort study, *Postgraduate Medicine*, 2020, 132, 1, 56-61.  
Doi : 10.1080/00325481.2019.1685298
13. CHESHER G.B., JACKSON D.M. : The quasi morphine withdrawal syndrome: Effect of cannabinol, cannabidiol and terahydrocannabinol, *Pharmacology, Biochemistry and Behavior*, 1985, 23, 13-15.
14. CICHEWICZ D.L., MARTIN Z.L., SMITH F.L., WELCH S.P. : Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol : dose-response analysis and receptor identification, *Journal of Pharmacology and Experimental Therapeutics* 1999, 289, 859-867.  
PMID : 10215664.
15. CICHEWICZ D.L., McCARTHY E.A. : Antinociceptive synergy between delta (9)-tetrahydrocannabinol and opioids after oral administration, *Journal of Pharmacology and Experimental Therapeutics*, 2003, 304, 1010-1015.

- PMID : 12604676.
16. CICHEWICZ D.L., WELCH S.P.: Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol, *Journal of Pharmacology and Experimental Therapeutics*, 2003, 305, 812-817.  
PMID 12606610.
17. CICHEWICZ D.L.: Synergistic interactions between cannabinoid and opioid analgesics, *Life Sciences*, 2004, 74, 11, 1317-1324.  
PMID : 14706563
18. CLEM S.N., BIGAND T.L., WILSON M. : Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid Addiction, *Pain Management Nursing*, 2019, 1-5.  
Doi : 10.1016/j.pmn.2019.06.009
19. COOPER Z.D., HANEY M. : Opioid antagonism enhances marijuana's effects in heavy marijuana smokers, *Psychopharmacology (Berl)*, 2010, 211, 2, 141-148.  
Doi : 10.1007/s00213-010-1875-y
20. COOPER Z.D., BEDI G., RAMESH D. et al. : Impact of co-administration of oxycodone and smoked cannabis on analgesia and abuse liability, *Neuropsychopharmacology*, 2018, 43, (10), 2046-2055.  
Doi : 10.1038/s41386-018-0011-2
21. CORCHERO J., AVILA M.A., FUENTES J.A., MANZANARES J.: Delta-9-Tetrahydrocannabinol increases prodynorphin and proenkephalin gene expression in the spinal cord of the rat, *Life Science*, 1997, 61, PL 39-43.
22. CORCHERO J., FUENTES J.A., MANZANARES J.: Delta 9-Tetrahydrocannabinol increases pro-opio-melanocortin gene expression in the arcuate nucleus of the rat hypothalamus. *European Journal of Pharmacology*, 1997, 323, 193-195.  
PMID : 9128838.
23. CORCHERO J., ROMERO J., BERRENDERO F., FERNANDEZ-RUIZ J., RAMOS J.A., FUENTES J.A., MANZANARES J.: Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen, *Brain Research. Molecular Brain Research*, 1999, 67, 148-157.  
PMID : 10101241.
24. CORCHERO J., FUENTES J.A., MANZANARES J. : Cannabinoid/opioid crosstalk in the central nervous system, *Critical Review in Neurobiology*, 2004, 16, 159-172.  
PMID : 15581411.
25. CORCHERO J., OLIVA J.M., GARCIA-LECUMBERRI C, MARTIN S., AMBROSIO E., MANZANARES J.: Repeated administration with Delta9-tetrahydrocannabinol regulates mu-opioid receptor density in the rat brain, *Journal of Psychopharmacology*, 2004, 18, 54-58.  
PMID : 15107185.
26. COX M.L., HALLER V.L., WELCH S.P.: Synergy between delta9-tetrahydrocannabinol and morphine in the arthritic rat, *European Journal of Pharmacology*, 2007, 567, 125-130.  
PMID : 17498686.
27. Da FONSECA PACHECO D., KLEIN A., De CASTRO PEREZ A., DUARTE I.D. et al. : The mu-opioid receptor agonist morphine, but not agonists at delta- or kappa-opioid

- receptors, induces peripheral antinociception mediated by cannabinoid receptors, *British Journal of Pharmacology*, 2008, 154, 5, 1143-1149.  
Doi : 10.1038/bjp.2008.175
28. Del ARCO I., NAVARRO M.; BILBAO A., FERRER B., PIOMELLI D., RODRIGUEZ de FONSECA F.: Attenuation of spontaneous opiate withdrawal in mice by the anandamide transport inhibitor AM404, *European Journal of Pharmacology*, 2002, 454, (1), 103-104.
29. FREDERICKSON R.C., HEWES C.R., AIKEN J.W. : Correlation between the in vivo and an in vitro expression of opiate withdrawal precipitated by naloxone : their antagonism by I-(-)-delta9-tetrahydrocannabinol, *Journal of Pharmacology and Experimental Therapeutics*, 1976, 199, (2), 375-384.  
PMID : 988178
30. GRIFFITH C., La FRANCE B. : The Benefits and Effects of Using Marijuana as a Pain Agent to Treat Opioid Addiction, *Journal of Hospital & Medical Management*, 2018, 4, n°2:7, 1-4.  
Doi : 10.4172/2471-9781.100051
31. HANEY M., BISAGA A., FOLTIN R.W. : Interaction between naltrexone and oral THC in heavy marijuana smokers, *Psychopharmacology (Berl)*, 2003, 166, 1, 77-85.  
Doi : 10.1007/s00213-002-1279-8
32. HANEY M. : Opioid antagonism of cannabinoid effects : differences between marijuana smokers and non-marijuana smokers, *Neuropsychopharmacology*, 2007, 32, 6, 1391-1403.  
Doi : 10.1038/sj.npp.1301243
33. HANEY M., RAMESH D., GLASS A., COOPER Z. et al. : Naltrexone maintenance decreases cannabis self-administration and subjective effects in daily cannabis smokers, *Neuropsychopharmacology*, 2015, 40, 2489-2498.
34. HERMANN D., KLAGEES E., WELZEL H. et al. : Low efficacy of non-opioid drugs in opioid withdrawal symptom, *Addiction Biology*, 2005, 10, 2, 165-169.
35. HIRSCHHORN I.D., ROSECRANS J.A. : Morphine and delta 9-tetrahydrocannabinol: tolerance to the stimulus effects, *Psychopharmacologia*, 1974, 36, 243-253.
36. HURD Y.L., YOON M., MANINI A.F., HERNANDEZ S., OLMEDO R., OSTMAN M., JUTRAS-ASWAD D. : Early Phase in the Development of Cannabidiol as a Treatment for Addiction : Opioid Relapse Takes Initial Center Stage, *Neurotherapeutics*, 2015, 12, 807-815.  
Doi : 10.1007/s13311-015-0373-7
37. HURD Y.L., SPRIGGS S., ALISHAYEV J., WINDEL G., GURGOV K., KUDRICH C., OPRESCU A.M., SALSITZ E. : Cannabidiol for the Reduction of Clue-Induced Craving and Anxiety in Drug-Abstinent Individuals with Heroin Use Disorder : A Double-Blind Randomized Placebo-Controlled Trial, *AJP in Advance*, 2019, 1-12.  
Doi : 10.1176/appi.ajp.2019.18101191
38. IYER V., SLIVICKI R.A., THOMAZ A.C., CRYSTAL J.D., MACKIE K., HOHMANN A.G. : The cannabinoid CB2 receptor agonist LY2828360 synergizes with morphine to suppress neuropathic nociception and attenuates morphine reward and physical dependence, *European Journal of Pharmacology*, 2020, 886, 173544, 1-15.  
Doi : 10.1016/j.ejphar.2020.173544
39. JUSTINOVA Z., TANDA G., MUNZAR P., GOLDBERG S.R. : The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys, *Psychopharmacology*, 2004, 173, 186-194.

40. JUSTINOVA Z., MUNZAR P., PANLILIO L.V., YASAR S., REDHI G.H., TANDA G., GOLDBERG S.R. : Blockade of THC seeking behavior and relapse in monkeys by the cannabinoid CB (1)-receptor antagonist rimonabant, *Neuropsycho-pharmacology*, 2008, 33, 2870-2877.  
PMID : 18305459
41. KAYMAKCALAN S, AYHAN I.H., TULUNAY F.C.: Naloxone-induced or postwithdrawal abstinence signs in delta 9-tetrahydrocannabinol-tolerant rats, *Psychopharmacology*, 1977, 55, 243-249.
42. KATSIDONI V. et al.: Cannabidiol inhibits the reward-facilitating effect of morphine : involvement of 5-HT1A receptors in the dorsal raphe nucleus, *Addiction Biology*, 2013, 18, 2, 286-296.  
Doi : 10.1111/j.1369-1600.2012.00483.x
43. LEDENT C., VALVERDE O., COSSU G., PETITET F., AUBERT J. F., BESLOT F., BOHME G.A., IMPERATO A., PEDRAZZINI T., ROQUES, B.P., VASSART, G., FRATTA W., PARMENTIER M. : Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB 1 receptor knockout mice, *Science*, 1999, 283, 401-404.
44. LEM S.N., BIGAND T., WILSON M. : Cannabis Use Motivations among Adults Prescribed Opioids for Pain versus Opioid, *Addiction*, 2019.
45. LI J.X., McMAHON L.R., GERAK L.R., BECKER G.L., FRANCE C.P. : Interactions between delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys : discrimination and antinociception, *Psychopharmacology*, 2008, 199, 199-208.
46. LICHTMAN A.H., SHEIKH S.M., LOH H.H., MARTIN B.R. : Opioid and Cannabinoid Modulation of Precipitated Withdrawal in Δ9-Tetrahydrocannabinol and Morphine-Dependent Mice, *The Journal of Pharmacology and Experimental Therapeutics*, 2001, 298, (3), 1007-1014.
47. LUCAS P., WALSH Z. : Medical cannabis access, use, and substitution for prescription opioids and other substances : a survey of authorized medical cannabis patients, *International Journal of Drug Policy*, 2017, 42, 30-35.
48. LUCAS P. : Rationale for cannabis-based interventions in the opioid overdose crisis, *Harm Reduction Journal*, 2017, 14, 58.  
Doi : 10.1186/s12954-017-0183-9
49. LYNCH M.E., CLARK A.J. : Cannabis reduces opioid dose in the treatment of chronic non-cancer pain, *Journal of Pain Symptom Management*, 2003, 25, 6, 496-498.
50. MANINI A.F., YIANNOULOS G., BERGAMASCHI M.M., HERNANDEZ S., OLMEDO R., Barnes A.J., et al. : Safety and Pharmacokinetics of Oral Cannabidiol When Administered Concomitantly with Intravenous Fentanyl in Humans, *Journal of Addiction Medicine*, 2015, 9, (3), 204-210.  
Doi : 10.1097/ADM.0000000000000118
51. MANWELL L.A., MALLET P.E. : Comparative effects of pulmonary and parenteral Δ9-tetrahydrocannabinol exposure on extinction of opiate-induced conditioned aversion in rats, *Psychopharmacology*, 2014, 1-11.  
Doi : 10.1007/s00213-014-3798-5
52. MANZANERES J., CORCHERO J., ROMERO J.J. et al. : Pharmacological and biochemical interactions between opioids and cannabinoids, *Trends in Pharmacological Sciences*, 1999, 20, 287-294.
53. MARKOS J.R., HARRIS H.M., GUL W., EISOHLY M.A., SUFKA K.J. : Effects of Cannabidiol on Morphine Conditioned Place Preference in Mice, *Planta Medica*, 2018, 84, (4), 221-224.

Doi : 10.1055/s-0043-117838

54. McMICHAEL B.J., Van HORN R.L., VISCUSI W.K. : The impact of cannabis access laws on opioid prescribing, *Journal of Health Economics*, 2019, 69, 102273.  
Doi : 10.1016/j.jhealeco.2019.102273
55. MITCHELL M.R., BERRIDGE K.C., MAHLER S.V. : Endocannabinoid-Enhanced « Liking » in Nucleus Accumbens Shell Hedonic Hotspot Requires Endogenous Opioid Signals, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 166-170.  
Doi : 10.1089/can.2018.0021
56. NAVARRO M., CHOWEN J., ROCIO A., CARRERA M.R., del ARCO I., de FONSECA F.R. et al. : CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats, *NeuroReport*, 1998, 9, 3397-3402.
57. NAVARRO M., CARRERA M.R., FRATTA W., RODRIGUEZ de FONSECA F. et al. : Functional interaction between opioid and cannabinoid receptors in drug self-administration, *Journal of Neuroscience*, 2001, 21, 5344-5350.  
PMID : 11438610
58. NIELSEN S., SABIONI P., TRIGO J.M. et al. : Opioid-sparing effect of cannabinoids : A systematic review and meta-analysis, *Neuropsychopharmacology*, 2017, 42, 1752-1765.
59. OLFSON M., WALL M.M., LIU S.-M., BLANCO C. : Cannabis Use and Risk of Prescription Opioid Use Disorder in the United States, *American Journal of Psychiatry*, 2017, 175, 1, 47-53.  
Doi : 10.1176/appi.ajp.2017.17040413
60. PIOMELLI D., WEISS S., BOYD G., LICARDO PACULA R., COOPER Z. : Cannabis and the Opioid Crisis, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 108-116.  
Doi : 10.1089/can.2018.29011 rtl
61. POWELL D., PACULA R.L., JACOBSON M. : Do Medical Marijuana Laws Reduce Addiction and Deaths Related to Pain Killers? *RAND Corporation*, 2015.  
*Journal of Health Economics*, 2018, 58, 29-42.  
[https://www.rand.org/pubs/external\\_publications/EP67480.html](https://www.rand.org/pubs/external_publications/EP67480.html)
62. REIMAN A., WELTY M., SOLOMON P. : Cannabis as a Substitute for Opioid-Based Pain Medication : Patient Self-Report, *Cannabis and Cannabinoid Research*, 2018, 2, 1, 160-166.  
Doi : 10.1089/can.2017.0012
63. REN Y., WHITTARD J., HIGUERA-MATAS A., MORRIS C.V., HURD Y.L. : Cannabidiol, a non-psychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances, *Journal of Neuroscience*, 2009, 29, 47, 14764-14769.  
Doi : 10.1523/JNEUROSCI.4291-09.2009
64. RESPADD : Opioïdes : le cannabidiol pour réduire la dépendance ?, *Respadd, Actualités des addictions*, juillet 2019, n°100.  
[Respadd100-Opioïdes-le cannabidiol pour réduire la dépendance.pdf](#)
65. RIOS C., GOMES I., DEVI L.A. : Mu opioid and CB1 cannabinoid receptor interactions : Reciprocal inhibition of receptor signaling and neurogenesis, *British Journal of Pharmacology*, 2006, 148, 387-395.
66. ROBLEDO P., BERRENDERO F., OZAITA A., MALDONADO R. : Advances in the field of cannabinoid-opioid cross-talk, *Addiction Biology*, 2008, 13, 213-224.  
Doi : 10.1111/j.1369-1600.2008.00107.x

67. SABRINA SPANO M., FATTORE L., COSSU G., DEIANA S., FADDA P., FRATTA W. : CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behavior in the rat, *British Journal of Pharmacology*, 2004, 143, 343-350.
68. SCAVONE J.L., STERLING R.C., Van BOCKSTAELE E.J. : Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal, *Neuroscience*, 2013, 248, 637-654.  
Doi : 10.1016/j.neuroscience.2013.04.034
69. SICOT R. : Consommation associée de cannabis chez 66 patients dépendants aux opiacés, Thèse pour le Doctorat de Médecine, Université René Descartes (Paris 5), 2007, 72 p.
70. SMITH F.L., CICHEWIEZ D., MARTIN Z.L., WELCH S.P. : The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol, *Pharmacology Biochemistry and Behavior*, 1998, 60, 559-566.
71. SOLINAS M., GOLDBERG S.R. : Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems, *Neuropsychopharmacology*, 2005, 30, 11, 2035-2045.  
Doi : 10.1038/sj.npp.1300720
72. SOLINAS M., ZANGEN A., THIRLET N., GOLDBERG S.R. : Beta-endorphin elevations in the ventral tegmental area regulate the discriminative effects of Delta-9 tetrahydrocannabinol, *European Journal of Neuroscience*, 2004, 19, 3183-3192.  
Doi : 10.1111/j.0953-816X.2004.03420.x
73. SPANO M.S., FATTORE L., COSSU G., DEIANA S., FADDA P., FRATTA W. : CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat, *British Journal of Pharmacology*, 2004, 143, 343-350.
74. VALVERDE O., NOBLE F., BESLOT F., DAUGE V., FOURNIÉ-ZALUSKI M.C., ROQUES B.P. : Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins : reduction in morphine withdrawal syndrome without change in rewarding effect, *European Journal of Neuroscience*, 2001, 13, (9), 1816-1824.
75. WACHTEL S.R., de WIT H. : Naltrexone does not block the subjective effects of oral Delta (9)-tetrahydrocannabinol in humans, *Drug and Alcohol Dependence*, 2000, 59, 251-260.  
PMID : 10812285.
76. WAKLEY A.A., CRAFT R.M. : THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats, *Behavioural Pharmacology*, 2011, 22, 489-497.
77. WANG X.Q., MA J., CUI W., YUAN W.X., ZHU G., YANG Q., HENG L.J., GAO G.D. : The endocannabinoid system regulates synaptic transmission nucleus accumbens by increasing DAGL- $\alpha$  expression following short-term morphine withdrawal, *British Journal of Pharmacology*, 2016, 173, (7), 1143-1153.
78. WELCH S.P., EADS M. : Synergistic interactions of endogenous opioids and cannabinoid systems, *Brain Research*, 1999, 848, 1-2, 183-190.  
PMID : 10612710
79. WIESE B., WILSON-POE A.R. : Emerging Evidence for Cannabis'Role in Opioid Use Disorder, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 179-189.  
doi : 10.1089/can.2018.0022 .
80. WILDES M., BIGAND T.L., LAYTON M.E., WILSON M. : Cannabis Use and Cognition in Adults Prescribed Opioids for Persistent Pain, *Pain Management Nursing*, 2019.  
Doi : 10.1016/j.pmn.2019.06.014

81. WILLS K.L., PARKER L.A.: Effect of Pharmacological Modulation of the Endocannabinoid System on Opiate Withdrawal : A Review of the Preclinical Animal literature, *Frontiers in Pharmacology*, 2016, 7, article 187, 9 pp.  
Doi : 10.1111/bph.12969
82. WILSON M., GOGULSKI H.Y., CUTTLER C., BIGAND T.L., OLUWOYE O., BARBOSA-LEIKER C., ROBERTS M.A. : Cannabis use moderates the relationship between pain and negative affect in adults with opioid use disorder, *Addictive Behaviors*, 2017. Doi :10.1016/j.addbeh.2017.10.012

### Cannabinoïdes et “Opioid crisis”

1. Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population, *Adolescent Medicine, JAMA Internal Medicine, JAMA Network*, 2018.  
<https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2676999>
2. Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees, *Adolescent Medicine, JAMA Internal Medicine, JAMA Network*, 2018.  
<https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2677000>
3. AULT A. : Endorsing Cannabis as an Opioid Substitute “Irresponsible”, *Medscape*, February 12, 2019.  
[www.medscape.com/viewarticle/908991](http://www.medscape.com/viewarticle/908991)
4. BACHHUBER M.A., SALONER B., CUNNINGHAM C.O., BARRY C.L. : Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010, *JAMA Internal Medicine*, 2014, 174, 10, 1668-1673.  
Doi : 10.1001/jamainternmed.2014.4005
5. BRADFORD A.C., BRADFORD W.D., ABRAHAM A. et al. : Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population, *JAMA Internal Medicine*, 2018, 178, 5, 667-672.  
Doi : 10.1001/jamainternmed.2018.0266
6. CARLINI B. : Role of Medicinal Cannabis as Substitute for Opioids in Control of Chronic Pain : Separating Popular Myth from Science and Medicine, *Alcohol and Drug Abuse Institute, University of Washington*, 2018, 1-7.
7. CHIHURI S., LI G. : State marijuana laws and opioid overdose mortality, *Injury Epidemiology*, 2019, 6, 38. Doi : 10.1186/s40621-019-0213-z
8. DWIGHT K.B. : How medical cannabis can help fight against the US opioid crisis, *Health Europa*, 11<sup>th</sup> March 2020.  
[www.healtheuropa.eu/how-medical-cannabis-can-help-fight-against-the-us-opioid-crisis/98482/](http://www.healtheuropa.eu/how-medical-cannabis-can-help-fight-against-the-us-opioid-crisis/98482/)
9. FLEXON J.L., STOLZENBERG L., D'ALESSIO S.J. : The effect of cannabis laws on opioid use, *International Journal of Drug Policy*, 2019, 74, 152–159.  
Doi : 10.1016/j.drugpo.2019.09.013
10. GRIFFITH C., La FRANCE B. : The Benefits and Effects of Using Marijuana as a Pain Agent to Treat Opioid Addiction, *Journal of Hospital & Medical Management*, 2018, 4, 2:7, 1-4.  
Doi : 10.4172/2471-9781.100051

11. HURD Y.L. : Cannabidiol : Swinging the Marijuana Pendulum From “Weed” to Medication to Treat the Opioid Epidemic, *CellPress - Trends in Neurosciences*, 2017. 40(3), 124-127.  
Doi : 10.1016/j.tins.2016.12.006
12. KAUFMAN D.E., NIHAL A.M., LEPOO J.D., STAPLES K.M., McCALL K.L., PIPER B.J. : Opioid mortality following implementation of medical marijuana programs (1999-2017) in the United States, *BioRxiv*, preprint first posted online June 14, 2019.  
Doi : 10.1101/670059
13. LI G., CHIHURI S. : Is marijuana use associated with decreased use of prescription opioids ? Toxicological findings from two US national samples of drivers, *Substance Abuse Treatment, Prevention, and Policy*, 2020, 15, 12. Doi : 10.1186/s13011-020-00257-7
14. LUCAS P. : Rational for cannabis-based interventions in the opioid overdose crisis, *Harm Reduction Journal*, 2017, 14, (1), 58.  
Doi : 10.1186/s12954-017-0183-9
15. McMICHAEL B.J., Van HORN R.L., VISCUSI W.K. : The impact of cannabis access laws on opioid prescribing, *Journal of Health Economics*, 2019, 69, 102273.  
Doi : 10.1016/j.jhealeco.2019.102273
16. MELVILLE N.A. : Role for Cannabis in Treatment for Opiod Addiction ?, *Medscape*, February 06, 2017.  
[www.medscape.com/viewarticle/875431](http://www.medscape.com/viewarticle/875431)
17. PHILLIPS E., GAZMARARIAN J. : Implications of prescriptions drug monitoring and medical cannabis legislation on opioid overdose mortality, *Journal of Opioid Management*, 20178, 13, (4), 229-239.
18. PIOMELLI D., WEISS S., BOYD G., PACULA R.L., COOPER Z.D. : Cannabis and the Opioid Crisis, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 108-116.
19. REIMAN A., WELTY M., SOLOMON P. : Cannabis as a Substitute for Opioid-Based Pain Medication : Patient Self-Report, *Cannabis and Cannabinoid Research*, 2017, 2, (1), 160-166.  
Doi : 10.1089/can.2017.0012
20. SHOVER C.L., DAVIS C.S., GORDON S.C., HUMPHREYS K. : Association between medical cannabis laws and opioid overdose mortality has reversed over time, *PNAS*, 2019, 1-3.  
Doi : 10.1073/pnas.1903434116
21. SOHLER N.L., STARRELS J.L., KHALID L., BACHHUBER M.A., ARNSTEN J.H., JOST J., CUNNINGHAM C.O. : Cannabis Use is Associated with Lower Odds of Prescription Opioid Analgesic Use Among HIV\_Infected Individuals with Chronic Pain, *Substance Use and Misuse*, 2018, 1-6.  
Doi : 1080/10826084.2017.1416408
22. STEA J.N. : Can Cannabis Solve the Opioid Crisis ? Probably not - but it might be part of the solution, *Scientific American*, March 15, 2019.  
<https://blogs.scientificamerican.com/observations/can-cannabis-solve-the-opioid-crisis/>
23. TAKAKUWA K.M., HERGENRATHER J.Y., SHOFER F.S., SCHEARS R.M. : The Impact of Medical Cannabis on Intermittent and Chronic Opioid Users with Back Pain : How Cannabis Diminished Prescription Opioid Usage, *Cannabis and Cannabinoid Research*, 2020, Vol X, Number X, 1-8.  
Doi : 10.1089/can.2019.0039

24. VYAS M.B., LeBARON V.T., GILSON A.M. : The use of cannabis in response to the opioid crisis : A review of the literature, *Nursing Outlook*, 2018, 66, (1), 56-65.  
Doi : 10.1016/j.outlook.2017.08.012
25. WIESE B., WILSON-POE A.R. : Emerging Evidence for Cannabis'Role in Opioid Use Disorder, *Cannabis and Cannabinoid Research*, 2018, 3, 1, 179-189.  
Doi : 10.1089/can.2018.0022
26. YASGUR B.S. : Medical Cannabis No Solution to the Opioid Crisis, *Medscape*, June 11, 2019.  
[www.medscape.com/viewarticle/914256](http://www.medscape.com/viewarticle/914256)

## Cannabinoides et Syndrome de Gilles de la Tourette

1. ABI-JAOUDE E., CHEN L., CHEUNG P., BHIKRAM T., SANDOR P.: Preliminary evidence on Cannabis Effectiveness and Tolerability for Adults with Tourette Syndrome, *Journal of Neuropsychiatry and Clinical Neurosciences*, 2017, 29, 4, 391-400.
2. CURTIS A., CLARK C.E., RICKARDS H.E. : Cannabinoids for Tourette's Syndrome, *Cochrane Data Base Systematic Review*, 2009, 7, 4.
3. DEUTSCH S.I., ROSSE R.B., CONNOR J.M. et al. : Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia and marijuana dependence treated with dronabinol, *CNS Spectr*, 2008, 13, 5, 393-403.
4. GROTHENHERMEN F. : Chanvre en Médecine. Redécouverte d'une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017, p 90.
5. HASAN A., ROTHENBERGER A., MUNCHAU A. et al. : Oral delta-9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in a adolescent by increasing intracortical inhibition : a case report, *Journal of Clinical Psychopharmacology*, 2010, 30, 2, 190-192.
6. HEMMINGS M., YELLOWLEES P.M. : Effective treatment of Tourette's syndrome with marijuana, *Journal of Psychopharmacology*, 1993, 7, 389-391.
7. JAKUBOVSKI E., MÜLLER-VAHL K. : Speechlessness in Gilles de la Tourette Syndrome : Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two patients, *International Journal of Molecular Sciences*, 2017, 18, 1739.
8. KANAAN A.S., JAKUBOVSKY E., MULLER-VAHL K. : Significant Tic Reduction in An Otherwise Treatment-Resistant Patient with Gilles de la Tourette Syndrome following Treatment with Nabiximol, *Brain Sciences*, 2017, 7, 47, 1-6.
9. MILOSEV L.M., PSATHAKIS N., SZEJKO N., JAKUBOVSKI E., MÜLLER-VAHL K.R. : Treatment of Gilles de la Tourette Syndrome with Cannabis-Based Medicine : Results from a Retrospective Analysis and Online Survey, *Cannabis and Cannabinoid Research*, 2019, 4, (4), 265-274.  
Doi : 10.1089/can.2018.0050.eCollection 2019.
10. MÜLLER-VAHL K.R., SCHNEIDER U., KOLBE H., EMRICH H.M. : Treatment of Tourette-Syndrome with delta-9-tetrahydrocannabinol, *American Journal of Psychiatry*, 1999, 156, 495.
11. MÜLLER-VAHL K.R., KOBLENZ A., JÖBGES M., KOLBE H. et al. : Influence of treatment of Tourette syndrome with delta-9-tetrahydrocannabinol (delta-9-THC) on neuropsychological performance, *Pharmacopsychiatry*, 2001, 34, 1, 19-24.
12. MÜLLER-VAHL K.R., SCHNEIDER U., KOBLENZ A. et al. : Treatment of Tourette's syndrome with delta 9-tetrahydrocannabinol (THC) : a randomized crossover trial, *Pharmacopsychiatry*, 2002, 35, 2, 57-61.
13. MÜLLER-VAHL K.R., SCHNEIDER U., PREVEDEL H. et al. : Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome : a 6-week randomized trial, *Journal of Clinical Psychiatry*, 2003, 64, 4 459-465.
14. MÜLLER-VAHL K.R., PREVEDEL H., THELOE K., KOLBE H., EMRICH H.M., SCHNEIDER U. : Treatment of Tourette syndrome with delta-9-

- tetrahydrocannabinol (delta-9-THC) : no influence on neuropsychological performance, *Neuropsychopharmacology*, 2003, 28, 2, 384-388.
- 15. MÜLLER-VAHL K.R. : Cannabinoids reduce symptoms of Tourette's syndrome, *Expert Opinion in Pharmacotherapy*, 2003, 4, 10, 1717-1725.
  - 16. PICHLER E.M., KAWOHL W., SEIFRITZ E., ROSER P. : Pure delta-9-tetrahydrocannabinol and its combination with cannabidiol in treatment-resistant Tourette syndrome : a case report, *International Journal of Psychiatry in Medicine*, 2018, DOI: [10.1177/0091217418791455](https://doi.org/10.1177/0091217418791455)
  - 17. SANDYK R., AWERBUCH G. : Marijuana and Tourette's Syndrome, *Journal of Clinical Psychopharmacology*, 1988, 8, 444-445.
  - 18. SZEJKO N., JAKUBOVSKI E., FREMER C., KUNERT K., MÜLLER-VAHL K. : Delta-9-tetrahydrocannabinol for the treatment of a child with Tourette syndrome : case report, *European Journal of Medical Case Reports*, 2018, 2, 2, 39-41.
  - 19. SZEJKO N., JAKUBOVSKI E., FREMER C., MÜLLER-VAHL K.R. : Vaporized Cannabis is Effective and Well-Tolerated in an Adolescent with Tourette Syndrome, *Medical Cannabis and Cannabinoids*, 2019, 2, 60-63. Doi : 10.1159/000496355

## Cannabinoides et Hyperactivité -Déficit de l'Attention (HA-DA, TDAH)

Cannabis for Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD). *Studies and Information.*

<https://www.cannabisreports.com/cannabis-studies/cannabis-for-attention-deficit-disorder-add-and-attention-deficit-hyperactivity-disorder-adhd>

1. AHARONOVICH E., GARAWI F., BISAGA A., BROOKS D., RABY W.N., RUBIN E., NUNES E.V., LEVIN F.R. : Concurrent cannabis use during treatment for comorbid ADHD and cocaine dependence : effects on outcome, *American Journal of Drug and Alcohol Abuse*, 2006, 32, (4), 629-635.  
Doi : 10.1080/00952990600919005
2. CARPENTIER P.J., LEVIN F.R. : Pharmacological Treatment of ADHD in Addicted Patients : What Does the Literature Tell Us ?, *Harvard Review of Psychiatry*, 2017, 25, (2), 50-64.  
Doi : 10.1097/HRP.0000000000000122
3. CASTELLI M., FEDERICI M., ROSSI S., De CHIARA V., NAPOLITANO F., STUDER V., MOTTA C., SACCHETTI L., ROMANO R., MUSSELLA A., BERNARDI G., SIRACUSANO A., GU H.H., MERCURI N.B., USIELLO A., CENTONZE D. : Loss of striatal cannabinoid CB1 receptor function in attention-deficit/hyperactivity disorder mice with point-mutation of the dopamine transporter, *European Journal of Neuroscience*, 2011, 34, (9), 1369-1377.  
Doi : 10.1111/j.1460-9568.2011.07876.x
4. COOPER R.E., WILLIAMS E., SEEGOBIN, TYE C., KUNTSI J., ASHERSON P. : Cannabinoids in attention-deficit/hyperactivity disorder : A randomized-controlled trial, *European Neuropsychopharmacology*, 2017, 27, (8), 795-808.  
Doi : 10.1016/j.euroneuro.2017.05.005
5. FERGUSSON D.M., BODEN J.M. : Cannabis use and adult ADHD symptoms, *Drug and Alcohol Dependence*, 2008, 95, (1-2), 90-96.  
Doi : 10.1016/j.drugalcdep.207.12.012
6. GURURAJAN A., TAYLOR D.A., MALONE D.T. : Cannabidiol and clozapine reverse MK-801-induced deficits in social interaction and hyperactivity in Sprague-Dawley rats, *Journal of Psychopharmacology*, 2012.  
Doi : 10.1177/0269881112441865
7. HERGENRATHER J.Y., AVIRAM J., VYSOTSKI Y., CAMPISI-PINTO S., LEWITUS G.M., MEIRI D. : Cannabinoid and Terpenoid Doses are Associated with Adult ADHD Status of Medical Cannabis Patients, *Rambam Maimonides Medical Journal*, 2020, 11, (1), 1-14.  
Doi : 10.5041/RMMJ.10384
8. LAFENETRE P., CHAOULOFF F., MARSICANO G. : Bidirectional regulation of novelty-induced behavioral inhibition by the endocannabinoid system, *Neuropharmacology*, 2009, 57, (7-8), 715-721.  
Doi : 10.1016/j.neuropharm.2009.07.014
9. LOFLIN M., EARLEYWINE M., De LEO J., HOBKIRK A. : Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use, *Substance Use & Misuse*, 2014, 49, (4), 427-434.

Doi : 10.3109/10826084.2013.841251

10. LUO S.X., LEVIN F.R. : Towards Precision Addiction treatment : New Findings in Comorbid Substance Use and Attention-Deficit Hyperactivity Disorders, *Current Psychiatry Reports*, 2017, 19, (3), 14.  
Doi : 10.1007/s11920-017-0769-7
11. LY C., GEHRICKE J.G. : Marijuana use is associated with inattention in men and sleep quality in women with Attention-Deficit/Hyperactivity Disorder : a preliminary study, *Psychiatry Research*, 2013, 210, (3), 1310-1312.  
Doi : 10.1016/j.psychres.2013.08.003
12. NOTZON D.P., MARIANI J.J., PAVLICOVA M., GLASS A., MAHONY A.L., BROOKS D.J., GRABOWSKI J., LEVIN F.R. : Mixed-Amphetamine Salts Increase Abstinence From Marijuana in Patients With Co-Occurring Attention-Deficit/Hyperactivity Disorder and Cocaine Dependence, *The American Journal on Addictions*, 2016, 25, (8), 666-672.  
Doi : 10.1111/ajad.12467
13. PETKER T, DEJESUS J, LEE A, GILLARD J, OWENS M.M, BALODIS I, AMLUNG M, GEORGE T, OSHRI A, HALL G, SCHMIDT L, MACKILLOP J. : Cannabis use, cognitive performance, and symptoms of attention deficit/hyperactivity disorder in community adults, *Experimental and Clinical Psychopharmacology*, 2020.  
Doi : 10.1037/phn0000354
14. STROHBECK-KUEHNER P., SKOPP G., MATTERN R. : Cannabis improves symptoms of ADHD, *Cannabinoids*, 2008, 3, (1), 1-3.

## Cannabinoides et PTSD

1. AMERICANS for SAFE ACCESS : Veterans and Medical Cannabis, Advancing Legal medical Marijuana Therapeutics and Research, 2015, [www.AmericansForSafeAccess.org](http://www.AmericansForSafeAccess.org), 59 p.
2. AMERICANS for SAFE ACCESS : Veterans and Medical Cannabis, [www.safeaccessnow.org/veterans\\_booklet](http://www.safeaccessnow.org/veterans_booklet), 72 p.
3. AREVALO C., de MIGUEL R, HERNANDEZ-TRISTAN R. : Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters, *Pharmacological Biochem Behaviours*, 2001, 70, 1, 123-131.
4. BERGER W. et al : Pharmacologic alternatives to antidepressants in post-traumatic stress disorder : a systematic review, *Prog Neuropsychopharmacol Biol Psychiatry*, 2009, 33, 2, 169-180.
5. BITENCOURT R.M., TAKAHASHI R.N. : Cannabidiol as a Therapeutic Alternative for post-traumatic Stress Disorder : from Bench Research to Confirmation in Human Trial, *Frontiers in Neuroscience*, 2018, 12, 502.  
Doi : 10.3389/fnins.2018.00502
6. BODEN M.T. et al : Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence, *American Journal of Addiction*, 2013, 22, 3, 277-284.
7. BONN-MILLER M.O., VUJANOVIC A.A., FELDNER M.T., BERNSTEIN A., ZVOLENSKY M.J. : Posttraumatic stress symptom severity predicts marijuana use coping motives among traumatic event-exposed marijuana users, *Journal of Traumatic Stress*, 2007, 20, 577-586.
8. BONN-MILLER M.O. et al : Cannabis use among military veterans after residential treatment for posttraumatic stress disorder, *Psychological Addiction Behavior*, 2011, 25, 3, 485-491.  
<http://www.maps.org/news/media/6599-press-release-statement-on-the-adequacy-of-marijuana-provided-by-nida-for-phase-2-clinical-trials-for-ptsd-in-veterans>
9. BREMNER J.D., SOUTHWICK S.M., DARNELL A. et al : Chronic PTSD in Vietnam combat veterans : course of illness and substance abuse, *American Journal of Psychiatry*, 1996, 153, 3, 369-375.
10. CADTH Rapid Response Reports : Long-term Nabilone Use : a Review of the Clinical Effectiveness ans Safety (in PTSD), *Canadian Agency for Drugs and Technologies in Health*, Ottawa (ON), 16 October 2015.  
[www.ncbi.nlm.nih.gov/pubmed/26561692](http://www.ncbi.nlm.nih.gov/pubmed/26561692)
11. CALHOUNP.S., SAMPSON WS, BOSWORTH H.B. et al : Drug use and validity of substance use self-reports in veterans seeking help for posttraumatic stress disorder, *Journal of Consulting and Clinical Psychology*, 2000, 68, 5, 923-927.
12. CAMERON C., WATSON D., ROBINSON J. : Use of a synthetic cannabinoid in a correctional population for postraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications : a retrospective evaluation, *Journal of Clinical Psychopharmacology*, 2014, 34, 5, 559-564.
13. CHATWAL J.P., RESSLER K.J. : Modulation of fear and anxiety by the endocannabinoid system, *CNS Spectrums*, 2007, 12, 3, 211-220.

14. CHATWAL J.P., MAGUSCHAK K.A., RESSLER K.J.: Enhancing Cannabinoid Neurotransmission Augments the Extinction of Conditioned Fear, *Neuropsychopharmacology*, 2005, 30, 3 516, -524.
15. CHILCOAT H.D., BRESLAU N. : Posttraumatic Stress Disorder and drug disorders. Testing causal pathways, *Archives of General Psychiatry*, 1998, 55, 913-917.
16. CORNELIUS J.R. et al : PTSD contributes to teen and young adult cannabis use disorders, *Addiction Behaviour*, 2010, 35, 2, 91-94.
17. EARLEYWINE M., BOLLES J. : Cannabis, Expectancies, and Post-Traumatic Stress Symptoms : A Preliminary Investigation, *Journal of Psychoactive Drugs*, 2014, 4, 3, p. 171.
18. FOA E.B. et al. : Effective Treatments for PTSD, *Practice Guidelines from the International Society for Traumatic Stress Studies*, second ed 2009, New York, Guilford Press.
19. FRASER G.A. : The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD), *CNS Neuroscience and Therapeutics*, 2009, 15, 1, 84-88.  
Doi : 10.1111/j.1755-5949.2008.00071.x
20. GAETANI S., DIPASQUALE P., ROMANO A., RIGHETTI L., CASSANO T., PIOMELLI D., CUOMO V. : The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs, *International Revue of Neurobiology*, 2009, 85, 57-72.
21. GACEK S. : DEA Approves First Ever Marijuana Study for Veterans with PTSD, [www.medicaljane.com](http://www.medicaljane.com), 2016 April 25
22. GENTES E.L., SCHRY A.R., HICKS T.A., CLANCY C.P., COLLIE C.F., KIRBY A.C., DENNIS M.F., HERTZBERG M.A., BECKHAM J.C., CALHOUN P.S. : Prevalence and Correlates of Cannabis Use in an Outpatient VA Posttraumatic Stress Disorder Clinic, *Psychology of Addictive Behaviors*, 2016, 30, (3), 415-421.  
Doi : 10.1037/adb0000154
23. GREER G.R., GROB C.S., HALBERSTADT A.L. : PTSD Symptom Reports of Patients Evaluated for the New Mexico Medical Cannabis Program, *Journal of Psychoactive Drugs*, 2014, 46, 1.
24. HAUER D., SCHELLING G., GOLA H. et al: Plasma Concentrations of Endocannabinoids and Related Primary Fatty Acid Amides in Patients with Post-Traumatic Stress Disorder, *PLOS One*, 2013, 8, 5, e62741, 11 p.  
PMID : 23667516.
25. HILL M.N., BIERER L.M., MAKOTKINE I. et al : Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the world trade center attacks, *Psychoneuroendocrinology*, 2013. PMID : 24035186.
26. HINDOCHA C., COUSIJN J., RALL M., BLOOMFIELD M.A.P. : The Effectiveness of Cannabinoids in the Treatment of Posttraumatic Stress Disorder (PTSD) : A Systematic Review, *Journal of Dual Diagnosis*, 2020, 16, (1), 120-139.  
Doi : 10.1080/00207454.2020.1730832
27. JETLY R., HEBER A., FRASER G., BOISVERT D. : The efficacy of Nabilone, a synthetic cannabinoid in the treatment of PTSD-associated nightmares : a preliminary randomized, double-blind, placebo-controlled cross-over design study, *Psychoneuroendocrinology*, 2015, 51, 585-588.
28. JOHNSON K., MULLIN J.L., MARSHALL E.C. et al : Exploring the mediational role of coping motives for marijuana use in terms of the relation between anxiety

- sensitivity and marijuana dependance, *American Journal of Addiction*, 2010, 19, 3, 277-282.
29. JOHNSON M.J., PIERCE J.D., MAVANDADI S., KLAUS J., DeFELICE D., INGRAM E., OSLIN D.W. : Mental health symptom severity in cannabis using and non-using veterans with probable PTSD, *Journal of Affective Disorders*, 2016, 190, 439-442.
  30. KHANTZIAN E.J. : The self-medication hypothesis of addictive disorders : focus on heroin and cocaine dependence, *American Journal of Psychiatry*, 1985, 142, 11, 1259-1264.
  31. LOFLIN M.J.E., BABSON K., SOTTILE J., NORMANA S.B., GRUBER S., BONN-MILLER M.O. : A cross-sectional examination of choice and behavior of veterans with access to free medicinal cannabis, *The American Journal of Drug and Alcohol Abuse*, 2019, 45, (5), 506-513. Doi : 10.1080/00952990.2019.1604722
  32. MANERA C., ARENA C., CHICCA A. : Synthetic Cannabinoid Receptor Agonist and Antagonists : Implication on CNS Disorders, *Recent Patents on CNS Drug Discovery*, 2015, 10, 2, 142-156.
  33. MAPS – SISLEY S. : Placebo-Controlled, Triple-Blind, Randomized Crossover Pilot Study of the Safety and Efficacy of Five Different Potencies of Smoked or Vaporized Marijuana in 76 Veterans with Chronic, Treatment-Resistant Posttraumatic Stress Disorder (PTSD), *Protocol MJP-1, Multidisciplinary Association for Psychedelic Studies (MAPS)*, November 5, 2010, 55 p.
  34. MARSICANO G. et al. : The endogenous cannabinoid system controls extinction of aversive memories, *Nature*, 2002, 418, 6897, 530-534.
  35. MASHIAH M. : Medical Cannabis as Treatment for Chronic Combat PTSD. Promising Results in an Open Pilot Study, Patients Out of Time conference, Tucson, Arizona, April 28, 2012.
  36. McKENNA M. : Cannabis and PTSD, <http://www.rxmarijuana.com/ptsd.htm>
  37. NAVARRO M. et al. : Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in rat, *Neuroreport*, 1997, 8, 2, 491-496.
  38. O'NEIL M.E., NUGENT S.M., MORASCO B.J., FREEMAN M., LOW A., KONDO K., ZAKHER B., ELVEN C., MOTU'APUAKA M., PAYNTER R., KANSAGARA D. : Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder. A Systematic Review, *Annals of Internal Medicine*, 2020, 1-10.  
Doi : 10.7326/M17-0477
  39. PASSIE T., EMRICH H.M., KARST M., BRANDT S.D., HALPERN J.H. : Mitigation of post-traumatic stress symptoms by *Cannabis* resin : A review of the clinical and neurobiological evidence, *Drug Testind and Analysis*, 2012, 4, 7-8, 649-659. PMID 22736575.
  40. PATEL S., HILLARD C.J. : Adaptations in Endocannabinoid signaling in response to repeated homotypic stress : a novel mechanism for stress habituation, *European Journal of Neuroscience*, 2008, 27, 11, 2821-2829.
  41. PIETRZAK R.H., HUANG Y., CORSI-TRAVALI S. et al : Cannabinoid Type 1 Receptor Availability in the Amygdala Mediates Threat Processing in Trauma Survivors, *Neuropsychopharmacology*, 2014, May 12, PMID : 24820537.
  42. RABINAK C.A., BLANCHETTE A., ZABIK N.L., PETERS C., MARUSAK H.A., IADIPAOLO A., ELRAHAL F. : Cannabinoid modulation of corticolimbic activation to threat in trauma-exposed adults : a preliminary study, *Psychopharmacology*, 2020, 1-14.  
Doi : 10.1007/s00213-020-05499-8

43. REZNIK I. : Medical cannabis use in post-traumatic stress disorder : a naturalistic observational study, *Abstract at Cannabinoid Conference 2011*, 8th-10th September, Bonn, Germany.
  44. ROITMAN P., MECHOULAM R., COOPERKAZAR R., SHALEV A. : Preliminary, Open-Label, Pilot Study of Add-On Oral Delta9 THC in chronic Post-Traumatic Stress Disorder, *Clin Drug Investig*, 2014, 34, 587-591.
  45. SCHOR J. : Cannabinoids and Posttraumatic Stress Disorder, *Natural Medicine Journal*, 2014.
  46. SCUDERI C et al. : Cannabidiol in medicine a review of its therapeutic potential in CNS disorders, *Phytotherapeutic Research*, 2009, 23, 5, 597-602.
  47. SHANNON S., OPILA-LEHMAN J. : Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder : A Case Report, *Perm J*, 2016, 20, 4, 108-111, PMID : 27768570.
  48. STERNICZUK R., WHELAN J. : Cannabis use among Canadian Armed Forces Veterans, *Journal of Military, Veteran and Family Health*, 2016, 2, 2, 43-52.
  49. TREZZA V., CAMPOLONGO P. : The endocannabinoid system as a possible target to treat both the cognitive and emotional features of post-traumatic stress disorder (PTSD), *Frontiers in Behavioral Neurosciences*, 2017, Aug 9, 7, 100.
  50. UHERNIK A.L., MONTOYA Z.T., BALKINSOON C.D., SMITH J.P. : Learning and Memory is Modulated by Cannabidiol When Administred During Trace Fear-Conditionning, *Neurobiology of Learning and Memory*, 2018.
  51. WILKINSON S.T., STEFANOVICS E., ROSENHECK R.A. : Marijuana use is associated with worse outcomes in symptom severity and violent behavior in patients with posttraumatic stress disorder, *Journal of Clinical Psychiatry*, 2015, 76, 9, 1174-1180, PMID : 26455669.
  52. YAMADA D., TAKEO J., KOPPENSTEINER P., WADA K., SEKIGUCHI M. : Modulation of Fear Memory by Dietary Polyunsaturated Fatty Acids via Cannabinoid receptors, *Neuropsychopharmacology*, 2014.
  53. YARNELL S. : The Use of Medicinal Marijuana for Posttraumatic stress disorder : A Review of the Current Literature, [www.Psychiatrist.com](http://www.Psychiatrist.com) , *The Cannabis Collection*, 2015, 17, 3.
  54. ZANELATI T.V. et al. : Antidepressant-like effects of cannabidiol in mice : possible involvement of 5-HT1A receptors, *British Journal of Pharmacology*, 2010, 159, 1, 122-128.
- Doi : 10.1111/j.1476-5381.2009.00521.x

## Cannabinoïdes et stress

1. CAMPOS A.C et al : Cannabidiol blocks long-lasting behavioral consequences of predator threat stress : possible involvement of 5HT1A receptors, *Journal of Psychiatric Research*, 2012, 46, 11, 1501-1510.
2. DLUGOS A., CHILDS E., STUHR K.L., HILLARD C., de WIT H. : Acute Stress Increase Circulating Anandamide and Other N-Acylethanolamines in Healthy Humans, *Neuropsychopharmacology*, 2012, 37, 11, 2416-2427, PMCID : 3442338.
3. FUSAR-POLI P., CRIPPA J.A., BHATTACHARYYA S., ZUARDI A.W. et al : Distinct Effects of delta 9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional Processing, *Archives of General Psychiatry*, 2009, 66, 1, 95-105.
4. HILL M.N., PATEL S., CAMPOLOGO P. et al : Functional Interactions between Stress and the Endocannabinoid System : From Synaptic Signaling to Behavioral Output, *The Journal of Neuroscience*, 2010, 30, 45, 14980-14986.
5. KOREM N., AKIRAV I. : Cannabinoids Prevent the Effects of a Footshock Followed by Situational Reminders on Emotional Processing, *Neuropsychopharmacology*, 2014 june 5, PMID : 24897957.
6. MOREIRA F.A. et al : Neuroanatomical substrates involved in cannabinoid modulation of defensive responses, *Journal of Psychopharmacology*, 2012, 26, 1, 40-55.
7. PATEL S., HILLARD C.J. : Adaptations in Endocannabinoid signaling in response to repeated homotypic stress : a novel mechanism for stress habituation, *European Journal of Neuroscience*, 2008, 27, 11, 2821-2829.
8. REYES PRIETO N.M., ROMANO LOPEZ A., PEREZ MORALES M., PECH O. et al : Oleamide restores sleep in adult rats that were subjected to maternal separation, *Pharmacological Biochemistry Behaviour*, 2012, 103, 2, 308-312.
9. RUELHE S., APARISI REY A., REMMERS F., LUTZ B. : The endocannabinoid system in anxiety, fear memory and habituation, *Journal of Psychopharmacology*, 2012, 26, 1, 23-39.

## Cannabinoides en pédiatrie (TED, autismes, troubles psycho-comportementaux...)

1. ARAN A., CASSUTO H., LUBOTZKY A., WATTAD N., HAZAN E.: Brief Report : Cannabidiol-Rich cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems - A Retrospective Feasibility Study, *Journal of Autism and Developmental Disorders*, 2018, Oct 31,  
Doi : 10.1007/s10803-018-3808-2
2. ARAN A., EYMON M., HAREL M. et al. : Lower circulating endocannabinoid levels in children with autism spectrum disorder, *Molecular Autism*, 2019, 10, 2.
3. ARVEILLER J., SUEUR C. : Iatrogénèse et production du savoir sur les toxicomanies, *L'Évolution Psychiatrique*, 1989, 54, 2, 333-353.
4. BARCHEL D., STOLAR O., DE-HAAN T. et al. : Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities, *Frontiers in Pharmacology*, 2019, 9, 1521.
5. BAR-LEV SCHLEIDER L., MECHOULAM R., SABAN N. et al. : Real life experience of medical cannabis treatment in autism : Analysis of safety and efficacy, *Scientific Reports*, 2019, 9, 200.
6. BARNES G., SULLIVAN J., SEARS L. et al. : Safety and tolerability of GWP42006 (CBDV) in subjects with drug resistant epilepsy and autism, Presented at : *American Epilepsy Society Annual Meeting*, New Orleans, LA, November 30-December 4, 2018, Poster 3.288.
7. BHATTACHARYYA S. : Cannabidiol As A Treatment In Different Stages Of Psychosis- Efficacy And Mechanisms, *Schizophrenia Bulletin*, 2018, 44, (suppl\_1), S27-S27.
8. BIH C.I. et al. : Molecular targets of cannabidiol in neurological disorders, *Neurotherapeutics*, 2015, 12, 4, 699-730.
9. BILGE S., EKICI B. : CBD-enriched cannabis for autism spectrum disorder : an experience of a single center in Turkey and reviews of the literature, *Journal of Cannabinoid Research*, 2021, 3, 53, 1-11.  
Doi : 10.1186/s42238-021-00108-7
10. BOU KHALIL R. : Would some cannabinoids ameliorate symptoms of autism ?, *European Child and Adolescent Psychiatry*, 2012, 21, 237-238.
11. BRIGIDA A.L., SCHULTZ S., CASCONE M. et al. : Endocannabinoid Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations, *International Journal of Molecular Sciences*, 2017, 18, 1425, 13 p.
12. BUSQUETS-GARCIA A., GOMIS-GONZALES M., GUEGAN T. et al. : Targeting the endocannabinoid system in the treatment of fragile X syndrome, *Nature Medicine*, 2013, 19, 5, 603-607.
13. CAMPOS A.C. et al. : Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders, *Frontiers in Pharmacology*, 2017.
14. CAREAGA M., VAN DE WATER J., ASHWOOD P. : Immune dysfunction in autism : a pathway to treatment, *Neurotherapeutics*, 2010, 7, 3, 283-292.
15. CAREAGA M., ASHWOOD P. : Autism spectrum disorder : from immunity to behavior, *Methods in Molecular Biology*, 2012, 934, 219-240.

16. CHAKRABARTI B., PERSICO A., BATTISTA N. et al. : Endocannabinoid signaling in autism, *Neurotherapeutics*, 2015, 12, 837-847.
17. CONSROE P., SANDYK R. : Potential role of cannabinoids for therapy of neurological disorders, in Murphy L., Bartke A. eds, *Marijuana/Cannabinoids, Neurobiology and Neurophysiology*, Boca Raton, CRC Press, 1992, 459, 524.
18. CONSROE P. : Brain Cannabinoid systems as targets for the therapy of neurological disorders, *Neurobiological Diseases*, 1998, 5, 534-541.
19. Da SILVA JUNIOR E.A., MEDEIROS W.M.B., TORRO N., de SOUSA J.M.M., de ALMEIDA I.B.C.M., da COSTA F.B., PONTES K.M., NUNES E.L.G., da ROSA M.D., de ALBUQUERQUE K.L.G.D. : Cannabis and cannabinoid use in autism spectrum disorder : a systematic review, *Trends in Psychiatry and Psychotherapy*, 2021, 1-10. Doi : 10.47626/2237-6089-2020-0149
20. DEVINSKY O., CROSS J.H., LAUX L. et al. : Trial of Cannabidiol for drug-resistant seizures in the Dravet Syndrome, *New England Journal of Medicine*, 2017, 376, 2011-2020.
21. Di MARZO V., MELCK D., BISOGNO T. et al. : Endocannabinoids : endogenous cannabinoid receptor ligands with neuromodulatory action, *Trends in Neurosciences*, 1998, 21, 521-528.
22. EFRON D., FREEMAN J.L., CRANWICK N., PAYNE J., MULRANEY M., PRAKASH C., LEE K.J., TAYLOR K., WILLIAMS K. : A pilot randomized placebo-controlled trial of cannabidiol to reduce severe behavioural problems in children and adolescents with intellectual disability, *British Journal of Clinical Pharmacology*, 2020. Doi : 10.1111/bcp.14399
23. FOGACA M.V. et al. : Cannabinoids, Neurogenesis and Antidepressant Drugs : is there a Link ?, *Current Neuropharmacology*, 2013, 11, (3), 263-275.
24. FOLDY C., MALENKA R.C., SUDHOF T.C. : Autism-associated neuroligin-3 mutations commonly disrupt tonic endocannabinoid signaling, *Neuron*, 2013, 78, 3, 498-509.
25. GARBETT K., EBERT P.J., MITCHELL A. et al. : Immune transcriptome alterations in the temporal cortex of subjects with autism, *Neurobiology of Disease*, 2008, 30, 303-311.
26. GRINSPON L. : A Novel Approach to the Symtomatic Treatment of Autism, *O'Shaughnessy's*, summer 2010.
27. GROTHENHERMEN F. : Chanvre en Médecine. Redécouverte d'une plante médicinale. Guide pratique des applications thérapeutiques du Cannabis, du THC et du CBD, Edition Solanacée, 2017.
28. GROTHENHERMEN F. : CBD. Un cannabinoïde au vaste potentiel thérapeutique, Edition Solanacée, Suisse, 2018, p 14.
29. GU B. : Cannabidiol provides viable treatments opportunity for multiple neurological pathologies of autism spectrum disorder, *Global Drugs and Therapeutics*, 2017. Doi : 10.15761/GTD.1000134
30. GU B., ..., CARNEY P.R., PHILPOT B.D. : Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice, *Journal of Clinical Investigation*, 2019, 129, (12), 5462-5467. Doi : 10.1172/JCI130419
31. HABIB S.S., AL-REGAIEY K., BASHIR S., IQBAL M. : Role of Endocannabinoids on Neuroinflammation in Autism Spectrum Disorder Prevention, *Journal of Clinical and Diagnostic Research*, 2017, 11, 6, 3p.

32. HADLAND S.E., KNIGHT J.R., HARRIS S.K. : Medical Marijuana : Review of the Science and Implications for Developmental Behavioral Pediatric Practice, *Journal of Developmental and Behavioral Pediatrics*, 2015, 36, 2, 115-123.
33. HAUSMAN-KEDEM M., MENASCU S., KRAMER U. : Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents – An observational, longitudinal study, *Brains & Development*, 2018, in press.
34. HOSIE S., MALONE D.T., LIU S. et al. : Altered amygdala excitation and CB1 receptor modulation of aggressive behavior in the neuroligin-3R451C mouse model of autism, *Frontiers in Cellular Neuroscience*, 2018, 12, 234.
35. INGOLD F.R., SUEUR C., KAPLAN C. : Contribution à une exploration des propriétés thérapeutiques du Cannabis, *Annales Médico-Psychologiques*, 2015, 173, 5, 453-459.
36. IUVONE et al. : Neuroprotective effect of Cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells, *Journal of Neurochemistry*, 2004, 89, 1, 134-141.
37. JUNG K.M., SEPERS M., PIOMELLI D., O.J. MANZONI et al. : Uncoupling of the endocannabinoid signalling complex in a mouse model of fragile X syndrome, *Nature Communications*, 2012, 3, 1080.
38. KARHSON D.S. et al. : Plasma anandamide concentrations are lower in children with autism spectrum disorder, *Molecular Autism*, 2018, 12, 9, 18.
39. KERR D.M., DOWNEY L., CONBOY M. et al. : Alterations in the endocannabinoid system in the rat valproic acid model of autism, *Behavioural Brain Research*, 2013, 249, 124–132.
40. KOPPEL B.S., BRUST J.C., FIFE T. et al. : Systematic review : efficacy and safety of medical marijuana in selected neurologic disorders : report of the Guideline Development Subcommittee of the American Academy of Neurology, *Neurology*, 2014, 82, 1556-1563.
41. KRUGER T., CHRISTOPHERSEN E. : An Open Label Study of the Use of Dronabinol (Marinol) in the Management of Treatment-resistant Self-Injurious Behavior in 10 Retarded Adolescent Patients, *Journal of Developmental and Behavioral Pediatrics*, 2006, 27, 5, 433.
42. KURZ R., BLAAS K. : Use of dronabinol (delta-9-THC) in autism : A prospective single-case-study with an early infantile autistic child, *Cannabinoids*, 2010, 5, 4, 4-6.
43. LEWEKE F.M. et al. : Cannabidiol as an antipsychotic agent, *European Psychiatry*, 2007, 22, 1.
44. LEWEKE F.M., PIOMELLI D. et al. : Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia, *Translational Psychiatry*, 2012, 2, 3, e94.
45. LEWEKE F.M., MUELLER J.K., LANGE B., FRITZ S. et al. : Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia : Implications for Pharmacological Intervention, *CNS Drug*, 18 July 2018, doi.org/10.1007/s40263-018-0539-z.
46. LI X., CHAUHAN A., SHEIKH A.M., PATIL S. et al. : Elevated immune response in the brain of autistic patients, *Journal of Neuroimmunology*, 2009, 207, (1-2), 111-116.
47. MANERA C., ARENA C., CHICCA A. : Synthetic cannabinoid receptor agonist and antagonists : implication in CNS disorders, *Recent Patents on CNS Drug Discovery*, 2015, 10, 2 142-156.

48. MARTIN H.G.S., NEUHOFER D., MANZONI O.J.J. : The Endocannabinoid System in Fragile X Syndrome, Chapter 12, in « *Fragile X Syndrome – From Genetics to Targeted Treatment* », 2017, 241-259.  
Doi : 10.1016/B978-0-12-804461-2.00012-3
49. MEAD J., ASHWOOD P. : Evidence supporting an altered immune response in ASD, *Immunology Letters*, 2015, 163, 1, 49-55.
50. MELANCIA F., SCHIAVI S., SERVADIO M. et al. : Sex-specific autistic endophenotypes induced by prenatal exposure to valproic acid involve anandamide signaling, *British Journal of Pharmacology*, 2018, 175, 3699–3712.
51. MILES K. : Marijuana-like Chemical May Help Autism and X Fragile Syndrome Symptoms, 2012.
52. NADAL X., Del RIO C., CASANO S., MUÑOZ E. et al. : Tetrahydrocannabinolic acid is a potent PPAR $\gamma$  agonist with neuroprotective activity, *British Journal of Pharmacology*, 2017, 174, 23, 4263-4276, doi : 10.1111/bph.14019.
53. NAGAYAMA T. et al. : Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures, *Journal of Neurosciences*, 1999, 19, 2987-2995.
54. NIELSEN S., GERMANOS R., WEIER M. et al. : The use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis : a systematic Review of Reviews, *Current Neurology and Neuroscience Reports*, 2018, 18, 8, 12 pp.
55. ONAIVI E.S., BENNO R., HALPERN T., MEHANOVIC M. et al. : Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse model of Autism Spectrum Disorders, *Current Neuropharmacology*, 2011, 9, 209-214.
56. PAZOS M.R., MOHAMMED N., LAFUENTE H. et al : Mechanisms of cannabidiol neuroprotection in hypoxi-ischemic newborn pigs : role of 5HT(1A) and CB2 receptors, *Neuropharmacology*, 2013, 71, 282-291.
57. PERTWEE R.G. : The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids : Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin, *British Journal of Pharmacology*, 2008, 153, 2, 199-215.
58. PERTWEE R.G. : Receptors and Channels Targeted by Synthetics Cannabinoid receptor agonists and antagonists, *Current Medicinal Chemistry*, 2010, 17, 14, 1360-1381.
59. PERTWEE R. : Cannabinoids and multiple sclerosis, *Pharmacology & Therapeutics*, 2002, 95, 2, 165-174.
60. PERTWEE R.G. editor : Handbook of Cannabis, Oxford University Press, United Kingdom, 2016.
61. POLEG S., GOLUBCHIK P., OFFEN D. et al. : Cannabidiol as a suggested candidate for treatment of autism spectrum disorder, *Progress in Neuropsychopharmacology and Biological Psychiatry*, 2019, 89, 90–96.
62. PRETZSCH C.M., FREYBERG Jan, VOINESCU B., LYTHGOE D., HORDER J., MENDEZ M.A., WICHERS R., AJRAM L., IRVIN G., HEASMAN M., EDDEN R.A.E., WILLIAMS S., MURPHY D.G.M., DALY E., McALONAN G.M. : Effects of cannabidiol on brain excitation and inhibition systems ; a randomized placebo-controlled single dose trial during magnetic resonance spectroscopy in adults with and without autism spectrum disorder, *Neuropsychopharmacology*, 2019, 0, 1-8.  
Doi : 10.1038/s41386-019-0333-8
63. RANGANATHAN M., de SOUZA D. et al. : Efficacy of Cannabidiol in the treatment of early psychosis, *Sixth Biennial SIRS Conference*, 2018.

64. RIMLAND B., Marijuana thérapeutique : un traitement intéressant pour l'autisme?, *Autism Research Review International*, 2003, 17, 1 3-4.
65. ROHLEDER C., MULLER J. K., LANGE B., LEWEKE F.M. : Cannabidiol as a Potential New Type of an Antipsychotic. A critical Review of the Evidence, *Frontiers in Pharmacology*, 2016.
66. SALA M., BRAIDA D., LENTINI D. et al. : Pharmacological rescue of impaired cognitive flexibility, social deficits, increased aggression, and seizure susceptibility in oxytocin receptor null mice : a neurobehavioral model of autism, *Biological Psychiatry*, 2011, 69, 875-882.
67. SEEMAN P. : Cannabidiol is a partial agonist at dopamine D2-High receptors, predicting its antipsychotic clinical dose, *Translational Psychiatry*, 2016.
68. SCUDERY C. ET AL. : Cannabidiol in medicine : a review of its therapeutic potential in CNS disorders, *Phytotherapy Research*, 2009, 23, 5, 597-602.
69. SCHULTZ S., SINISCALCO D. : Endocannabinoid system involvement in autism spectrum disorder : An overview with potential therapeutic applications, *Molecular Sciences*, 2019.  
Doi : 10.3934/molsci.2019.1.27
70. SHANNON S., OPILA-LEHMAN J. : Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder : A Case Report, *The Permanent Journal*, 2016, 20, 4, 108-111.
71. SINISCALCO D., SAPONE A., GIORDANO C et al. : Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders, *Journal of Autism and Developmental Disorders*, 2013, 43, 2686-2695.
72. SUEUR C. : État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21<sup>e</sup> siècle, *Psychotropes*, 2017, 23, 3, 125-163.
73. SUEUR C., INGOLD F.X. : Les Cannabis thérapeutique en Neurologie et Psychiatrie, *GRECC*, 2019.
74. TARTAGLIA N., BONN-MILLER M., HAGERMAN R. : Treatment of Fragile X Syndrome with Cannabidiol : A Case Series study and brief Review of the Literature, *Cannabis and Cannabinoid Research*, 2019, 4, 1,  
Doi : 10.1089/can.2018.0053
75. VARGAS D.L., NASCIMBENE C., KRISHNAN C., ZIMMERMAN A.W., PARDO C.A. : Neuroglial activation and neuroinflammation in the brain of patients with autism, *Annals of Neurology*, 2005, 57, 1, 67-81.
76. VEZYROGLOU K., CROSS J.H. : Targeted Treatment in Childhood Epilepsy Syndromes, *Epilepsy, Current treatment Options Neurology*, 2016, 18, 29, 12 pp.
77. WEI D., LEE D., COX C., KARSTEN C., PIOMELLI D. et al. : Endocannabinoid signaling mediates oxytocin-driven social reward, *PNAS*, 2015, 112, 5, 14084-14089.
78. XU N., LI X., ZHONG Y. : Inflammatory cytokines : potential biomarkers of immunologic dysfunction in autism spectrum disorders, *Mediators of Inflammation*, 2015.
79. ZAMBERLETTI E., GABAGLIO M., PAROLARO D. : The endocannabinoid system and autism spectrum disorders: Insights from animal models. *Int J Mol Sci*, 2017, 18, pii: E1916.
80. ZUARDI A.W. et al. : Effects of cannabidiol in animal models predictive of antipsychotic activity, *Psychopharmacology*, 1991, 104, 2, 260-264.
81. ZUARDI A.W. et al. : Antipsychotic effects of cannabidiol, *Journal of Clinical Psychiatry*, 1995, 56, 10, 485-486.

82. ZUARDI A.W. et al.: Cannabidiol monotherapy for treatment-resistant schizophrenia, *Journal of Psychopharmacology*, 2006, 20, 5, 683-686.
83. ZUARDI A.W. et al. : Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug, *Brazilian Journal of Medical and Biological Research*, 2006, 39, 421-429.
84. ZUARDI A.W., CRIPPA J.A.S. et al. : A critical review of the Antipsychotic Effects of Cannabidiol : 30 Years of a translational Investigation, *Current Pharmaceutical Design*, 2012, 18, 5131-5140.